Factors affecting CYP2C9-mediated metabolism by Hutzler, James Matthew
Graduate Theses, Dissertations, and Problem Reports 
2001 
Factors affecting CYP2C9-mediated metabolism 
James Matthew Hutzler 
West Virginia University 
Follow this and additional works at: https://researchrepository.wvu.edu/etd 
Recommended Citation 
Hutzler, James Matthew, "Factors affecting CYP2C9-mediated metabolism" (2001). Graduate Theses, 
Dissertations, and Problem Reports. 1434. 
https://researchrepository.wvu.edu/etd/1434 
This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research 
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is 
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain 
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license 
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, 
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. 
For more information, please contact researchrepository@mail.wvu.edu. 
FACTORS AFFECTING CYP2C9-MEDIATED 
METABOLISM 
 
 
James Matthew Hutzler 
 
A DISSERTATION 
Submitted to 
The School of Pharmacy 
at 
West Virginia University 
 
In partial fulfillment of the requirements 
for the degree of  
 
DOCTOR OF PHILOSOPHY 
 
In 
Basic Pharmaceutical Sciences 
 
  
Timothy S. Tracy, Ph.D., Chair 
Peter M. Gannett, Ph.D. 
Robert K. Griffith, Ph.D. 
David Lalka, Ph.D. 
Grazyna D. Szklarz, Ph.D. 
Kenneth R. Korzekwa, Ph.D. 
 
 
Department of Basic Pharmaceutical Sciences 
 
Morgantown, West Virginia 
 
2001 
 
Keywords:  cytochrome P450 2C9, flurbiprofen, naproxen, piroxicam, dapsone, atypical 
kinetics 
 
Copyright 2001 James Matthew Hutzler 
ABSTRACT 
 
FACTORS AFFECTING CYP2C9-MEDIATED METABOLISM 
 
James Matthew Hutzler 
 
Cytochrome P450 enzymes can exhibit non-Michaelis-Menten, or atypical kinetics.  In 
particular, dapsone activates CYP2C9-mediated flurbiprofen 4’-hydroxylation.  However, 
the mechanism of activation of CYP2C9 is poorly understood.  The activation of 
flurbiprofen, naproxen, and piroxicam metabolism by dapsone was investigated, fitting 
kinetic data to a two-site effector model, indicating that the CYP2C9 active site may have 
multiple binding regions.  In addition the structural requirements for activation of 
CYP2C9 were explored using structural analogs of dapsone, with results suggesting that 
a sulfone group between two benzene rings is necessary for activation.  CYP2C9 
*2(R144C) and *3(I359L) allelic variants and the F114L mutant enzymes have also been 
used to see if these amino acid changes alter dapsone activation of CYP2C9.  In this 
study, flurbiprofen 4’-hydroxylation was activated ~5-fold in the F114L mutant, but only 
~2-fold for wild-type enzyme in the presence of dapsone.  Also, piroxicam 5’-
hydroxylation was not activated by dapsone in the F114L mutant, which had higher 
piroxicam hydroxylase activity than CYP2C9 wild-type, suggesting a role for F114 in 
activation.  In addition, substrate metabolism was studied in CYP2C9/19 chimeric and 
CYP2C19 mutant enzymes.  Results suggest that amino acids 228-292 are important for 
catalysis of flurbiprofen, naproxen, and piroxicam.  In addition, the CYP2C19 KSN 
mutant has the greatest activity towards flurbiprofen 4’-hydroxylation, indicating that 
changes at residues 241, 286, and 289 confer activity to CYP2C19.  It has also been 
discovered that hydroxy-dapsone, the major phase I metabolite of dapsone activates 
flurbiprofen metabolism, although through a different mechanism.  Spectral binding 
studies confirm kinetic data, indicating that dapsone directly affects the binding of 
flurbiprofen, whereas hydroxy-dapsone does not.  Additional studies with ibuprofen 
indicates that dapsone alters the binding orientation of this substrate, as the ratio of 3-OH 
to 2-OH ibuprofen changes in the presence of dapsone.  Lastly a urine and plasma assay 
for detection of flurbiprofen and 4’-hydroxy flurbiprofen was developed for use in 
analysis of samples in a clinical study investigating activation of metabolism in vivo.  It 
was found that dapsone activates flurbiprofen 4’-hydroxylation in vivo about 10%, much 
less than that observed in vitro. 
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CHAPTER 1 
 
 
 
Literature Review 
2 
1.1.  Introduction to Atypical Kinetics 
 
It is well established that the cytochrome P450 monooxygenase family of 
enzymes are the most important enzymes involved in the biotransformation of both 
xenobiotic and endobiotic hydrophobic compounds [1;2].  The cytochrome P450 
enzymes most often play a protective role against foreign chemicals, although they are 
also implicated in the bioactivation of certain procarcinogens [e.g. benzo[a]pyrene], and 
in many metabolism-based drug-drug interactions in patients taking concomitant 
medications.  Consequently, it is the goal of drug metabolism and toxicology labs to not 
only determine CYP450 isoform contribution for the metabolism of a given compound, 
but also to understand the various factors that affect the activity and behavior of these 
isoforms.  Classically, the metabolism of a particular compound is described kinetically 
using the Michaelis-Menten equation, which yields estimates of maximal reaction 
velocity (Vmax) and substrate affinity (Km).  However, it is becoming increasingly evident 
that the kinetic profile of the metabolism of some drugs may be better described by a 
non-Michaelis-Menten, or atypical kinetic model, complicating interpretation of data.  
Examples of these atypical kinetic profiles have become more numerous over the past 
several years and are proposed to fall into five categories: activation, autoactivation, 
substrate inhibition, partial inhibition, and biphasic metabolism [3].  Activation is evident 
when P450 enzyme activity for a substrate is increased in the presence of another 
substrate, due to structural or electronic changes of the enzyme, and is often referred to as 
heterotropic positive cooperativity (activator is different than the substrate).  
Autoactivation (homotropic positive cooperativity) occurs when a compound activates its 
own metabolism, as has been observed with such compounds as carbamazepine [3]and 
3 
progesterone [4], resulting in a sigmoidal kinetic profile.  Kinetic parameters from 
sigmoidal data are often estimated using the Hill equation, with the Hill coefficient 
describing the degree of sigmoidicity (n>1).  Substrate inhibition occurs when the 
reaction velocity of product formation decreases once a particular substrate concentration 
is surpassed, resulting in a convex reaction profile, while partial inhibition is when 
incomplete inhibition is observed even in the presence of saturating concentrations of 
inhibitor.  The final atypical kinetic phenomenon reported is a biphasic saturation profile, 
indicative of an enzyme with both a low affinity and a high affinity binding component.  
This is similar to a dual-enzyme model, but interpreted as a single enzyme with multiple 
binding regions [3].   
Previously, atypical kinetic profiles were most likely overlooked, citing assay or 
experimental variability, or not observed, perhaps due to lack of sensitive analytical 
techniques or the paucity of data points collected, particularly at the low end of the 
substrate concentration range.  However, with today’s improved analytical technology, 
scientists in drug metabolism are capable of designing more complete kinetic studies to 
fully characterize the biotransformation of the compounds of interest, and thus are 
becoming more cognizant of these atypical kinetic events.  This is reflected by the 
increase in atypical kinetic profiles reported in the literature over the past few years.  
 
1.2.  Activation (Heterotropic Positive Cooperativity) 
 
 
Activation of drug metabolism was first observed many years ago in microsomes 
from rat tissue, as 7,8-benzoflavone (α-naphthoflavone) was shown to activate the 
hydroxylation of benzo[a]pyrene in control and phenobarbital treated rats [5].  Several 
4 
other studies undertaken shortly thereafter concurred with these findings [6-8], but the 
particular isoforms involved in this metabolism and activation had not been isolated or 
identified.  Later studies established that purified CYP3A enzymes are directly activated 
by 7,8-benzoflavone [4;9].  Schwab and colleagues concluded that both progesterone 6β-
hydroxylation and 17β-estradiol 2-hydroxylation are activated by 7,8-benzoflavone in 
man and rabbit, based on the observation that the Km of these reactions decreased and 
Vmax increased in the presence of 7,8-benzoflavone.  Similarly, Shou and co-workers 
demonstrated that 7,8-benzoflavone activates phenanthrene metabolism by increasing the 
Vmax, although the Km was unaffected.  Also discovered was that 7,8-benzoflavone is a 
substrate for CYP3A4, as phenanthrene was found to decrease the Vmax of 7,8-
benzoflavone metabolism, without affecting the Km.  This particular finding generated 
ideas as to the mechanism of activation (discussed later).  
Because of the numerous studies showing 7,8-benzoflavone activation of 
CYP3A4 (Table 1.1), it has been labeled as the classic CYP3A4 activator.  However, 
several groups have observed that compounds other than 7,8-benzoflavone may activate 
CYP3A4 activity.  Maenpaa et al. [10] have shown that testosterone stimulates the 
formation of 4-hydroxymidazolam from midazolam in liver microsomes and expressed 
CYP3A4, while Ludwig et al. [11] observed that meloxicam metabolism is activated by 
quinidine in a dose-dependent manner.  Interestingly, quinidine also activates the 
metabolism of diclofenac to its 5-hydroxy derivative and warfarin to its 4’- and 10-
hydroxy metabolite in human liver microsomes, recombinant CYP3A4, and in human 
hepatocyte suspensions, indicating that this interaction occurs in intact cells, and is likely 
not an in vitro artifact [12;13].  These observations are not altogether surprising, 
5 
considering the number of substrates with varying sizes and molecular weights that 
CYP3A4 accommodates.  In fact, Wang et al. [14] suggest that these types of interactions 
with CYP3A4 are substrate dependent, implying that perhaps the interactions driving 
these atypical kinetic observations depend at least partially upon a compound’s physical 
and chemical properties.  One particularly interesting observation from Wang and 
colleagues was that 50-100 µM testosterone inhibited midazolam 1’-hydroxylation, but 
stimulated the formation of the 4-hydroxylated product, suggesting an alteration of 
regiospecificity, perhaps due to the presence of testosterone in the active site.  In 
addition, testosterone did not interact at all with nifedipine metabolism, but partially 
inhibited terfenadine t-butyl-hydroxylation [14].  
Just as compounds other than 7,8-benzoflavone can activate CYP3A4, the activity 
of other isoforms may be stimulated by the presence of certain compounds.  For example, 
Korzekwa et al. [3]have shown that dapsone activates CYP2C9-mediated metabolism of 
both flurbiprofen and naproxen, albeit to differing degrees, further supporting the 
contention that these interactions may be substrate dependent.  Furthermore, Korzekwa et 
al. demonstrated that dapsone is also metabolized by CYP2C9, analogous to 7,8-
benzoflavone metabolism by CYP3A4 [3].  Thus, there appears to be some possible 
mechanistic similarities for activation between these isoforms.  Table 1.1 shows some of 
the important examples of activation that have been observed in various expression 
systems. 
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1.3.  Autoactivation (Homotropic Positive Cooperativity) 
 
With regards to autoactivation, according to a review by Ekins et al. [15], the 
most frequently reported CYP3A4 substrates that display autoactivation kinetics include 
aflatoxin B1, amitriptyline, and progesterone, though some other compounds displaying 
autoactivation kinetics have been reported (Table 1.2).  In addition to CYP3A4, it has 
been demonstrated that E. coli expressed and RECO expressed CYP1A2 show 
autoactivation kinetics for ethoxyresorufin O-deethylation [15].  However, 
ethoxyresorufin O-deethylation in human liver microsomes and insect expressed sources 
of CYP1A2 showed classical Michaelis-Menten kinetics, suggesting that atypical kinetic 
profiles may not only be substrate dependent, but also enzyme source dependent.  One 
other CYP450 that displays autoactivation kinetics is CYP2B6, as Ekins et al. [16] 
observed that CYP2B6-mediated testosterone 16β-hydroxylation metabolism data are 
best fit to the Hill equation (n=1.3).  More recent evidence suggests that phase II enzymes 
can display autoactivation kinetics as well.  In a study by Fisher et al. [17], kinetic 
profiles of estradiol-3-glucuronide and acetaminophen-O-glucuronide were best fit to the 
Hill equation, as Eadie-Hofstee plots of the data were indicative of autoactivation.  This 
observation is the first report involving autoactivation of glucuronosyltransferases in 
microsomal incubations, although bilirubin conjugation by UGT1A1 in hepatocytes has 
been shown to display autoactivation kinetics as well [18].  These data suggests that 
atypical kinetics may not be limited to phase I metabolic reactions.  
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1.4.  Substrate Inhibition  
 
Substrate inhibition is another atypical kinetic phenomenon that has been 
observed in in vitro studies.  Although the mechanism of substrate inhibition has yet to be 
fully determined, it has been described by a two-site model in which one binding site is 
productive, while the other site is inhibitory and operable at high substrate 
concentrations, resulting in decreased velocity with increasing concentrations [19].  One 
early study showed that tenoxicam 5’-hydroxylation by the CYP2C family strongly 
inhibits its own metabolism at concentrations higher than 100-150 µM [20].  
Interestingly, our lab has demonstrated that piroxicam 5’-hydroxylation also 
demonstrates substrate inhibition in both human liver microsomes and purified 
baculovirus expressed CYP2C9, although not in expressed CYP2C9 microsomes (T.S. 
Tracy et al.-submitted for publication).  Yet another CYP2C9 substrate displaying 
substrate inhibition kinetics is the new COX-2 selective NSAID celecoxib [21].  
Furthermore, Spracklin et al. [22] have observed that halothane metabolism by CYP2E1 
to trifluoroacetic acid and bromide displays substrate inhibition, one of the few examples 
of atypical kinetics with CYP2E1.  With regard to CYP3A4, Schrag and Wienkers [23] 
observed that triazolam 1’-hydroxylation displayed substrate inhibition kinetics at higher 
concentrations, confirmed by an Eadie-Hofstee plot, which showed a hook in the upper 
quadrant, indicative of substrate inhibition.  Most recently, Lin et al. [24] have observed 
substrate inhibition kinetics for several compounds that are routinely used as probes for 
particular CYP450 isoforms.  For example, CYP1A2-catalyzed ethoxyresorufin 
metabolism to resorufin, CYP2D6-catalyzed dextromethorphan metabolism to 
8 
dextrorphan, as well as testosterone and progesterone metabolism by CYP3A4 all 
displayed substrate inhibition kinetics [24].  The data for ethoxyresorufin is particularly 
interesting, considering the work done by Ekins and coworkers [15] suggesting 
autoactivation of ethoxyresorufin metabolism, not substrate inhibition.  At this time, the 
incongruency of these findings is not readily explained, though as stated earlier, enzyme 
source and inter-lab variability may be factors.  Several examples of substrate inhibition 
are shown in Table 1.3.   
1.5.  Partial Inhibition 
 
Partial inhibition occurs when a compound acting as either a substrate or inhibitor 
for a particular CYP450 isoform incompletely inhibits another substrate’s metabolism, 
even under saturating concentrations of the inhibitor.  It has been suggested that both 
substrate and inhibitor may have access to the reactive oxygen within the active site, 
forming a substrate-inhibitor-enzyme complex that is still productive [19].  It is no 
surprise then, that partial inhibition is often observed with CYP3A4, since this enzyme 
has been shown to accommodate multiple substrates simultaneously.  While studying the 
simultaneous metabolism of testosterone and erythromycin by CYP3A4, Wang et al. [25] 
observed that the inhibition mechanism for this interaction was not purely competitive.  
At a fixed concentration of 60 µM testosterone, the rate of 6β-hydroxylation was greatly 
reduced by high concentrations of erythromycin, suggesting competitive inhibition 
between substrates.  However, at higher fixed amounts of testosterone (250 and 500 µM), 
only partial inhibition of 6β-hydroxylation was observed [25].  This suggested that both 
compounds were being simultaneously metabolized, and may have distinct binding 
regions within the active site.  Wang and co-workers have also observed partial inhibition 
9 
by midazolam and terfenadine of CYP3A4-mediated testosterone metabolism [14].  In a 
similar study, Korzekwa et al. [3] discovered that phenanthrene displayed partial 
inhibition of 7,8-benzoflavone metabolism, while not affecting its Km, suggesting that 
7,8-benzoflavone was not displaced from the active site.  To date, few other identified 
examples exist for partial inhibition, although it is likely that this phenomenon has been 
observed for other CYP isoforms, and not labeled as such, or perhaps saturating inhibitor 
concentrations were not reached.  
1.6.  Biphasic Kinetics  
 
A biphasic kinetic profile is characterized by an initial Michaelis-Menten-like 
increase in velocity with increasing substrate concentration. However, the profile does 
not become asymptotic, with the reaction profile eventually becoming linear with 
increasing substrate concentration.  This results in the inability to predict an apparent 
Vmax and thus, Km.  Some examples include naproxen demethylation by CYP2C9, in 
which saturation is unobtainable up to 1800 µM, and CYP3A4-mediated naphthalene 
metabolism to 1-naphthol [3].  More recent evidence for biphasic kinetics includes 7-
ethoxycoumarin O-deethylation and aminopyrine N-demethylation in recombinant yeast 
microsomes expressing rat CYP1A1 and yeast NADPH-P450 reductase [26].  This is the 
first report showing atypical kinetics of P4501A1-mediated 7-ethoxycoumarin 
metabolism, an often used probe for CYP1A1 activity.  In addition, Oda et al. [27] 
discovered that levo-α-acetylmethadol (LAAM) demethylation, as well as nor-LAAM 
demethylation to dinor-LAAM exhibits biphasic Eadie-Hofstee plots in cDNA expressed 
CYP3A4 enzyme.  Most recently, it was discovered that the rates of 4-nitrophenol and 
formaldehyde production from the O-demethylation of 1-methoxy-4-nitrobenzene by 
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CYP1A2 isolated from rabbit liver produced biphasic plots [28].  As suggested by the 
above studies, examples of biphasic kinetics are becoming more prevalent, with several 
CYP isoforms apparently exhibiting this type of behavior (Table 1.4).   
1.7.  Mechanistic Models of Atypical Kinetics  
 
Since the first observation of 7,8-benzoflavone activating the metabolism of 
benzo[a]pyrene, much effort has been put forth to understand the mechanism of this and 
other atypical kinetic events.  Shou et al. [9] first suggested that both substrate and 
activator may be simultaneously present in the active site, both having access to the 
reactive oxygen.  This conclusion was based on kinetic evidence that 7,8-benzoflavone 
increased the Vmax of phenanthrene metabolism without changing the Km.  Conversely, 
phenanthrene decreased the Vmax of 7,8-benzoflavone metabolism without increasing the 
Km, suggesting that neither compound displaces the other from the active site, resulting in 
near-simultaneous metabolism.  This study provided the first indirect evidence that more 
than one molecule could be present in, and influence the active site.  In related and 
perhaps the most comprehensive initial work examining atypical kinetics, Korzekwa et 
al. [3] provide further evidence for the theory of multiple binding regions within the 
active site.  This group suggested that a two-site binding model may be used to describe 
all atypical kinetic observations, including those observed in isoforms other than 
CYP3A4.  Korzekwa and coworkers also demonstrated several of the theoretical 
saturation profiles for an enzyme showing sigmoidal, biphasic, and substrate inhibition 
kinetics, comparing the Km and Vmax parameters of the two proposed binding sites.  One 
of the most interesting observations from this study was that of the biphasic metabolism 
of naproxen by CYP2C9, as well as naphthalene by CYP3A4.  The authors suggest that 
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this profile may also be explained by a two site binding model, one site having a low 
affinity (Km), low capacity (Vmax), the other with high affinity and high capacity.  This 
type of profile is similar to that of a two-enzyme model, except that the data is derived 
from a single purified or expressed enzyme.  
Site-directed mutagenesis studies by Harlow and Halpert [29] have added 
compelling structural evidence supporting the multi-site hypothesis.  Their group 
constructed a L211F/D214E double mutant of CYP3A4, which was designed to mimic 
the action of effector (7,8-benzoflavone) by reducing the size of the active site with the 
bulkier phenylalanine and glutamate residues.  Results showed that the double mutant 
exhibited an increased rate of testosterone and progesterone 6β-hydroxylation and a 
lower level of activation by 7,8-benzoflavone, suggesting that the active site was the most 
likely location of activator (effector) binding.  In addition, studies have shown that 
residues 301, 304, 305, and 309, predicted to be within substrate recognition site 4 of 
CYP3A4, are also involved in steroid and effector binding [30;31].  Other studies 
supporting the multi-site hypothesis include those of Ngui et al. [12] and Schrag and 
Wienkers [23].  Briefly, Ngui and coworkers observed that quinidine stimulated 
diclofenac metabolism, while maintaining normal access to the ferriheme-oxygen 
complex, while Schrag and Wienkers observed an alteration of the metabolite ratio (4-
hydroxy triazolam/1’-hydroxy triazolam) for triazolam due to the presence of 
testosterone, referred to as differential kinetics (when an effector activates the 
metabolism of a given substrate at one position but inhibits metabolism at a different 
position).  In addition, Hosea et al. [32] provide evidence for multiple binding sites for 
CYP3A4 through spectral binding studies with a number of CYP3A4 substrates and a 
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series of peptide ligands, while Szklarz and Halpert [33] have generated a three-
dimensional homology model of CYP3A4, which shows the ability to dock multiple 
substrates, or substrate and effector within the active site simultaneously. 
In agreement with Korzekwa et al., Lin et al. [24] suggest that substrate inhibition 
may be explained by a two-site binding model, in which the two sites may either be 
neighboring or distant from each other within the active site.  They hypothesize that in 
the case of substrate inhibition, one site is favorable for oxidation, while the other site is 
nonproductive, which differs from the theory that both sites may have access to the 
reactive oxygen.  This is further explained by suggesting that when a substrate binds to 
the inhibitory site (at high concentrations), the complex (SES) is less capable of forming 
product than the ES complex.  A scheme representing the possible enzyme-substrate-
effector interactions and product formation has been presented in a recent paper by Shou 
et al. [19].  Nonetheless, whether one or the other or both sites are productive will likely 
depend on the physical and chemical properties of the compounds in question.   
Though most studies show evidence for a multi-site binding model, other 
possibilities such as the presence of an allosteric site have not been completely disproven.  
Ueng et al. [34] suggested an allosteric model for CYP3A4, although the proximity of the 
allosteric site relative to the active site is not defined.  Another study hypothesized that as 
many as three conformers of CYP3A4 exist, based on kinetic studies of carbon monoxide 
binding, depending on the substrate bound to CYP3A4 [35].  This group later suggested 
that activation of benzo[a]pyrene (BaP) metabolism by 7,8-benzoflavone resulted from 
an allosteric mechanism in which the presence of 7,8-benzoflavone converts an 
unproductive enzyme conformation to a productive one, resulting in increased levels of 
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BaP metabolite [36].  One of the most intriguing explanations for the cause of atypical 
kinetics is one in which the multiple binding-site model and a conformationally based 
model are combined, as suggested by Atkins et al. [37].  The author’s reasoning is that 
multiple conformations alone can not account for sigmoidal velocity versus substrate 
concentration curves, while the multiple binding-site theory does not fully explain the 
lack of reciprocal effects of certain drug interactions.  Therefore, a scheme is proposed by 
which two enzyme conformers are in equilibrium, and each conformer can bind two 
substrates at a single active site.  Another possibility suggested by Ekins et al. [15] is the 
contribution of water molecules in the active site and hydrogen bonding.  They theorized 
that the displacement of water molecules by a second substrate or effector may cause 
fluctuations in the conformation of the enzyme, perhaps leading to changes in active site 
characteristics and enhanced catalytic activity.  
The interaction between CYP450 and cytochrome b5 and oxidoreductase may 
also be involved in the production of atypical kinetic profiles.  It is possible that effector 
binding increases or enhances the interaction of CYP450 with either or both cytochrome 
b5 and oxidoreductase.  However, Ngui et al. [12] were able to exclude the role of 
cytochrome b5 in the stimulation of diclofenac metabolism by quinidine, as the effect of 
quinidine was maximal in the absence of cytochrome b5.  In addition, Ngui and 
coworkers observed no change in cytochrome c reduction by oxidoreductase in the 
presence of quinidine.  Similarly, our lab has observed that flurbiprofen 4’-hydroxylation 
is activated by dapsone, despite the absence of cytochrome b5 (T.S.T. and J.M.H., 
unpublished observations).  However, in a study using rat liver microsomes by Lee et al. 
[38], it is suggested that the mechanism of cytochrome P450 activation involves electron 
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transfer steps, likely from cytochrome b5.  This was based on the observation that the 
formation of NAPQI from acetaminophen was not stimulated by 5 mM caffeine or 50 
µM 7,8-benzoflavone in liver microsomes when supported with cumene hydroperoxide 
via the peroxide shunt, while approximately 3-fold activation was observed for both 
caffeine and 7,8-benzoflavone in NADPH-supported incubations [38].  In addition, Lee 
and coworkers observed that an inhibitory cytochrome b5 antibody significantly 
diminished the activation of NAPQI formation by caffeine, but not 7,8-benzoflavone, 
suggesting different mechanisms of activation by these compounds.  Interestingly, 
Yamazaki et al. [39] observed that apo-b5 (without heme), was as effective as holo-b5 
(with heme) in stimulating testosterone 6β-hydroxylation and nifedipine oxidation in a 
system containing NADPH-P450 reductase, suggesting that b5 may activate CYP3A4 by 
inducing a conformational change in the enzyme, and not by increasing electron flow.  
However, it has recently been suggested that apo-b5 may be converted to holo-b5 by a 
heme transfer reaction from the CYP3A4 preparation, which may explain stimulation of 
CYP3A4 activity [40]. 
While much evidence exists for the preceding mechanisms of atypical kinetics, no 
one theory has been proven conclusively.  It is possible that one or a combination of the 
above- mentioned mechanisms, or some as yet undetermined mechanism(s) is/are likely 
operable and contributing to the atypical kinetic profiles of many drugs.   
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1.8.  Kinetic Modeling of Atypical Kinetics 
 
Along with observing atypical kinetic profiles comes the task of determining how 
to properly model the data, so as to generate accurate kinetic parameter estimates.  As 
mentioned previously, atypical kinetic profiles have in the past likely been overlooked or 
ignored.  However, it is now apparent that ignoring or truncating nonhyperbolic data can 
lead to erroneous kinetic parameter estimates, as standard Michaelis-Menten hyperbolic 
curves are forced through the data, rather than the use of a more appropriate kinetic 
model.  For example, it has been suggested that substantial underestimation of Vmax may 
occur when substrate inhibition is observed if the high concentration data points are 
ignored [41].  This is validated by Lin and co-workers, who observed that the estimated 
Vmax values for several reactions showing substrate inhibition were 0.91- to 1.8-fold 
lower when fitted to the Michaelis-Menten equation, rather than a more appropriate 
substrate inhibition equation [24].  Likewise, Houston and Kenworthy [41] suggest that 
for a sigmoidal kinetic profile, either underestimation or overestimation of intrinsic 
clearance (Clint) may occur if a hyperbolic curve is forced through the data, with the Km 
(S50) term most likely affected.  Therefore, it is imperative that the proper kinetic model 
be used to estimate kinetic parameters from the data, although there may be several 
solutions that satisfactorily model the same set of data [42].  With respect to the equations 
used for modeling atypical kinetic data, most have been derived to describe the presence 
of multiple binding sites within the active site.  A comprehensive discussion of the 
modeling of atypical kinetic data and the equations typically used can be found in several 
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articles [3;41;43;44], with each showing enzyme-substrate-effector kinetic schemes from 
which these equations are generated. 
 
1.9.  Artifactual Sources of Atypical Kinetics 
 
Though the presence of atypical kinetics appears to be real, it is important to 
perform experiments in a fashion so as to eliminate any artifactual causes of atypical 
kinetic profiles.  Several examples of artifactual sources of sigmoidicity and substrate 
inhibition have been mentioned by Houston and Kenworthy [41].  Examples cited include 
significant substrate depletion, nonspecific binding of substrate to the incubation matrix, 
cellular active transporter systems, lack of analytical sensitivity, and low substrate 
solubility.  Significant substrate depletion results in deviations from initial rate 
conditions, and leads to erroneous estimation of kinetic parameters, even in the absence 
of atypical kinetics.  As a result, it is important to monitor substrate consumption, and 
even effector consumption, if the effector happens to be metabolized as well.  
Nonspecific binding to microsomal proteins has been shown to be another potential 
problem in in vitro studies [45;46].  One such example is the observation that addition of 
750 µg/ml inactive control microsomes produced a 1.8-fold increase in the apparent S50 
for amitriptyline metabolism, although no effect on the Vmax or Hill coefficient was 
observed [46].  As a result, it may be beneficial to run the experiment at the lowest 
possible protein concentration to help avoid any artifactual results.  With respect to low 
analytical sensitivity and solubility issues, these cause a lack of confidence in 
quantitation or “effective” substrate concentration at the low, and high end of the 
concentration range, respectively.  In addition, Houston and Kenworthy suggest attaining 
17 
a minimum of ten data points before concluding the presence of atypical kinetic profiles.  
Meanwhile, Shou et al. [43] suggest attaining upwards of 20-30 data points, especially 
around the inflection points to better define the fitted curve.   
Other considerations when conducting these types of studies may be salt and 
organic solvent concentrations in the incubation.  Schrag and Wienkers [47] have 
observed that pyrene metabolism by CYP3A4 is sigmoidal in the absence of magnesium, 
but biphasic in the presence of 10 mM magnesium.  In this work, evidence suggested a 
change in CYP3A4 active site conformation in the presence of magnesium, resulting in 
the different kinetic profile.  In a similar study, Maenpaa et al. [10] observed that the 
addition of 5 and 50 mM MgCl2 to microsomal incubations resulted in minimal changes 
in midazolam 1’-hydroxy and 4-hydroxy metabolites, while the addition of 150 mM 
MgCl2 resulted in substantial inhibition of both metabolites.  Meanwhile, 1’-hydroxy and 
4-hydroxy midazolam formation was completely inhibited by 30 mM CaCl2 in 
microsomal incubations.  In another study, acetonitrile and acetone were found to activate 
the NADPH-dependent tolbutamide hydroxylation nearly 3-fold in human liver 
microsomes and CYP2C9-reconstituted system when incubated at 2 to 4% final organic 
solvent concentrations [48].  From these examples, it is evident that investigators must 
remain cognizant of the many different conditions that may be artifactual sources of 
atypical kinetics.  In addition, the above list is probably not all inclusive and thus, there 
may be other confounding factors involved in the observation of atypical kinetics as well. 
 
1.10.  In vivo Considerations 
 
Although it is known that atypical kinetics exist in vitro, an important question is 
whether they also occur in vivo, since they may have considerable pharmacological or 
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toxicological implications.  However, according to Houston and Kenworthy [41], 
whether or not these types of interactions occur in vivo, and if they are clinically relevant 
is not the primary issue.  Even if these interactions are not observed in vivo, their 
presence in vitro will affect how data is scaled from the in vitro to the in vivo situation.  
Thus, it is best to fully describe the in vitro data and then abstract the useful parameter(s) 
for extrapolation [41].  Nonetheless, in vivo studies designed to determine the presence of 
atypical kinetics would be beneficial, but only a few have actually been performed.  The 
first example of activation of drug metabolism in vivo were studies by Lasker et al. 
[49;50], who observed that the i.p. administration of flavone, nobiletin, tangeretin or 7,8-
benzoflavone concurrently with zoxazolamine immediately stimulated the total body 
metabolism of zoxazolamine to its 6-hydroxy metabolite in neonatal rats in a time course 
consistent with activation.  This activation was found to be dose and dosing-time 
dependent, as little activation of zoxazolamine metabolism was observed with a low dose 
of zoxazolamine, as well as when the activator was administered 2-4 hours before 
zoxazolamine [50].  It is noteworthy that Lasker and co-workers explored the possibility 
that the flavone compounds could activate zoxazolamine metabolism by displacing it 
from binding sites on plasma protein or from binding sites in the total body homogenates 
by performing equilibrium dialysis studies. Results showed no difference in 
zoxazolamine binding in the presence of flavone.  Based on this observation, it was 
determined that this activation in rats was likely CYP450-mediated, and thus the first 
noted example of in vivo activation of drug metabolism.   
More recently, it has been discovered that activation of CYP450-mediated drug 
metabolism may be observed in vivo in monkeys.  In previous studies, Tang et al. [51] 
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observed that the formation of diclofenac metabolites via CYP3A4 increased more than 
4-fold in human liver microsomes in the presence of quinidine.  Since similar results 
were seen in monkey liver microsomes, Tang and co-workers followed this work with an 
in vivo study in monkeys and observed that in the presence of quinidine, diclofenac 
clearance was enhanced in three male rhesus monkeys by 57, 56, and 56%, respectively 
[51].   The plasma protein binding and blood/plasma ratio of diclofenac remained 
unchanged in the presence of quinidine, and plasma samples were taken in a time frame 
too short for the de novo synthesis of CYP proteins.  This suggested that the interaction 
was CYP450-mediated and the reduction in diclofenac levels compared to control was 
not due to induction [51].  To date, no in vivo studies have been conducted to see if this 
atypical kinetic phenomenon may be observed in humans.   
 
1.11.  Cytochrome P450 2C9 
 
 
With the substantial increase in examples of atypical kinetics over the past few 
years, much work needs to be done to better understand and predict these events and the 
contributing isoforms.  To date, most work has been done studying atypical kinetics in 
CYP3A4.  However, as mentioned in the previous sections, other CYP450 isoforms have 
been shown to exhibit atypical kinetics as well, including the CYP2C9 isoform.  Few 
studies have been conducted on the atypical kinetics displayed by this isoform.  As a 
result, the work described herein will focus on the CYP2C9 isoform, and factors that 
regulate its activity, including exploring potential mechanisms of atypical kinetics, and 
whether they occur in vivo. 
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The CYP2C enzyme subfamily found in the human liver comprises approximately 
20% of total hepatic CYP enzymes [52;53], with CYP2C9 being the major isoform.  The 
CYP2C9 protein is composed of 490 amino acids, with a calculated molecular mass of 
~55.6 KDa, and is responsible for metabolizing a vast array of xenobiotic substrates, 
most of which are weak acids with pKa values ranging from 3.8-8.1 [54].  Examples 
include (S)-warfarin [55], phenytoin and tolbutamide [56], and several non-steroidal anti-
inflammatory drugs, including diclofenac [57], ibuprofen [58], piroxicam [20], naproxen 
[59;60], and flurbiprofen [61;62].  A comprehensive review of CYP2C9 substrates and 
inhibitors has been presented by Miners and Birkett [54].  Interestingly, CYP2C9 is 
polymorphic, with three alleles originally being identified as wild-type (CYP2C9*1), the 
R144C variant (CYP2C9*2), and the I359L variant (CYP2C9*3), and allele frequencies 
of 0.86, 0.08 and 0.06, respectively [63;64].  Recently, however, an I359T (CYP2C9*4) 
allelic variant was identified in Japanese epileptic patients [65], while a D360E 
(CYP2C9*5) variant was discovered that is apparently only expressed among African 
Americans at an allele frequency of 0.03 [66].  These allelic variants of CYP2C9 have 
been shown to variably affect the metabolism of a number of CYP2C9 substrates.  For 
example, CYP2C9*2 (R144C) allelic variant has been shown to reduce the Vmax for 
tolbutamide methyl-hydroxylation by up to threefold [64;67].  In addition, Crespi and 
Miller [68] observed that the R144C variant exhibited similar apparent Km values for (S)-
warfarin, diclofenac, and lauric acid hydroxylation compared to wild-type CYP2C9 
enzyme, but had slower rates of metabolism.  Meanwhile, CYP2C9*3 has a reduced 
capacity to metabolize (S)-warfarin [69], while CYP2C9*2 seems to not affect the 
apparent Km for (S)-warfarin 7-hydroxylation [67].  Lastly, the CYP2C9*4 variant has 
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been shown to decrease the apparent intrinsic clearance of diclofenac compared to wild-
type, primarily due to an effect on Vmax [70].   Although the allele frequencies for these 
variants are small, the fact that these amino acid changes generally cause a decrease in 
metabolic capacity has led to many questions about enzyme active site structure, and 
recognition of substrates. 
It has been proposed that CYP2C9, along with other CYP2 family isoforms, has 
six substrate recognition sites (SRSs), which variably contribute to the recognition and 
binding of certain substrates [71].  Many studies have evolved from this finding in an 
attempt to better understand the substrate selectivity of CYP2C9, as well as the binding 
interactions within the active site and overall three-dimensional structure of this protein.  
Initially, a three-dimensional  model of CYP2C9 was constructed by Korzekwa and Jones 
[72], which was based on amino acid sequence alignment data and the crystal structure of 
the bacterial enzyme CYP101.  This homology model was considered to have low 
resolution, and thus of limited utility in the prediction of substrate binding by CYP2C9.  
Other molecular modeling techniques, such as pharmacophore modeling, have been 
performed to probe the active site binding interactions of CYP2C9.  Jones et al. [73] 
rationalized the substrate specificity of nine substrates and one inhibitor of CYP2C9 in 
terms of a hydrogen bond donor/acceptor model to propose an active site template model.  
This model was described by A, the distance between the site of metabolism (Y) and the 
hydrogen bond donor heteroatom (X), and C, the angle between this and the hydrogen 
bond, with mean dimensions for the nine substrates and one inhibitor of A = 6.7 ± 1.0 Å, 
C = 133 ± 21°.  Mancy et al. [74] generated a pharmacophore model by analyzing the 
ability of 10 derivatives of tienilic acid, a known substrate of CYP2C9, to be 
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metabolized.  Results showed that only derivatives containing an acidic function 
underwent a 5-hydroxylation of their thiophene ring like tienilic acid.  In addition, the 
nonacidic derivatives were unable to competitively inhibit the hydroxylation of tienilic 
acid, suggesting that they not only did not undergo hydroxylation, but also were not 
recognized by the CYP2C9 enzyme.  This suggested that most substrates for CYP2C9 
interact through their acidic anionic site with a cationic residue of the CYP2C9 protein.  
One study in particular observed that arginine 97 is important for diclofenac 
hydroxylation, suggesting the presence of an important cationic binding region in the 
active site, since when this amino acid was mutated to a neutral moiety, diclofenac 
hydroxylation was greatly reduced [75].  Other studies confirm the importance of an 
anionic binding region within the CYP2C9 active site [76;77], both of which also 
mention the importance of a hydrophobic zone between the substrate hydroxylation site 
and the anionic site.  In addition, a molecular model of CYP2C9 was generated using the 
3D-QSAR method CoMFA (comparative molecular field analysis) and 29 coumarin ring-
containing compounds to evaluate both steric and electrostatic interactions within the 
active site[78].  This predictive model has since been updated with 14 new compounds 
[79], due in part to the findings of Haining et al. [80] who observed the importance of a 
hydrophobic residue within the CYP2C9 active site.  More specifically, it was observed 
that an F114L mutant decreased the Vmax for (S)-warfarin 7-hydroxylation 4-fold, and 
increased the Km 13-fold, suggesting the ability of certain aromatic ligands to π-stack to 
the F114 residue, with the L114 residue apparently eliminating this interaction.  Another 
QSAR study analyzing CY2C9 competitive inhibitors has been performed by Ekins et al. 
[81].  This group generated a 3D/4D QSAR pharmacophore model of the common 
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structural features of CYP2C9 inhibitors using Catalyst, a commercially available 3D-
QSAR technique that does not require manual alignment of molecules, unlike the 
CoMFA studies of CYP2C9 [78;79].  Meanwhile, Afzelius et al. [82] generated a 3D-
QSAR model for 29 structurally diverse competitive inhibitors of CYP2C9, and 
performed molecular modeling studies with the help of a homology model of CYP2C9, 
based on the coordinates of rabbit CYP2C5, the first mammalian CYP enzyme for which 
there is a crystal structure [83].  Results from this study showed the ability to predict Ki 
values to within 0.5 log units of the experimental Ki values, which was more robust than 
the QSAR method by Ekins et al. [81].   
Cytochrome P4502C9 has usually been considered to be a well-behaved enzyme 
that follows the rules of normal Michaelis-Menten type kinetics.  However, it is now 
becoming clear that CYP2C9 shows some atypical kinetic profiles similar to CYP3A4, 
most notably activation by dapsone [3].  In this study, Korzekwa’s group suggested that 
activation, as well as other atypical kinetics events, may be explained by a model that 
suggests the presence of multiple binding regions within the CYP450 active site, each 
having its own kinetic characteristics.  However, only one group has explored this theory 
in their pharmacophore models.  This study explored the differences in metabolic 
stability between warfarin and phenprocoumon by CYP2C9, and provided evidence to 
support the multiple binding theory, as two binding sites were proposed, a π-stacking site 
and an ionic binding site for organic anions [84].  This finding is similar to the other 
pharmacophore studies previously mentioned, but is the first to interpret these sites as 
being distinct regions in the active site.  Despite these suggestions, minimal kinetic data 
from CYP2C9 has been generated to provide evidence for this theory.  The studies 
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described herein show the ability to kinetically model activation of CYP2C9-mediated 
metabolism of several compounds by dapsone with a two-binding site effector model, 
along with further evidence for the presence of multiple binding regions within the 
CYP2C9 active site.  In addition, other factors involved in the mechanism of activation of 
CYP2C9 will be explored to provide information necessary for eventually generating a 
pharmacophore model of multiple binding regions within the CYP2C9 active site.  
 
1.12.  Research Study Objectives 
 
1. Kinetically model dapsone activation of CYP2C9-mediated flurbiprofen 4’-
hydroxylation, naproxen O-demethylation, and piroxicam 5’-hydroxylation, as 
well as explore the effect of flurbiprofen on dapsone N-hydroxylation. 
2. Determine the structural requirements of dapsone activation of CYP2C9 by 
screening 17 analogs of dapsone for activation of flurbiprofen, naproxen, and 
piroxicam metabolism in human liver microsomes, followed by full kinetic 
studies to observe the effect of different concentrations of effector on CYP2C9 
activity. 
3. Explore other studies for understanding the mechanism of activation of CYP2C9, 
including the use of CYP2C9/19 chimeric enzymes, CYP2C19 mutant enzymes, 
spectral binding studies with CYP2C9, activation of CYP2C9 allelic variants, 
dapsone metabolite activation of CYP2C9, and alteration of regiospecificity of 
ibuprofen metabolism.  
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4. Validate a urine and plasma HPLC assay for use in analyzing samples to 
determine if activation of flurbiprofen 4’-hydroxylation by dapsone also occurs 
in vivo in humans. 
5. Analyze urine and plasma samples and perform pharmacokinetic modeling for a 
clinical study exploring the ability of dapsone to activate flurbiprofen 4’-
hydroxylation in 12 human subjects.   
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Table 1.1.  Reported Examples of Activation Kinetics 
Examples of activation kinetics (heterotropic positive cooperativity) reported in the 
literature in various in vitro systems. 
 
Enzyme Source Substrate Pathway Effector Reference 
RLMa Benzo[a]pyrene Hydroxylation 7,8-benzoflavone [5] 
HLMb Benzo[a]pyrene Hydroxylation 7,8-benzoflavone [7] 
HLM Progesterone 6β-hydroxylation 7,8-benzoflavone [4] 
HLM 17β-estradiol 2-hydroxylation 7,8-benzoflavone Ibid. 
HepG2 expressed CYP3A4 Phenanthrene Hydroxylation 7,8-benzoflavone [9] 
HepG2 expressed CYP3A4 Phenanthrene Hydroxylation 7,8-benzoflavone [3] 
E. coli purified CYP3A4  AflatoxinB1 8,9-epoxidation 7,8-benzoflavone [34] 
E. coli purified CYP3A4  Carbamazepine 10,11-epoxidation 7,8-benzoflavone Ibid. 
HLM Diazepam Hydroxylation 7,8-benzoflavone [85] 
HLM Diazepam N-demethylation 7,8-benzoflavone Ibid. 
HLM Phenacetin O-deethylation 7,8-benzoflavone [86] 
HLM Midazolam 4-hydroxylation Testosterone [10] 
HLM and B-lymphoblastoid 
expressed CYP3A4c 
Midazolam 4-hydroxylation Testosterone [14] 
HLM and B-lymphoblastoid 
expressed CYP3A4c 
Meloxicam 5’-methylhydroxylation Quinidine [11] 
HLM and B-lymphoblastoid 
expressed CYP3A4c 
Diclofenac 5-hydroxylation Quinidine [12] 
HLM and B-lymphoblastoid 
expressed CYP3A4c 
Warfarin 4’-and 10-hydroxylation Quinidine [13] 
Baculovirus purified CYP2C9  Flurbiprofen 4’-hydroxylation Dapsone [3] 
a rat liver microsomes, b human liver microsomes, c obtained from Gentest 
 
 
 
 
 
 
 
27 
Table 1.2.  Reported Examples of Autoactivation Kinetics 
Examples of autoactivation kinetics (homotropic positive cooperativity).   
For a more comprehensive review, see Ekins et al., 1998a. 
 
Enzyme Source Substrate Pathway Reference 
Baculovirus expressed CYP3A4 Diazepam Hydroxylation [43] 
Baculovirus expressed CYP3A4  Diazepam Demethylation Ibid. 
Vaccinia expressed CYP2C9 Dapsone Hydroxylation [3] 
B-lymphoblastoid expressed 
CYP2B6a 
Testosterone 16β-hydroxylation [16] 
HLMb Estradiol 3-glucuronidation [17] 
HLM Acetaminophen O-glucuronidation Ibid. 
a obtained from Gentest, b human liver microsomes 
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Table 1.3.  Reported Examples of Substrate Inhibition Kinetics 
Substrates reported to display substrate inhibition kinetics in various in vitro  
systems. 
 
Enzyme Source Substrate Pathway Reference 
HLMa Tenoxicam 5’-hydroxylation [20] 
cDNA-expressed CYP2E1b Halothane TFA formationc [22] 
cDNA-expressed CYP2E1b Halothane Bromide formation Ibid. 
HLM Fluoxetine Demethylation [87] 
HLM Fluoxetine Demethylation [88] 
HLM Triazolam 1’-hydroxylation [23] 
HLM Celecoxib Hydroxylation [21] 
Baculovirus expressed CYP2C9  Celecoxib Hydroxylation [24] 
Baculovirus expressed CYP1A2 Ethoxyresorufin Resorufin formation Ibid. 
Baculovirus expressed CYP3A4 Benzyloxyresorufin Resorufin formation Ibid. 
Baculovirus expressed CYP2D6  Dextromethorphan O-demethylation Ibid. 
Baculovirus expressed CYP3A4 Progesterone 6β-hydroxylation Ibid. 
Baculovirus expressed CYP3A4  Testosterone 6β-hydroxylation Ibid. 
a human liver microsomes, b obtained from Gentest, c trifluoroacetic acid 
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Table 1.4.  Reported Examples of Biphasic Kinetics 
Substrates reported to display biphasic kinetics in various in vitro systems. 
 
Enzyme Source Substrate Pathway Reference 
Vaccinia expressed CYP2C9  Naproxen O-demethylation [3] 
Baculovirus expressed CYP3A4  Naphthalene Hydroxylation Ibid 
Yeast expressed CYP1A1 7-ethoxycoumarin O-deethylation [26] 
Yeast expressed CYP1A1  Aminopyrine N-demethylation Ibid. 
HLMa and cDNA-expressed CYP3A4 Levo-α-acetylmethadol Demethylation [27] 
HLM and cDNA-expressed CYP3A4 Nor-levo-α-acetylmethadol Demethylation Ibid. 
E. coli purified CYP1A2 b 1-methoxy-4-nitrobenzene O-demethylation [28] 
a human liver microsomes, b rabbit enzyme 
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CHAPTER II 
 
 
 
Dapsone Activation of CYP2C9-Mediated Metabolism: 
Evidence for Activation of Multiple Substrates and a Two-Site 
Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter published in Drug Metabolism and Disposition [29, 1029-1034 (2001)]. 
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2.1.  Introduction 
 
It is becoming evident that many cytochrome P450-catalyzed reactions do not 
proceed with typical Michaelis-Menten kinetics.  Observations of atypical kinetic events 
such as activation, autoactivation, and substrate inhibition are becoming increasingly 
common, with the term “cooperativity” often being used to describe these types of 
phenomena.  To date, CYP3A4 has been the most studied isoform with respect to atypical 
kinetics due to the large number of reactions that it catalyzes and the complexity of its active 
site.  However, other relevant P450s have been shown to participate in a number of these 
abnormal kinetic events [1-3], making analysis of in vitro data problematic.  As a result, it 
has been suggested that atypical kinetics must be considered during in vitro-in vivo scaling of 
kinetic data.  Houston and Kenworthy [4] have demonstrated that failure to properly assess 
atypical kinetics may result in under or overestimation of in vivo clearance of drugs when 
based on in vitro kinetic parameter estimates.  Therefore, it is imperative that the cause and 
mechanism of these events be determined, as well as the isoforms affected.  
Our lab has previously demonstrated that CYP2C9-mediated flurbiprofen 4’-
hydroxylation and naproxen demethylation are activated by dapsone in human liver 
microsomes and baculovirus-expressed CYP2C9 [2].  However, kinetic effects of this 
activation have yet to be fully characterized.  While flurbiprofen is exclusively metabolized 
by CYP2C9 [5] and shows normal Michaelis-Menten kinetics [6], naproxen is metabolized 
by CYP2C9 and CYP1A2 [7;8] and has been shown to exhibit non-saturable biphasic 
kinetics in microsomes [7], as well as in expressed CYP2C9 [2].  The unsaturable metabolic 
profile observed in expressed CYP2C9 suggests that there may be two binding components 
within the CYP2C9 active site, one with a low Km, low Vmax, the other with a high Km and 
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high Vmax, similar to naphthalene metabolism by CYP3A4 [2].  Piroxicam, another NSAID 
reported to be metabolized by CYP2C9 [9], has been shown to exhibit atypical kinetics as 
well (substrate inhibition) in baculovirus expressed CYP2C9 (unpublished results), and has a 
quite different structure than either flurbiprofen or naproxen.  
Dapsone is a compound used to treat Pneumocystis carinii pneumonia in AIDS 
patients, and is metabolized by CYP2C9 at therapeutic concentrations to its hydroxylamine 
metabolite [10;11].  Thus, it appears that dapsone is also a substrate for the enzyme it 
activates, suggesting that dapsone may cause activation by binding in the active site of 
CYP2C9.  This scenario is analogous to 7,8-benzoflavone, which activates CYP3A4-
mediated phenanthrene metabolism, in addition to being a substrate for CYP3A4 [1].  
The purpose of the current study was to determine the effect of dapsone on the 
kinetics of (S)-flurbiprofen, (S)-naproxen, and piroxicam, three prototypical substrates of 
CYP2C9 with differing structures and kinetic profiles (Figure 2.1).  It was hypothesized that 
a kinetic model which suggests that both the substrate and effector may be present in the 
active site simultaneously, both having access to the active oxygen was applicable [1;2;12].  
Thus, kinetic data from expressed CYP2C9 were fit to the two-site model (equation 2.3) in 
addition to either the Michaelis-Menten equation (equation 2.1) or a two-site biphasic model 
(equation 2.2).  If our hypothesized two-site model for CYP2C9 is accurate, and the activator 
(dapsone) also serves as a substrate, then theoretically, near-simultaneous metabolism should 
occur, and metabolites from both compounds should be measurable.  Therefore, the effect of 
flurbiprofen on dapsone hydroxylation kinetics was also examined by measuring dapsone 
hydroxylamine formation and fitting data to the Michaelis-Menten equation.   
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2.2.  Methods 
 
Chemicals and reagents.  Acetonitrile and dibasic potassium phosphate were 
obtained from Fisher Scientific Co. (Pittsburgh, PA).  (S)-Flurbiprofen, 4’-hydroxy 
flurbiprofen, and 2-fluoro-4-biphenyl acetic acid (internal standard) were gifts from 
Pharmacia, Inc. (Kalamazoo, MI). (S)-naproxen and desmethylnaproxen were gifts from 
Syntex Laboratories Inc. (Palo Alto, CA).  Piroxicam and dapsone were obtained from 
Sigma Chemical Co. (St. Louis, MO), while 5’-hydroxy piroxicam was a gift from Pfizer 
Inc. (Groton, CT.).  Dapsone hydroxylamine was synthesized by the method of Uetrecht et 
al. [13] and was a gift from Robert Branch at the University of Pittsburgh.  All other 
chemicals were obtained from commercial sources and were of the highest purity available. 
Incubation Conditions.  Incubation mixtures in a 6X6 matrix design contained 1 pmol 
purified CYP2C9 (5 pmol for piroxicam) co-expressed with reductase (Camitro Corporation, 
Menlo Park, CA), with either (S)-flurbiprofen (2-300 µM), (S)-naproxen (10-1800 µM), or 
piroxicam (5-900 µM) incubated with dapsone (0-100 µM) in 50 mM potassium phosphate 
buffer at pH 7.4.  Final incubation volume was 0.2 ml and reactions were initiated with 1 mM 
NADPH and allowed to incubate at 37°C for 20 minutes (45 minutes for piroxicam).  
Incubations with flurbiprofen were quenched by adding 200 µl acetonitrile containing internal 
standard (180 ng/mL 2-fluoro-4-biphenylacetic acid), followed by addition of 40 µl ½-strength 
H3PO4.  Incubations with naproxen were quenched by adding 200 µl acetonitrile followed by 
addition of 40 µl ½-strength H3PO4, while piroxicam reactions were quenched by adding 20 µl 
perchloric acid, followed by directly placing incubation tubes on ice.  Samples from all 
incubations were then centrifuged at 10,000 rpm for 5 minutes, placed into autosampler vials, 
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and 10-100 µl injected onto HPLC system.   In experiments examining flurbiprofen effect on 
dapsone hydroxylamine formation, flurbiprofen concentrations were 0, 2, 5, and 10 µM, with 
dapsone concentrations ranging from 1-300 µM.  To prevent degradation of the dapsone 
hydroxylamine metabolite, 1 mM ascorbic acid was included in the 50 mM potassium phosphate 
buffer in those cases where this metabolite was being measured.  The reaction was stopped by 
the addition of 0.1 ml of cold methanol.  Samples were then spun at 20,000g for 5 minutes at 3°C 
in an Eppendorf 5417R centrifuge and 15 µl injected onto an LC/MS system for immediate 
dapsone hydroxylamine analysis to prevent instability issues.  All other conditions were as 
described above.   
Analysis of 4’-hydroxy flurbiprofen.  4’-Hydroxy flurbiprofen was analyzed by HPLC 
with fluorescence detection and comparison to a standard dissolved in 50:50 (v/v), 
acetonitrile:50 mM potassium phosphate buffer pH 7.4.  The HPLC system consisted of a 
Waters 501 HPLC pump, a Waters 717 autosampler and a Waters 470 fluorescence detector 
set at an excitation wavelength of 260 nm and an emission wavelength of 320 nm.  The mobile 
phase consisted of 45:55 (v/v), acetonitrile:20 mM K2HPO4, pH 3.0 pumped at 1 ml/min through 
a Brownlee Spheri-5 C18 4.6 x 100 mm column. 4’-Hydroxy flurbiprofen and internal standard 
eluted at approximately 2.2 and 4.8 minutes, respectively. 
Analysis of desmethylnaproxen.  Desmethylnaproxen was analyzed identically to 
4’-hydroxy flurbiprofen except that the fluorescence detector was set at an excitation 
wavelength of 230 nm and an emission wavelength of 340 nm, and no internal standard 
was used.  Desmethylnaproxen eluted at approximately 2.1 minutes. 
Analysis of 5’-hydroxy piroxicam.  5’-Hydroxy piroxicam was analyzed by HPLC 
with UV detection (365 nm).  The HPLC system was as described above, but was fitted 
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to a Waters 486 UV detector.  The mobile phase consisted of 50:50 (v/v), acetonitrile:50 
mM K2HPO4, pH 3.0 pumped at 1 mL/min through a Phenomenex Luna C18 5 µm, 4.6 x 
150 mm column.  Retention time for 5’-hydroxy piroxicam was approximately 4.3 
minutes.   
Analysis of dapsone hydroxylamine.  HPLC/ESI-MS was performed on a Perkin Elmer 
Sciex API 150ex single quadrupole mass spectrometer connected to a Perkin Elmer Series 200 
LC pump and autosampler.  The mass spectrometer was fitted with a turbo ion-spray source and 
operated in positive-ion SIM (selective ion monitoring) electrospray mode, with an ESI spray 
voltage of 5.0 kV and source temperature of 450°C.  The turbo ion-spray gas flow rate was set at 
7000 cc/min.  Tuning of the ESI source and MS was accomplished by infusing a solution 
containing 20 µg/ml dapsone hydroxylamine into the mobile phase flow path post column via a 
T connector using a Harvard Apparatus (Holliston, MA) manual injector.  The instrument was 
controlled by a Dell Optiplex GX1 computer running Analyst version 1.1 software.  Dapsone 
hydroxylamine formation was confirmed by appearance of the MH+ ion at m/z of 265.1, and 
chromatographic retention time corresponding to that of a synthetic standard dissolved in 
DMSO.  Stability of dapsone hydroxylamine metabolite was exhibited over the time required to 
analyze all of the incubation samples.  Analytical separation was accomplished using a Zorbax 
SB-C8 2.1 x 50 mm, 5 µm microbore column with a gradient elution profile.  Solvent flow 
through the column was 0.7 ml/min with 30% of the flow being diverted to the mass 
spectrometer.  Gradient elution consisted of mobile phase A [Methanol] and mobile phase B 
[100 mM Ammonium Acetate (pH 4.38)].  The gradient was initiated at a ratio of 10%A:90%B.  
This ratio was altered in a linear fashion to 80%A:20%B over 1 minute, and held for 2.4 minutes 
to allow elution of dapsone hydroxylamine.  The system was then returned to initial conditions 
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over 0.1 minutes and allowed to equilibrate for 4.4 minutes prior to the next injection.  The flow 
was diverted to waste for 1 minute post injection to prevent fouling of the interface from polar 
compounds in the solvent front.  Dapsone hydroxylamine eluted at approximately 2.9 minutes.   
Data Analysis and Equations.  Kinetic parameters for flurbiprofen, piroxicam, and dapsone 
hydroxylation were estimated using the nonlinear regression function in Sigma Plot (Version 
6.0), and the standard Michaelis-Menten velocity equation: 
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•
=   (2.1) 
Kinetic parameters for naproxen demethylation were estimated using a two-site biphasic  
equation: 
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where Clint is referred to as intrinsic clearance and represents the linear portion of the 
biphasic kinetic curve (Vmax2/Km2). 
The same data (36 points) from fits to equations 2.1 and 2.2 were also fit to a two-site model 
equation [2] utilized for surface plot analysis of flurbiprofen 4’-hydroxylation, naproxen 
demethylation and piroxicam 5’-hydroxylation in the presence of dapsone was as follows:  
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where S is the substrate, B is the effector, Vmax and Km are kinetic constants for substrate 
metabolism, KB is the binding constant for the effector, α is the change in Km resulting from 
effector binding, and β is the change in Vmax from effector binding.  For activation, α<1 
and/or β>1.   
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2.3.  Results 
 
Dapsone Activation of Purified CYP2C9.  The kinetic parameters for flurbiprofen 
and piroxicam hydroxylation were determined by fitting data to the Michaelis-Menten 
equation (equation 2.1), while parameters for naproxen demethylation were estimated by 
fitting data to a two-site biphasic model equation (equation 2.2).  Dapsone activated 
flurbiprofen 4’-hydroxylation in purified CYP2C9 (Figure 2.2), increasing Vmax from 
12.6 to 20.6 pmol/min/pmol P450 while lowering the Km from 28.9 to 10.0 µM (Table 
2.1).  Meanwhile, the Figure 2.3 shows that the Vmax for piroxicam hydroxylation was 
increased from 0.08 to 0.20 pmol/min/pmol P450, with the Km reduced from 183 to about 
50 µM (Table 2.1).  Likewise, naproxen demethylation was activated by the presence of 
dapsone with the data fit to a biphasic equation reflecting the kinetic profile of the 
reaction (Figure 2.4).  The Vmax for naproxen demethylation was increased from 11.7 to 
34.7 pmol/min/pmol P450, while the Km was decreased from 433 to 67.4 µM (Table 2.2), 
a greater-fold change than observed with either flurbiprofen or piroxicam.  While the 
Clint (Vmax2/Km2) value did not change, it contributed to a lesser extent in defining the 
kinetic profile of naproxen in the presence of dapsone (Table 2.2).  This is observed by 
the increase in Clint of the first naproxen binding site (Vmax1/Km1) from 0.027 with no 
dapsone to 0.52 in the presence of 100 µM dapsone, thus displaying that the Clint of the 
second site (Vmax2/Km2) contributes a smaller percentage to total naproxen demethylation 
when dapsone is present.  Kinetic parameters for flurbiprofen, naproxen and piroxicam 
metabolism were also estimated using the two-site model equation (equation 2.3).  Data 
from Table 2.3. further suggests that dapsone activates the metabolism of these three 
compounds, as all α values are below 1, and all β values are above 1.  It is also 
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interesting to note that the binding constant for dapsone varies according to the substrate 
being activated (Table 2.3).  The three-dimensional activation plot for flurbiprofen can be 
seen in Figure 2.5, demonstrating activation of flurbiprofen hydroxylation by dapsone.  
However, flurbiprofen appeared to not substantially affect the formation of dapsone 
hydroxylamine, as similar velocity curves were obtained in the presence of 0, 2, 5, and 10 
µM flurbiprofen (Figure 2.6).  Vmax values for dapsone hydroxylation ranged from 36-44 
pmol/min/pmol P450, while Km values ranged from 81-144 µM (data not shown).  
Similarly, a three-dimensional plot exhibiting activation of naproxen demethylation is 
shown in Figure 2.7, while in Figure 2.8, an Eadie-Hofstee plot shows the effect of 
dapsone on the kinetic profile of naproxen.  In the absence of dapsone, a biphasic plot is 
observed, whereas the presence of 100 µM dapsone causes the biphasic profile of 
naproxen to become linear.  As a result, naproxen demethylation in the presence of 100 
µM dapsone was also fit to the Michaelis-Menten curve, with a Vmax of 37.0 
pmol/min/pmol P450 and a Km of 80 µM (Table 2.2).  Lastly, a three-dimensional plot in 
Figure 2.9 shows that piroxicam, a structurally different CYP2C9 substrate, is also 
activated by dapsone.  
Stability of Dapsone Hydroxylamine.  Dapsone hydroxylamine is known to be an 
unstable compound in potassium phosphate buffer [14;15]. A standard solution was 
prepared in potassium phosphate buffer containing 1 mM ascorbic acid and a 15 µl 
injection was made from the same vial every 20 minutes at room temperature and 
analyzed according to methods described in Materials and Methods.  When subjected to 
our incubation conditions over 5 hours, the peak area coefficient of variation was 2.3% 
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(data not shown), demonstrating that quantitation would not be affected by metabolite 
instability.   
 
2.4.  Discussion 
 
Results from this study suggest that dapsone activates multiple substrates of 
CYP2C9, being described by a model in which dapsone (effector) and substrate may fit 
in the active site simultaneously.  The increase in Vmax and decrease in Km for 
flurbiprofen 4’-hydroxylation while dapsone hydroxylamine metabolite is also 
measurable provide additional evidence for this theory.  In addition, the naproxen 
metabolic profile was changed from biphasic to hyperbolic in the presence of dapsone, 
and piroxicam, a third CYP2C9 substrate with a distinct structure, was also metabolically 
activated by dapsone. 
It was once believed that most P450-mediated reactions obeyed normal 
Michaelis-Menten enzyme kinetics, allowing for relatively simple prediction of kinetic 
parameters.  However, atypical CYP450 kinetics are now being recognized more 
frequently in the area of drug metabolism, which complicates scaling kinetic data from 
the in vitro to the in vivo situation.  To date, CYP3A4 has been the most studied isoform 
in terms of atypical kinetic behavior.  For example, studies by Schwab et al. [16] and 
Shou et al. [1] have shown that purified CYP3A4 enzymes are directly activated by 7,8-
benzoflavone.  This is particularly interesting because like dapsone, 7,8-benzoflavone is a 
substrate for the enzyme that it activates.  More recent data suggests that P450 enzymes 
other than CYP3A4 may behave in an atypical manner.  Korzekwa et al. [2] suggest that 
CYP1A1 mediated naphthalene metabolism shows a sigmoidal saturation curve and that 
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Hep G2 expressed CYP2B6, CYP2C8, CYP2C9, and CYP3A5 may also exhibit non 
Michaelis-Menten kinetics, depending on the substrate.  Likewise, Ekins et al. [3] have 
shown that CYP1A2 displays autoactivation kinetics for ethoxyresorufin metabolism, 
although results appear to be enzyme source dependent.  Despite these studies describing 
activation, no clear mechanism has been determined, although many models have been 
proposed.  Ueng et al. [17] have described a model which suggests that an allosteric site 
is involved in the cooperativity of certain CYP3A4 reactions, but the proximity of this 
site is not defined.  Harlow and Halpert suggest that effector binding is most likely in the 
active site along with the substrate, but go on to propose that oxidation only occurs at one 
binding region within the active site [18].  Another possibility that has been put forth is 
the idea of kinetically distinguishable conformers of CYP3A4 [19], which was proposed 
based on kinetic studies of carbon monoxide binding.  However, the model we believe 
that most accurately describes the activation phenomenon is that of Shou and Korzekwa 
[1;2;12], which suggests that both substrate and effector are bound in the active site 
simultaneously with distinctive binding regions and access to the reactive oxygen.  It 
should be stated that this model does not distinguish between allosteric or active site 
effector binding. 
From our experiments, we have observed near-simultaneous metabolism of 
flurbiprofen and dapsone, although it is likely that there is only one productive 
orientation at a given time.  Nonetheless, this provides support to the primary hypothesis 
that substrate and activator may bind in the active site simultaneously, potentially ruling 
out the theory of an allosteric site causing cooperativity.  The main basis for this 
hypothesis is that dapsone is also a substrate for CYP2C9.  Although the CYP2C9 active 
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site is not as large as CYP3A4 , it still may be able to accommodate two rather small 
compounds.  In fact, NMR studies by Banci et al. [20] have shown that both pyridine and 
imidazole can fit into the P450cam active site simultaneously.  Furthermore, flurbiprofen 
4’-hydroxylation, naproxen demethylation, and piroxicam 5’-hydroxylation Km values 
were all decreased in the presence of dapsone (Tables 2.1 and 2.2), suggesting that 
dapsone does not displace these compounds from the active site.  An interesting 
discovery which provides further evidence to the two-site hypothesis is the kinetic profile 
of naproxen.  In the absence of dapsone, naproxen exhibits a biphasic kinetic profile, as 
shown by the Eadie-Hofstee plot in Figure 2.8, which suggests in itself that CYP2C9 may 
have a low Km, low Vmax binding component, and a high Km, high Vmax binding 
component.  As a result, data were fit to a two-site biphasic equation instead of the 
Michaelis-Menten equation.  However, naproxen demethylation in the presence of 100 
µM dapsone was best fit with the Michaelis-Menten equation (Table 2.2).  The inset in 
Figure 2.8 demonstrates that addition of 100 µM dapsone normalizes naproxen kinetics, 
resulting in a linear Eadie-Hofstee plot and supporting a fit using the standard Michaelis-
Menten equation.   This change in kinetic profile is most likely due to dapsone binding to 
the high Km site when present in high concentrations, occupying that site such that only 
one binding region of CYP2C9 is operable in naproxen metabolism.  This idea is further 
supported by the fact that although the Clint of the second binding site (Vmax2/Km2) did 
not change, it did contribute to a lesser extent to the kinetic profile of naproxen in the 
presence of dapsone (Table 2.2).  Piroxicam metabolism is apparently also activated by 
dapsone, which is interesting considering its structural differences and larger size as 
compared to naproxen and flurbiprofen.  It is worthy to note that piroxicam has been 
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shown to exhibit substrate inhibition in microsomes and baculovirus-expressed CYP2C9 
(unpublished data).  However, this was not observed in the expression system used for 
this study, confirming previous reports that many of these kinetic events are expression 
system dependent [3].   
Fitting of data from all three substrates to the two-site model (equation 2.3) was 
done to estimate a single Km and Vmax, along with the effector binding constant (KB) and 
α and β values.  Results show α values (change in Km resulting from effector binding) 
less than 1, and β values (change in Vmax resulting from effector binding) greater than 1 
for all substrates (Table 2.3), suggesting that Km was reduced and Vmax increased in all 
cases.  It has been demonstrated previously that an α < 1 and/or a β > 1 is indicative of 
activation [2].  It should be realized that the present two-site model equation assumes that 
the kinetic profile for a substrate’s metabolism remains constant, which is not the case for 
naproxen.  However, a model reflecting this would be extremely complex and since no 
model exists which takes this change into consideration, the results for naproxen must be 
viewed in this context.   
Another component that can be determined when using the two-site model is the 
binding constant of dapsone.  It is apparent from Table 2.3 that this constant varies 
considerably depending on the substrate being activated, which argues for different 
binding orientations in the active site or changes in binding efficiency.  Other results 
from this study show that the presence of flurbiprofen does not substantially influence the 
formation of dapsone hydroxylamine, although conditions were optimized for 
flurbiprofen hydroxylation, as activation conditions were desired.  Close examination of 
data points in Figure 2.6 indicates an inadequate estimation of Vmax, which may be the 
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cause for minimal differences in Km estimates (81-144 µM).  In addition, dapsone has 
been shown previously to have a sigmoidal kinetic profile [2], suggesting two binding 
regions for dapsone, one of which is cooperative.  However, the sigmoidal portion of 
dapsone’s kinetic profile was present at very low dapsone concentrations, so either not 
enough low concentration data points were taken in this study to observe sigmoidal 
kinetics or perhaps the presence of flurbiprofen normalized dapsone kinetics, resulting in 
a hyperbolic profile.  Nonetheless, Michaelis-Menten fits for dapsone hydroxylation in 
the presence of flurbiprofen appear to be relatively superimposable, suggesting similar 
kinetic parameters for each condition.  
One factor which may affect activation is the presence of cytochrome b5 which 
has been shown to affect the catalytic activity of certain P450 reactions [21].  However, 
our results with baculovirus-expressed CYP2C9 show that activation of flurbiprofen 4’-
hydroxylation is not b5 dependent, as activation still occurs in the absence of cytochrome 
b5 (data not shown).  It is also possible that dapsone somehow affects the coupling of 
NADPH-CYP reductase with CYP to increase catalytic activity of CYP2C9, as was 
suggested by Shou et al. [1] with 7,8-benzoflavone and CYP3A4.  Another potential 
contributor to the activation mechanism may be the interaction with or displacement of 
water molecules from the enzyme active site, thus affecting hydrogen bonding within the 
active site.  The exit of water molecules from the active site could possibly change the 
conformation of the enzyme if the hydrogen bonds were in positions essential for 
stabilizing the protein structure [3].  It is possible that one, all or even additional factors 
are contributing to some degree to the activation mechanism of dapsone. 
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Overall, evidence from this study suggests that dapsone activates the metabolism 
of multiple substrates of CYP2C9 by binding within the active site in a region that causes 
positive cooperativity.  Thus, studies exploring the CYP2C9 active site will be important, 
beginning with determining the effects of allelic variants and mutants of CYP2C9 on 
dapsone activation, which may more conclusively prove that active site binding 
interactions are of significance.  With respect to CYP2C9, the *2 (R144C) and *3 
(I359L) allelic variants and F114L mutant have been shown to variably affect the 
metabolism of certain compounds [22;23], and thus are currently being studied to help 
elucidate the mechanism of activation.  Studies exploring analogs of dapsone to 
determine structural requirements of activation will be reported in the next chapter. 
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Figure 2.1. Structures of Three CYP2C9 Substrates   
Structures of the three CYP2C9 substrates studied for activation by dapsone.   
Arrows indicate site of metabolism. 
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Table 2.1.5 Michaelis-Menten Parameter Estimates for Flurbiprofen and Piroxicam 
Kinetic parameter estimates for flurbiprofen 4'-hydroxylation and piroxicam  
5'-hydroxylation in the presence of dapsone.  Data were fit to the Michaelis-Menten  
model (equation 2.1).    
             (S)-Flurbiprofen                Piroxicam 
Dapsone Km (SE) Vmax (SE) Km (SE) Vmax (SE) 
(µM) (µM) (pmol/min/pmol P450) (µM) (pmol/min/pmol P450) 
0 28.9 (4.2) 12.6 (0.5) 183 (56) 0.08 (0.01) 
2 24.8 (4.2) 15.0 (0.7) 97.3 (14) 0.07 (0.003) 
5 17.6 (2.9) 16.3 (0.8) 64.8 (10) 0.07 (0.002) 
10 12.6 (1.2) 17.4 (0.4) 134 (35) 0.11 (0.01) 
50 9.80 (1.1) 20.7 (0.6) 53.7 (5.6) 0.17 (0.004) 
100 10.0 (1.8) 20.6 (1.0) 49.4 (2.0) 0.20 (0.002) 
Figure 2.2. Michaelis-Menten Fits for Flurbiprofen 4’-Hydroxylation in Presence of  
Dapsone. 
Activation of Flurbiprofen 4’-Hydroxylation by Dapsone.  Fits were to the Michaelis-
Menten Model (Equation 2.1), with parameter estimates shown in Table 2.1. 
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Figure 2.3. Michaelis-Menten Fits for Piroxicam 5’-Hydroxylation in Presence of  
Dapsone. 
Activation of Piroxicam 5’-Hydroxylation by Dapsone.  Fits were to the Michaelis-
Menten Model (Equation 2.1), with parameter estimates shown in Table 2.1. 
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Figure 2.4. Biphasic Fits for Naproxen Demethylation in Presence of Dapsone. 
Activation of Naproxen Demethylation by Dapsone.  Fits were to a Biphasic Model 
(Equation 2.2), with parameter estimates shown in Table 2.2.  Notice the change in 
kinetic profile from biphasic to Michaelis-Menten at 100 µM Dapsone. 
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Table 2.2.6 Biphasic Kinetic Parameter Estimates for Naproxen 
Kinetic parameter estimates for naproxen demethylation  
in the presence of dapsone.  Data were fit to a two-site biphasic 
model (equation 2.2).   
Dapsone Km1 (SE) Vmax1 (SE) Clint (SE) 
(µM) (µM) (pmol/min/pmol 
P450) 
(µl/min/pmolP450) 
0 433 (252) 11.7 (4.3) 0.002 (0.002) 
2 233 (73.5) 14.9 (2.4) 0.003 (0.001) 
5 250 (92.4) 21.8 (4.0) 0.002 (0.002) 
10 163 (30.8) 24.9 (2.0) 0.002 (0.001) 
50 58.9 (18.0) 27.4 (2.7) 0.007 (0.002) 
*100 67.4 (22.5) 34.7 (3.8) 0.002 (0.003) 
Clint represents the linear portion of the biphasic curve (Vmax2/Km2). 
*Also fit to Michaelis-Menten equation (Km=80.0 µM; Vmax= 
37.0pmol/min/pmolP450)
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Table 2.3.7 Two Site Model Kinetic Parameter Estimates for Flurbiprofen, 
Naproxen and Piroxicam 
Kinetic parameter estimates for flurbiprofen hydroxylation, naproxen demethylation, and 
piroxicam hydroxylation in the presence of dapsone.  Data were fit to the two-site model 
(equation 2.3). 
 
Substrate Km (SE) Vmax (SE) KB (SE)    
 (µM) (pmol/min/pmol P450) (µM) α (SE) β (SE) R2 
(S)-Flurbiprofen 26.5 (3.4) 12.2 (0.5) 17.6 (3.6) 0.3 (0.06) 1.7 (0.1) 0.99 
(S)-Naproxen 593 (128) 16.2 (1.6) 68.7 (23) 0.1 (0.04) 2.4 (0.3) 0.99 
Piroxicam 110 (17.1) 0.06 (0.003) 164 (77) 0.2 (0.1) 4.0 (0.3) 0.99 
Km is the Michaelis-Menten constant; Vmax is the maximal velocity; KB is the binding 
constant for the effector; α is the change in Km resulting from effector binding; β is the 
change in Vmax resulting from effector binding.  An α or β value=1 indicates no change in 
Km or Vmax, respectively. 
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Figure 2.5. Dapsone Activation of Flurbiprofen 4’-Hydroxylation (3-D Plot) 
Three-dimensional surface plot showing activation of flurbiprofen 4’- 
hydroxylation by dapsone in expressed CYP2C9.  The surface is the fit to equation 2.3. 
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Figure 2.6. Dapsone Hydroxylation by CYP2C9 
Two-dimensional plots demonstrating minimal change in dapsone hydroxylamine 
formation in the presence of 2, 5 and 10 µM flurbiprofen.  Kinetic parameters were 
estimated using equation 2.1. 
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Figure 2.7. Dapsone Activation of Naproxen Demethylation (3-D Plot) 
Three-dimensional surface plot showing activation of naproxen O-demethylation by 
dapsone in expressed CYP2C9.  The surface is the fit to equation 2.3. 
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Figure 2.8. Eadie-Hofstee Plot for Naproxen Demethylation 
Eadie-Hofstee plot for (S)-naproxen demethylation in the absence of dapsone showing 
biphasic kinetic profile.  Inset figure shows Eadie-Hofstee plot for (S)-naproxen in the 
presence of 100 µM dapsone, resulting in a linear kinetic profile. 
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Figure 2.9. Dapsone Activation of Piroxicam 5’-Hydroxylation (3-D Plot) 
Three-dimensional surface plot showing activation of piroxicam 5’-hydroxylation by 
dapsone in expressed CYP2C9.  The surface is the fit to equation 2.3. 
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CHAPTER III 
 
 
 
Dapsone Activation of CYP2C9-Mediated Metabolism: 
Structure Activity Relationships and Kinetics 
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3.1.  Introduction 
 
Flurbiprofen is exclusively metabolized by CYP2C9 [1;2], and thus serves as a 
useful probe for studying regulation of CYP2C9 activity.  Dapsone has previously been 
shown to activate CYP2C9-mediated flurbiprofen 4’-hydroxylation in human liver 
microsomes and baculovirus-expressed CYP2C9 [3].  In addition, kinetic studies on the 
activation of flurbiprofen 4’-hydroxylation, as well as naproxen demethylation and 
piroxicam 5’-hydroxylation by dapsone have recently been reported [4].  Data from this 
kinetic study were fit to a two-site effector model equation, showing an increase in Vmax 
and decrease in Km for the metabolism of these substrates in the presence of dapsone, 
suggesting the possibility of multiple binding regions within the CYP2C9 active site.  In 
addition, dapsone is metabolized by CYP2C9 at therapeutic concentrations to its 
hydroxylamine metabolite [5;6].  Thus, dapsone is a substrate for the enzyme it activates, 
further suggesting its presence in the active site during activation.  This situation is 
analogous to that observed with 7,8-benzoflavone, which activates CYP3A4-mediated 
phenanthrene metabolism, in addition to being a substrate for CYP3A4 [7].  
Many structure-activity relationship studies have been performed in describing 
substrate and inhibitor interactions with CYP2C9 [8-10].  However, similar studies have 
yet to be done for potential activators of CYP2C9.  In a study exploring activation of 
CYP3A4, a series of partial or modified structures of 7,8-benzoflavone were tested for 
their ability to activate or inhibit the metabolism of phenanthrene, chrysene, and 
benzo[a]pyrene in vitro [7] to determine the effector structural features necessary for the 
activation of CYP3A4.  We have conducted an analogous study for the activation of 
58 
CYP2C9 by dapsone.  We report data from a screen of 16 structural analogs of dapsone 
incubated at a single concentration with flurbiprofen, naproxen, or piroxicam in human 
liver microsomes.  This was done in an attempt to determine effector structural 
characteristics necessary for activation of CYP2C9.  In addition, ten of these analogs 
were selected, based on structure and results from the screening study, to perform kinetic 
studies and determine the overall effects of varying the concentration of analog on the 
metabolism of these model substrates, potentially gaining insight into the mechanism of 
activation by dapsone. 
 
3.2.  Methods 
 
Chemicals.  Acetonitrile and dibasic potassium phosphate were obtained from 
Fisher Scientific Co. (Pittsburgh, PA).  (S)-Flurbiprofen, 4’-hydroxy flurbiprofen, and 2-
fluoro-4-biphenyl acetic acid (internal standard) were gifts from Pharmacia Corp. 
(Kalamazoo, MI).  Dapsone, sulfamethoxazole, sulfamethazine and ketoprofen were 
purchased from Sigma Chemical Co. (St. Louis, MO) and all other dapsone analogs were 
purchased from Aldrich Chemical Co. (Milwaukee, WI).  All other chemicals were 
obtained from commercial sources and were of the highest purity available. 
Enzyme Preparations.  Human liver tissue for preparation of microsomes was 
obtained through the Liver Tissue Procurement and Distribution System.  Based on chart 
review, none of the patients from whom tissues were obtained was taking any 
medications known to inhibit or induce the P450s.  Microsomal samples were prepared 
according to established methods [11].  Protein content was measured by the method of 
Lowry et al. [12]and P450 content by the method of Omura and Sato [13]. 
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Human Liver Microsomal Incubation Conditions.  Human liver microsomes (0.2 
mg/ml final protein concentration, 1.0 mg/ml for piroxicam) were incubated in the 
presence of 1 mM NADPH and 100 mM K2HPO4, pH 7.4, in a total volume of 200 µl to 
screen for activation by dapsone analogs (Figure 3.1).  These analogs were chosen based 
on their structural similarity to dapsone, with modifications at various parts of the 
molecule thought to potentially be important for enzyme interactions, e.g., replacement of 
the amino group (dapsone) with methyl group (p-tolylsulfone). Reactions were carried 
out for 20 minutes at 37°C with either 10 µM (S)-flurbiprofen, (S)-naproxen, or 
piroxicam (45 minutes), and 10 µM dapsone or analog concentrations.  Samples 
containing flurbiprofen were quenched with 200 µl acetonitrile containing internal 
standard (180 ng/ml 2-fluoro-4-biphenylacetic acid), while those containing naproxen 
were quenched with 200 µl acetonitrile.  Next, 40 µl ½-strength H3PO4 was added to 
samples containing flurbiprofen or naproxen, followed by centrifugation at 10,000 rpm 
for 5 minutes, and 10-50 µl was injected onto HPLC system.  Samples containing 
piroxicam were quenched by addition of 20 µl perchloric acid and immediately placed on 
ice, followed by centrifugation at 10,000 rpm for 5 minutes, and 100 µl was injected onto 
the HPLC system.  Conditions for HPLC analysis of 4’-hydroxy flurbiprofen, 
desmethylnaproxen, and 5’-hydroxy piroxicam were as described below.  These reactions 
were shown to be linear with respect to time and protein concentration. 
Expressed CYP2C9 Incubation Conditions for Kinetic Studies.   Ten dapsone 
analogs were selected for full kinetic studies and included:  dapsone, phenylsulfone, p-
tolylsulfone, 4-nitrophenylsulfonylaniline (4-NPSA), benzophenone, ketoprofen, 
dicyclohexylketone, sulfadiazine, sulfamethoxazole, and sulfamethazine.  Incubation 
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mixtures in a 6X6 matrix design contained 1 pmol expressed CYP2C9 (5 pmol for 
piroxicam) co-expressed with reductase (gift from Camitro Corporation, Menlo Park, 
CA), with either (S)-flurbiprofen (2-300 µM), (S)-naproxen (10-1800 µM), or piroxicam 
(5-900 µM) incubated with dapsone or dapsone analog (0-100 µM) in 50 mM potassium 
phosphate buffer at pH 7.4.  Dapsone and analogs were dissolved in DMSO and added to 
0.2 mL incubations such that the final concentration of DMSO was less than 2.5%, and 
reactions were initiated with 1 mM NADPH and allowed to incubate at 37°C for 20 
minutes (45 minutes for piroxicam).  Control incubations also contained 2.5% DMSO.  
Samples were processed as stated above for microsomal incubation conditions. 
Analysis of 4’-hydroxy flurbiprofen.  4’-Hydroxyflurbiprofen was analyzed by 
HPLC with fluorescence detection.  The HPLC system consisted of a Waters 501 HPLC 
pump, a Waters 717 autosampler and a Waters 470 fluorescence detector set at an 
excitation wavelength of 260 nm and an emission wavelength of 320 nm.  The mobile 
phase consisted of acetonitrile:20 mM K2HPO4, pH 3.0 (45:55, v/v) pumped at 1 ml/min 
through a Brownlee Spheri-5 C18 4.6 x 100 mm column. 4’-Hydroxy flurbiprofen and 
internal standard eluted at approximately 2.2 and 4.8 minutes, respectively. 
Analysis of desmethylnaproxen.  Desmethylnaproxen was analyzed identically to 
4’-hydroxy flurbiprofen except that the fluorescence detector was set at an excitation 
wavelength of 230 nm and an emission wavelength of 340 nm, and no internal standard 
was used.  Desmethylnaproxen eluted at approximately 2.1 minutes. 
Analysis of 5’-hydroxy piroxicam.  5’-Hydroxy piroxicam was analyzed by HPLC 
with UV detection (365 nm).  The HPLC system was as described above, but was fitted 
to a Waters 486 UV detector.  The mobile phase consisted of 50:50 (v/v), acetonitrile:50 
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mM K2HPO4, pH 3.0 pumped at 1 mL/min through a Phenomenex Luna C18 5 µm, 4.6 x 
150 mm column.  Retention time for 5’-hydroxy piroxicam was approximately 4.3 
minutes.   
Data Analysis and Equations.  Kinetic data were fit to a two-site model [3] where 
appropriate, allowing surface plot analysis and estimation of effector-related changes on 
substrate Km and Vmax of flurbiprofen, naproxen, and piroxicam with the following 
equation:  
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where S is substrate, B is effector, Vmax and Km are kinetic constants for substrate 
metabolism, KB is the binding constant for the effector, α is the change in Km resulting 
from effector binding, and β is the change in Vmax from effector binding.  For activation, 
α<1 and/or β>1.  Percent activation/inhibition by dapsone analogs was calculated as the 
mean ± S.D. from incubations run in triplicate.  Flurbiprofen and piroxicam data that 
exhibited little consistent change in presence of effector (resulting in negative or 
unreasonable parameter estimates when fit to equation 1) were fit to the Michaelis-
Menten equation to estimate effector-related changes on metabolism: 
 
SKm
SVmv
+
•
=   (3.2) 
Naproxen data, again exhibiting little consistent change, were fit to the following 
biphasic kinetic equation to estimate effector-related changes on metabolism: 
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=  (3.3) 
where Clint is the intrinsic clearance, thought to be associated with a second binding 
region within the active site, and represents the linear portion of the biphasic kinetic 
curve. 
 
3.3.  Results 
 
Dapsone Analogs.  Dapsone has previously been shown to activate flurbiprofen 
4’-hydroxylation in liver microsomes [3].  Thus, in the present screening study, dapsone 
was included as a positive control and reference compound.  Flurbiprofen 4’-
hydroxylation was activated in human liver microsomes ~1.6 fold by dapsone, ~1.4 fold 
by phenylsulfone, and ~1.5 fold by p-tolylsulfone (Figure 3.2).  All other analogs either 
had no effect or were weak inhibitors.  Similar results were obtained in preparations from 
two other human livers (data not shown).  Interestingly, only dapsone activated naproxen 
demethylation (Figure 3.3), while most analogs were weak inhibitors.  However, 
diphenylcyclopropenone was a relatively strong inhibitor of naproxen demethylation 
(~50%).  In addition, the activation by dapsone was almost 3-fold, substantially more 
than for flurbiprofen metabolism.  For piroxicam hydroxylation, dapsone produced ~1.3-
fold activation, with phenylsulfone and p-tolylsulfone producing similar levels of 
activation (Figure 3.4).  It is interesting to note that these same analogs activated 
flurbiprofen hydroxylation, albeit to differing degrees.  Of the analogs screened, the 
inhibitor 4-NPSA is perhaps the most interesting, considering its structural similarity to 
dapsone, phenylsulfone, and p-tolylsulfone, all of which activated flurbiprofen and 
piroxicam hydroxylation.   
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Kinetic Studies.  Analogs for full kinetic studies were selected based on their 
different functional groups and spatial orientations compared to dapsone, as well as 
results observed in the initial screen.  Experimental data were fit to a two-site effector 
model (equation 3.1) where appropriate.  As has been previously shown (chapter 2), data 
from dapsone activation of flurbiprofen hydroxylation fits well to this model (Figure 3.5), 
with an α = 0.31, and a β = 1.73, indicating a decrease in Km and increase in Vmax, 
respectively (Table 3.1).  Similarly, phenylsulfone activated flurbiprofen 4’-
hydroxylation (Figure 3.6), with an α = 0.42, and a β = 2.80 (Table 3.1).  Analogs for 
which parameters were not estimated from equation 1 due to lack of consistent activation 
with increasing concentration of effector, inhibition, or lack of effect on flurbiprofen 4’-
hydroxylation included p-tolylsulfone, benzophenone, ketoprofen, dicyclohexylketone, 
sulfamethoxazole, sulfadiazine, and sulfamethazine.  4-NPSA, which contains a nitro 
group in the place of an amino group, acts as a good inhibitor of flurbiprofen 
hydroxylation (Table 3.2), with Dixon plot analysis suggesting a Ki of approximately 40 
µM (Figure 3.7).   
With regard to activation of naproxen demethylation, a good fit to the two-site 
effector model (equation 3.1) in the presence of dapsone was observed (Figure 3.8), with 
an α = 0.09 and β = 2.40 (Table 3.1), indicating a substantially greater decrease in Km 
and increase in Vmax (activation) compared to flurbiprofen.  Similar to analog screening 
data, no other analog produced activation comparable to dapsone, although both p-
tolylsulfone and sulfamethazine activated at high concentrations (Figures 3.9 and 3.10), 
with an increase in Vmax noted in the presence of effector (Table 3.3).   Interestingly, both 
phenylsulfone and 4-NPSA inhibited naproxen demethylation (Figures 3.11 and 3.12), 
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with kinetic parameters shown in Tables 3.4 and 3.5, respectively.  Inhibition by 4-NPSA 
was pronounced only at high concentrations.  Analogs for which parameters were not 
estimated included benzophenone, ketoprofen, dicyclohexylketone, sulfadiazine, and 
sulfamethoxazole, as no measurable effect was observed at any concentration.  Table 3.1 
also shows the kinetic parameters for activation of the metabolism of piroxicam, a 
structurally distinct CYP2C9 substrate.  Similar to flurbiprofen, piroxicam 5’-
hydroxylation in the presence of dapsone (Figure 3.13) and phenylsulfone (Figure 3.14) 
gave α and β parameter estimates indicative of activation (Table 3.1), while 
benzophenone activated at high concentrations (Figure 3.15), with an increase in both 
Vmax and Km (Table 3.6).  Interestingly, 4-NPSA completely inhibited formation of 5’-
hydroxy piroxicam.  All other analogs had minimal effects on piroxicam 5’-
hydroxylation.   
 
3.4.  Discussion 
 
It has previously been observed that CYP2C9 displays atypical kinetics, as 
evidenced by dapsone activation of CYP2C9-mediated flurbiprofen 4’-hydroxylation [3]. 
In addition, the kinetic effects of this activation on the metabolism of three prototypical 
CYP2C9 substrates (flurbiprofen, naproxen, and piroxicam) have been reported [4].  To 
gain insight into activation by dapsone, sixteen analogs of dapsone were studied with 
these same three substrates to determine structural requirements for activation of 
CYP2C9-mediated metabolism.  Additionally, ten of these analogs were selected for 
kinetic studies to determine the effect of varying the concentrations of effector on 
CYP2C9 activity.  Screening results suggest that the level of activation is substrate 
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dependent, and that a sulfone moiety between two benzene rings is necessary for 
activation of CYP2C9.  Activation of naproxen demethylation appears to be the most 
restrictive, as only dapsone was able to consistently activate this metabolic event.  
Kinetic studies produced similar results, although certain analogs exhibited effects at high 
concentrations.   
In terms of atypical kinetic behavior, CYP3A4 has been the most studied isoform.  
Several studies have shown that purified CYP3A4 enzymes are directly activated by 7,8-
benzoflavone [7;14].  This is particularly interesting since 7,8-benzoflavone is a substrate 
for the enzyme that it activates, analogous to dapsone and CYP2C9 [3;4], suggesting 
similar activation characteristics between these isoforms.  In addition, Shou et al. have 
explored the structural requirements for activation of CYP3A4 by studying the effects of 
structural analogs of 7,8-benzoflavone on CYP3A4 activity [7].  To this end, similar 
studies have been performed for CYP2C9.  Experimental data from dapsone analogs 
suggest that some very strict structural constraints are necessary for activation of 
CYP2C9, as dapsone, phenylsulfone, and p-tolylsulfone activated flurbiprofen and 
piroxicam metabolism (Figures 3.2 and 3.4, respectively), while only dapsone activated 
naproxen demethylation (Figure 3.3).  The common functional group within these 
activators is a sulfone group directly between two benzene rings.  Replacement of this 
sulfone with a carbonyl (benzophenone), sulfide (diphenylsulfide), sulfoxide 
(diphenylsulfoxide), or sulfilimine (diphenylsulfilimine) functional group resulted in 
elimination of activation properties, suggesting that the sulfone group directly between 
two benzene rings is vital for binding to an effector site region that results in positive 
cooperativity (activation) of CYP2C9.  In fact, some analogs were inhibitors of CYP2C9-
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mediated metabolism.  Interestingly, if one of the terminal amino groups on dapsone is 
replaced by a nitro (4-NPSA), then the analog becomes an inhibitor, whereas replacement 
of both terminal amino groups by two methyl groups (p-tolylsulfone) or left vacant 
(phenylsulfone) had little effect on the ability to activate flurbiprofen and piroxicam.  
With respect to naproxen, only dapsone activated its demethylation, with a substantially 
higher degree of activation than either flurbiprofen or piroxicam hydroxylation.  This 
suggests even greater effector structural requirements for activation of naproxen 
metabolism.  It is hypothesized that naproxen may have a different binding orientation 
than either flurbiprofen or piroxicam, resulting in slightly different requirements for 
activation of its metabolism.  In addition, other analogs with two benzene rings, two 
cyclohexyl groups or the sulfone moiety in a different spatial arrangement (sulfonamide 
analogs) generally resulted in inhibition, further arguing for the direct association of a 
sulfone group with two benzene rings for activation.  
Analogs for kinetic studies were selected based on results from screening data, in 
addition to selection based on variety of functional group composition.  Kinetic data 
generally agreed with the analog screening data, with activation by dapsone noted for all 
three reporter substrates.  In addition, data for phenylsulfone activation of flurbiprofen 
and piroxicam metabolism fit well to the two-site effector model, while no other analog 
substantially activated naproxen demethylation.  However, for some analogs, activation 
was observed at higher effector concentrations (Figures 3.9, 3.10, and 3.15), signifying a 
lower affinity of the “effector site” for some analogs.  Of these, benzophenone activation 
of piroxicam 5’-hydroxylation at high concentrations (Figure 3.15) was the most 
intriguing, considering it was the only analog without a sulfone group that caused any 
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type of activation.  The absence of the sulfone group may have been responsible for the 
lowered affinity for benzophenone, resulting in no effect at low concentrations.  In 
addition, there were examples in which increasing concentrations of effector had variable 
effects on the substrate’s metabolism (i.e. initial increase then a decrease in metabolism, 
or vice versa).  This concentration dependent observation, which resulted in an inability 
to fit data to the two-site effector model (equation 3.1), has been noted by other groups, 
as well.  Wang et al. observed that low concentrations of midazolam slightly activated 
terfenadine metabolism in human liver microsomes, but inhibited this pathway at higher 
concentrations [15].  The possibility should also be mentioned that some of the analogs 
may elicit their effects by other means than binding to the effector site, contributing to 
this variability.  An example in which the screening and kinetic data did not coincide 
included the effect of p-tolylsulfone on flurbiprofen 4’-hydroxylation, as well as on 
naproxen demethylation.  Screening data at a single concentration suggested that this 
analog activated flurbiprofen 4’-hydroxylation (Figure 3.2), and had no effect on 
naproxen demethylation (Figure 3.3).  Meanwhile, kinetic data obtained using multiple 
substrate and effector concentrations suggested minimal changes in flurbiprofen 4’-
hydroxylation (data not shown), while naproxen demethylation was activated at high 
concentrations of p-tolylsulfone (Figure3.9).  It is possible that some of this incongruency 
may be due to the different source of enzyme used for the two studies (human liver 
microsomes vs. expressed CYP2C9 microsomes).  In addition, kinetic studies suggest 
that phenylsulfone acts as an inhibitor of naproxen demethylation, eventually changing 
the kinetic profile from biphasic to hyperbolic at 100 µM (Figure 3.11), while it clearly 
activates both flurbiprofen and piroxicam hydroxylation (Figures 3.6 and 3.14).  The 
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observed change in naproxen kinetic profile from biphasic to hyperbolic in the presence 
of phenylsulfone is similar to that observed for dapsone (chapter 2), only inhibition is the 
end result instead of activation.  A clear explanation for this is not altogether apparent at 
this time.  It is possible that naproxen binds in a different orientation than either 
flurbiprofen or piroxicam, resulting in the difference in observed effects.  In fact, 
naproxen has been shown to display biphasic kinetics [3;4;16], suggesting multiple 
binding orientations for itself, which may contribute to this difference.  
One of the most intriguing analogs is 4-NPSA, which inhibited both flurbiprofen 
(Ki ~ 40 µM) and naproxen (Ki not estimated due to biphasic nature) metabolism, while 
completely eliminating piroxicam hydroxylase activity.  The similarities in structure of 4-
NPSA to dapsone, and yet the substantial differences in effect on CYP2C9-mediated 
metabolism are striking.  Possible explanations for these observations include steric and 
electronic effects of the nitro group compared to the amino group.  Many studies have 
suggested that the active site of CYP2C9 has positive residues which interact with 
negatively charged groups on substrates [17-20].  Perhaps some type of electrostatic 
interaction between the nitro group of 4-NPSA and one of these active site residues may 
orient it in such a way as to cause inhibition rather than activation.  Dixon plot analysis 
for flurbiprofen hydroxylation suggests that 4-NPSA is acting in a noncompetitive 
manner, for which binding of substrate and inhibitor is not mutually exclusive. Another 
interesting observation is that of the effect of p-tolylsulfone and sulfamethazine at high 
concentrations on naproxen demethylation, showing a minimal effect on Km but a rather 
substantial effect on Vmax (Table 3.3).  A similar effect on piroxicam 5’-hydroxylation 
was observed at high concentrations of benzophenone (Table 3.6).  Reasons for the direct 
69 
effect on Vmax, with minimal effect on Km could be numerous.  One possibility may be 
alteration of uncoupling mechanisms by the effector, most notably a decrease in 
hydrogen peroxide release due to exclusion of water molecules from the active site by the 
effector, resulting in enhanced catalytic activity [21].  Another possibility may be that the 
effector enhances the interaction of CYP450 with cytochrome b5, which has been shown 
to decrease uncoupling to hydrogen peroxide formation, thereby increasing the 
concentration of active oxygen species for catalysis [22]. 
Overall, analog results for activation of CY2C9 suggest that specific activator-
protein interactions may be involved in the recognition and binding of effector, as even 
small deviations from the core structure of dapsone resulted in variable effects or 
inhibition.  Results from this study do not conclusively establish whether the effector site 
lies within or separate from the active site.  Although the location of the effector site has 
not been conclusively proven, many models have been proposed.  Ueng et al. [23] have 
described a model suggesting that an allosteric site is involved in the cooperativity of 
certain CYP3A4 reactions, but the proximity of this site is not defined.  Harlow and 
Halpert suggest that effector binding is most likely in the active site along with the 
substrate, as they were able to create an active site double mutant of CYP3A4 that 
reduced positive cooperativity in the presence of 7,8-benzoflavone[24].  Another model 
proposed by Shou and Korzekwa suggests that both substrate and effector are bound in 
the active site simultaneously, each having a distinctive binding region and access to the 
reactive oxygen [3;7].  Recently, it was reported that this two-site binding model applies 
to CYP2C9 [4].  However, the most appropriate model may be dependent on the substrate 
and effector in question.  In addition, there is the possibility of conformational changes 
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due to binding of effector, for which these models can not predict.  Therefore, one of the 
most reasonable explanations for the cause of atypical kinetics is one in which the 
multiple binding-site model and a conformationally based model are combined, as 
suggested by Atkins et al. [25].  Regardless of the most appropriate model, kinetic data 
from previous studies suggest that the effector site for CYP2C9 is within the active site 
[4].  Therefore, it is important to more fully characterize critical active site binding 
regions and residues that may be involved in binding of dapsone and/or some of its 
analogs.  He et al. have suggested that the CYP2C9 active site has two regions that bind 
electronegative groups, one of which may be the sulfone group of dapsone [19].  In 
addition, the positive arginine residues at positions 97 and 105 have been shown to be 
important in the catalytic function of CYP2C9 [20].  It would be interesting to mutate 
these to neutral residues and observe if there is any effect on activation by dapsone.  In 
similar studies, Domanski et al. selected certain residues to mutate based on sequence 
alignments of CYP3A4 with bacterial enzymes, and have been able to demonstrate which 
residues are most likely involved in 7,8-benzoflavone activation of steroid hydroxylation 
[26;27].  This group concluded that progesterone and 7,8-benzoflavone bind at separate 
locations within the CYP3A4 active site, even though they both appear to have equal 
access to the reactive oxygen.  A reasonable starting point for CYP2C9 would be to 
determine the effects of allelic variants and mutants of CYP2C9 on activation, which may 
more conclusively prove that active site binding interactions are of substantial 
importance.  The *2 and *3 allelic variants and F114L mutant have been shown to 
variably affect the metabolism of certain compounds [28;29], suggesting similar 
characteristics as those observed with mutants of CYP3A4.  More specifically, the *2 
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allele change shows evidence of affecting the interaction of the P450 with oxidoreductase 
[30], which would affect electron flow and perhaps the activation process.  Studies 
exploring the critical residues of CYP2C9 involved in binding of various substrates and 
activation by dapsone have been performed and will be reported in the next chapter.  
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Figure 3.1.10 Structures of Dapsone and Analogs 
Dapsone and analogs examined for effect on flurbiprofen, naproxen, and piroxicam 
metabolism. 
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Figure 3.2.11 Screen of Dapsone Analog Effect on Flurbiprofen 4’-Hydroxylation 
Activation/inhibition of flurbiprofen 4’-hydroxylation by dapsone and analogs.  
Incubations were performed in triplicate with 10 µM flurbiprofen and 10 µM effector 
(dapsone or analog). 
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Figure 3.3.12 Screen of Dapsone Analog Effect on Naproxen Demethylation 
Activation/inhibition of naproxen demethylation by dapsone and analogs.  Incubations 
were performed in triplicate with 10 µM flurbiprofen and 10 µM effector (dapsone or 
analog). 
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Figure 3.4.13 Screen of Dapsone Analog Effect on Piroxicam 5’-Hydroxylation  
Activation/inhibition of piroxicam 5’-hydroxylation by dapsone and analogs.  Incubations 
were performed in triplicate with 10 µM flurbiprofen and 10 µM effector (dapsone or 
analog). 
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Table 3.1.8 Two-Site Kinetic Parameter Estimates for Dapsone and Analogs 
Kinetic parameters (SE) derived from two-site effector model (equation 3.1) for 
activation of CYP2C9-mediated metabolism. 
 
Flurbiprofen 4’-hydroxylation 
Analog Vmax Km KB α β R2 
NH2 S
NH2
O
O
Dapsone  
12.2 
(0.6) 
26.5 
(3.4) 
17.6 
(3.6) 
0.31 
(0.06) 
1.73 
(0.09) 
0.99 
S
O
O
Phenylsulfone  
6.5 
(0.6) 
26.0 
(6.1) 
113.3 
(98.7) 
0.42 
(0.28) 
2.80 
(0.44) 
0.95 
Naproxen Demethylation 
NH2 S
NH2
O
O
Dapsone  
16.2 
(1.6) 
593.4 
(128.2) 
68.7 
(22.7) 
0.09 
(0.03) 
2.40 
(0.26) 
0.99 
Piroxicam 5’-hydroxylation 
NH2 S
NH2
O
O
Dapsone  
0.07 
(0.01) 
22.6 
(10.5) 
76.5 
(73.4) 
0.45 
(0.45) 
5.92 
(0.94) 
0.94 
S
O
O
Phenylsulfone  
0.08 
(0.005) 
31.3 
(6.1) 
299.2 
(298.9) 
0.18 
(0.17) 
4.41 
(0.38) 
0.98 
Vmax is in pmol/min/pmol P450; Km and KB are in µM 
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Figure 3.5.14 Dapsone Activation of Flurbiprofen 4’-hydroxylation (3-D Plot) 
Three-dimensional surface plot showing activation of flurbiprofen 4’-hydroxylation by 
dapsone.  The surface is the fit to equation 3.1, and is the same as seen in chapter 2. 
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Figure 3.6.15 Phenylsulfone Activation of Flurbiprofen 4’-Hydroxylation (3-D Plot) 
Three-dimensional surface plot showing activation of flurbiprofen 4’-hydroxylation by 
phenylsulfone.  The surface is the fit to equation 3.1. 
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Figure 3.7.16 4-NPSA Inhibition of Flurbiprofen 4’ Hydroxylation (Dixon Plot) 
Dixon plot suggestive of noncompetitive inhibition of flurbiprofen 4’-hydroxylation by 4-
NPSA, with a Ki ~ 40 µM.   
 
 
 
Table 3.2.9 4-NPSA Inhibition of Flurbiprofen 4’ Hydroxylation  
Kinetic parameters (SE) for flurbiprofen 4’-hydroxylation estimated from Michaelis-
Menten equation (equation 3.2) in presence of 4-NPSA.  
SO2N
NH2
O
O
4-NPSA
 
0µM 2µM 5µM 10µM 50µM 100µM 
Vmax 9.0 (0.7) 8.3 (0.4) 7.6 (0.3) 7.4 (0.6) 5.3 (0.3) 3.0 (0.3) 
Km 31.0 (8.0) 23.0 (4.0) 19.8 (2.6) 39.0 (10.6) 27.8 (5.4) 28.8 (8.7) 
Vmax=pmol/min/pmol P450; Km=µM 
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Figure 3.8.17 Dapsone Activation of Naproxen Demethylation (3-D Plot) 
Three-dimensional surface plot showing activation of naproxen demethylation by 
dapsone.  The surface is the fit to equation 3.1, and is the same as seen in chapter 2.   
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Figure 3.9.18 Activation of Naproxen Demethylation by p-Tolylsulfone 
Activation of naproxen demethylation at high concentrations of p-tolylsulfone.  Fits were 
to a biphasic kinetic equation (equation 3.3).  Notice the change toward a more 
hyperbolic function in the presence of 100 µM p-tolylsulfone. 
 
Figure 3.10.19 Activation of Naproxen Demethlyation by Sulfamethazine 
Activation of naproxen demethylation at high concentrations of  
sulfamethazine.  Fits were to a biphasic kinetic equation (equation 3.3). 
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Table 3.3.10 Activation of Naproxen Demethylation by p-Tolysulfone and 
Sulfamethazine 
Kinetic parameters (SE) for naproxen demethylation  
estimated from biphasic kinetic equation (equation 3.3) showing 
activation by p-tolylsulfone and sulfamethazine at 50 and 100µM. 
 
CH3 S
CH3
O
O
p-Tolylsulfone
 
0µM 50µM 100µM 
Vmax 1 2.8 (0.6) 19.2 (4.1) 21.8 (4.4) 
Km1 45.7 (26.5) 130.5 (70.8) 67.0 (54.0) 
Clint 0.01 (.0003) 0.003 (.002) 0.003 (.003) 
 
N
N
CH3
CH3 N
H
S
O
O
NH2Sulfamethazine  
0µM 50µM 100µM 
Vmax 1 7.9 (0.4) 8.1 (0.4) 11.1 (0.9) 
Km1 208.6 (22.9) 155.7 (15.5) 233.8 (44.1) 
Clint 0.003 (.0002) 0.004 (.0002) 0.002 (.0004) 
Vmax1=pmol/min/pmol P450; Km1=µM; Clint=Vmax2/Km2  
(µl/min/pmol P450) 
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Figure 3.11.20 Inhibition of Naproxen Demethylation by Phenylsulfone 
Biphasic kinetic plots showing inhibition of naproxen demethylation 
by phenylsulfone.  Fits were to a biphasic kinetic equation (equation 3.3).  Note the 
change in profile to hyperbolic function in presence of 100 µM phenylsulfone. 
 
 
Table 3.4.11 Inhibition of Naproxen Demethylation by Phenylsulfone 
Kinetic parameters (SE) for naproxen demethylation estimated from biphasic kinetic 
equation (equation 3.3) showing inhibition by phenylsulfone. 
S
O
O
Phenylsulfone  
0µM 2µM 5µM 10µM 50µM 100µM 
Vmax 1 4.9 (1.7) 3.8 (0.1) 2.8 (0.6) 3.2 (1.4) 1.9 (0.1) 2.2 (0.3) 
Km1 140.5 (93.4) 52.4 (5.3) 34.2 (25.3) 53.7 (70.1) 3.7 (1.6) 2.3 (3.1) 
Clint 0.008 
(.0006) 
0.005 
(.0001) 
0.004 
(.0004) 
0.003 
(.001) 
0.002 
(.0001) 
0.001 
(.0003) 
Vmax1=pmol/min/pmol P450; Km1=µM; Clint=Vmax2/Km2 (µl/min/pmol P450) 
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Figure 3.12.21 Inhibition of Naproxen Demethylation by 4-NPSA 
Biphasic kinetic plots showing inhibition of naproxen demethylation 
by 4-NPSA, particularly at 100 µM.  Fits were to a biphasic kinetic equation  
(equation 3.3). 
 
 
Table 3.5.12 Inhibition of Naproxen Demethlyation by 4-NPSA 
Kinetic parameters (SE) for naproxen demethylation  
estimated from biphasic kinetic equation (equation 3.3) showing 
inhibition by 4-NPSA, most notably at 100µM. 
SO2N
NH2
O
O
4-NPSA
 
0µM 10µM 100µM 
Vmax 1 15.9 (7.1) 11.2 (4.4) 1.4 (0.2) 
Km1 695 (427.6) 586 (320.6) 124.3 (40.2) 
Clint 0.002 (.002) 0.003 (.001) 0.001 (.0001) 
Vmax1=pmol/min/pmol P450; Km1=µM; Clint=Vmax2/Km2  
(µl/min/pmol P450) 
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Figure 3.13.22 Dapsone Activation of Piroxicam 5’-Hydroxylation (3-D Plot) 
Three-dimensional surface plot showing activation of piroxicam  
5’-hydroxylation by dapsone.  The surface is the fit to equation 3.1 and is the same as 
seen in chapter 2. 
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Figure 3.14.23 Phenylsulfone Activation of Piroxicam 5’-Hydroxylation (3-D Plot) 
Three-dimensional surface plot showing activation of piroxicam 5’-hydroxylation by 
phenylsulfone.  The surface is the fit to equation 3.1. 
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Figure 3.15.24 Activation of Piroxicam 5’-Hydroxylation by Benzophenone 
Michaelis-Menten plots showing activation of piroxicam 5’-hydroxylation 
by benzophenone at 50 and 100 µM.  Fits were to the Michaelis-Menten equation 
(equation 3.2). 
 
Table 3.6.13 Activation of Piroxicam 5’-Hydroxylation by Benzophenone 
Kinetic parameters for piroxicam 5’-hydroxylation 
estimated by Michaelis-Menten equation (equation 3.2) showing  
activation by benzophenone at 50 and 100 µM. 
O
Benzophenone  
0µM 50µM 100µM 
Vmax  0.1 (.005) 0.17 (.005) 0.21 (.01) 
Km 74.8 (13.8) 85.5 (9.3) 121.5 (19.1) 
Vmax=pmol/min/pmol P450; Km=µM 
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Dapsone Activation of CYP2C9 Allelic Variants 
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4.1.  Introduction 
 
Many studies have suggested that certain CYP450 enzymes may behave in a non 
Michaelis-Menten or atypical fashion [1-3].  Our lab has demonstrated previously that 
dapsone activates CYP2C9-mediated flurbiprofen 4’-hydroxylation in microsomes and 
purified enzyme [2].  More recently, we have described the kinetic effects of dapsone 
activation of flurbiprofen metabolism, as well as effector structural requirements for this 
activation.  In these studies, data supported a two-site model, which suggested that 
dapsone and flurbiprofen bind to distinctive regions within the active site simultaneously, 
each having access to the active oxygen, and thus being metabolized.  Therefore, it is 
hypothesized that binding interactions within the active site are of prime importance to 
the CYP2C9 activation mechanism, which has yet to be fully characterized. 
Allelic variants of CYP2C9 (*2 (R144C) and *3 (I359L)) along with the F114L 
mutant have been shown to variably affect the metabolism of certain compounds [4-8].  
These differences in metabolism likely result from these residues being in a position 
important for either substrate binding, protein conformation, or perhaps electron flow to 
the P450, and thus may be an important factor in the activation mechanism.  The purpose 
of the current study was to determine the effects of dapsone on the metabolism of the 
CYP2C9 substrates (S)-flurbiprofen [9;10], (S)-naproxen [11;12], and piroxicam [13] 
when incubated with wild-type CYP2C9, allelic variants of CYP2C9, or the F114L 
mutant.  Wang et al. [14] suggested that in vitro drug-drug interaction patterns with 
CYP3A4 are substrate dependent, giving credence to analogous studies with CYP2C9.  
These three substrates potentially have different binding orientations in the CYP2C9 
active site, perhaps resulting in differences in the ability to be metabolically activated.  In 
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addition, effects of dapsone on flurbiprofen kinetics in allelic variants and the F114L 
mutant were measured to better understand the CYP2C9 enzyme structural requirements 
necessary for activation. 
By observing the effects of these variants and mutant on dapsone activation of 
various CYP2C9 substrates, insight may be gained into the active site interactions 
necessary for activation with respect to each substrate, providing us with mechanistic 
details for dapsone activation of CYP2C9. 
4.2.  Methods 
 
Chemicals.  Acetonitrile and dibasic potassium phosphate were obtained from 
Fisher Scientific Co. (Pittsburgh, PA).  (S)-flurbiprofen, 4’-hydroxyflurbiprofen, and 2-
fluoro-4-biphenylacetic acid (internal standard) were gifts from Pharmacia Corp. 
(Kalamazoo, MI).  (S)-naproxen and desmethylnaproxen were gifts from Syntex 
Laboratories Inc. (Palo Alto, CA).  Piroxicam and dapsone were purchased from Sigma 
Chemical Co. (St. Louis, MO), and 5’-hydroxy piroxicam was a gift from Pfizer Inc. 
(Groton, CT.).  CYP2C9 allelic variant and F114L mutant enzymes were provided by Dr. 
Allan Rettie of University of Washington.  All other chemicals were obtained from 
commercial sources and were of the highest purity available.   
Enzyme Preparation.  Baculovirus-mediated CYP2C9 expression and purification 
from insect cells were carried out by growth and passage of Trichopulsia ni (Gibco BRL) 
cells using the HyQCCM-3 medium (HyClone Laboratories).  Cotransfection of T. ni 
cells with Bsu361-digested BacPAK6 viral DNA and the appropriate CYP2C9 mutant 
transfer vector was carried out with the reagents and procedures provided by Clontech 
Laboratories, Inc. for construction and amplification of recombinant viral stocks.  Cells 
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were pelleted 2-3 days postinfection, resuspended, washed once in glycerol-containing 
buffer (100 mM potassium-phosphate, 20% glycerol, 0.33 mM DTT, and 1 mM EDTA 
(pH 7.4)), repelleted, and stored at -80°C until further use.  Cultures exhibiting 
expression levels of 75 nmol/L were used for enzyme purification.  Purification of 
enzyme was achieved from detergent-solubilized T. ni cell pellets using sequential 
chromotography on Octyl-Sepharose, DEAE-Sepharose, and ceramic hydroxyapatite to 
specific contents in excess of 10 nmol of holoenzyme/mg of protein for each enzyme.   
Purified CYP2C9 Enzyme Incubation Conditions.  All purified P450 enzymes 
were reconstituted with P450 reductase (PanVera, Madison, WI) and cytochrome b5 
(PanVera, Madison, WI) in a 1:2:1 ratio with dilauroylphosphatidylcholine vesicles (10 
µg) extruded through a 200 nm pore-sized membrane.  The reconstituted enzymes were 
incubated in the presence of either 10 µM (S)-flurbiprofen, (S)-naproxen, or piroxicam 
with 10 µM dapsone in 50 mM potassium phosphate buffer, pH 7.4 in a final volume of 
200 µL.  Reactions were initiated by the addition of 1 mM NADPH and carried out for 20 
minutes (piroxicam for 45 minutes) at 37°C.  Kinetic studies involving (S)-flurbiprofen 
and dapsone were performed as described above with (S)-flurbiprofen concentrations 
ranging from 2-150 µM.  Dapsone concentrations were 0, 2, and 5 µM.  All reactions 
were shown to be linear with respect to time and protein concentration.   
Analysis of 4’-hydroxy flurbiprofen.  4’-Hydroxy flurbiprofen was analyzed by 
HPLC with fluorescence detection.  Samples were quenched with 200 µL of acetonitrile 
containing 180 ng/mL of 2-fluoro-4-biphenylacetic acid (internal standard) and acidified 
with 40 µL ½-strength phosphoric acid.  Samples were then centrifuged at 10,000 rpm for 
5 minutes and 10-50 µL injected onto the HPLC system.  The HPLC system consisted of 
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a Waters 501 HPLC pump, a Waters 717 autosampler and a Waters 470 fluorescence 
detector set at an excitation wavelength of 260 nm and an emission wavelength of 320 
nm.  The mobile phase consisted of acetonitrile:20 mM K2HPO4, pH 3.0 (40:60) pumped 
at 1 mL/min through a PE-Brownlee Spheri-5 C18 4.6 x 100 mm column.  4’-hydroxy 
flurbiprofen and internal standard eluted at approximately 3.5 and 9.0 minutes, 
respectively.   
Analysis of desmethylnaproxen.  Desmethylnaproxen was analyzed identically to 
4’-hydroxy flurbiprofen except that the fluorescence detector was set at an excitation 
wavelength of 230 nm and an emission wavelength of 340 nm, and no internal standard 
was used.  Desmethylnaproxen eluted at approximately 2.1 minutes. 
Analysis of 5’-hydroxy piroxicam.  5’-Hydroxy piroxicam was analyzed by HPLC 
with UV detection (365 nm).  Samples were quenched with 20 µL of perchloric acid, 
vortexed and placed on ice.  Samples were then centrifuged at 10,000 rpm for 5 minutes 
and 100 µL injected onto HPLC system.  The HPLC system was as described above, but 
was fitted to a Waters 486 UV detector.  The mobile phase consisted of acetonitrile:50 
mM K2HPO4, pH 3.0 (50:50) pumped at 1 mL/min through a Phenomenex Luna C18 5 
µm, 4.6 x 150 mm column.  Retention time for 5’-hydroxy piroxicam was approximately 
4.3 minutes.   
Data Analysis.  Velocities were calculated as the mean of incubations done in 
triplicate.  Kinetic parameters were estimated following nonlinear regression using Sigma 
Plot (Version 6.0).   
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4.3.  Results 
 
Dapsone activation of flurbiprofen, naproxen, and piroxicam in CYP2C9 
variants.  Activation of flurbiprofen, naproxen, and piroxicam (Figure 4.1) metabolism 
by dapsone was determined in purified CYP2C9*1 (wild-type), *2 (R144C) and *3 
(I359L) variants, and F114L mutant by incubating each particular substrate at 10 µM 
with 10 µM dapsone in triplicate.  Flurbiprofen hydroxylation was activated about 2-fold 
in the presence of dapsone for CYP2C9 wild-type, as well as *2 and *3 variants (Figure 
4.2, A).  However, in the F114L mutant, flurbiprofen was activated almost 5-fold (Figure 
4.2, A).  Naproxen demethylation (Figure 4.2, B), was activated by dapsone almost 6-fold 
in the wild-type enzyme, substantially higher than observed for flurbiprofen.  The *2 
variant and F114L mutant displayed about the same level of activation as observed with 
wild-type enzyme, while only 1.5-fold activation was observed in the *3 variant.  Results 
of piroxicam hydroxylation (Figure 4.2, C) demonstrate an approximately 2-fold 
activation in the wild-type enzyme, with slightly higher activation in the *2 variant.  
Activation in the *3 variant could not be determined due to low initial activity in the 
absence of dapsone, although detectable activity was subsequently observed when 
dapsone was added.  Interestingly, no activation of piroxicam hydroxylation by dapsone 
was noted in the F114L mutant even though the turnover of piroxicam by this mutant was 
2-fold higher than observed with wild-type enzyme. 
Flurbiprofen kinetic studies.  To more completely assess this activation 
phenomenon, kinetic studies were carried out to determine the effect of dapsone on 
flurbiprofen 4’-hydroxylation in wild-type CYP2C9, its variants and  the F114L mutant.  
Kinetic parameter estimate results (Table 4.1) indicate that dapsone activates flurbiprofen 
94 
4’-hydroxylation in all enzymes tested, increasing Vmax, while lowering Km.  Two-
dimensional plots exhibiting this activation are presented in Figures 4.3-4.6, with inset 
Lineweaver-Burke plots indicative of ternary complex formation, as oppose to the ping-
pong model.  Only the Lineweaver-Burke plot for the *3 variant did not show ternary 
complex formation.  For wild-type CYP2C9, *2 variant, and F114L mutant, Vmax was 
increased only slightly.  However, Km values were substantially reduced with increasing 
dapsone concentration.  Conversely, the Vmax for flurbiprofen 4’-hydroxylation in the *3 
variant almost doubled in the presence of 5 µM dapsone, although initial activity was 
considerably lower.  The most substantial effect on Km was observed with the F114L 
mutant, where Km was reduced from 246 µM to 44 µM by dapsone co-incubation. 
 
4.4.  Discussion 
 
The activation of CYP enzymes in vitro has been observed for virtually every 
isoform involved in human drug metabolism.  However, little is known about the effect 
of this activation on substrate binding and in particular, the importance of various critical 
amino acid residues.  To this end, studies were undertaken to identify substrate 
differences with regard to CYP2C9 activation as well as differences among the common 
allelic variants of CYP2C9 and a mutant with a substitution made in a critical pi-stacking 
binding region.  In the current study, 10 µM dapsone activated flurbiprofen 4’-
hydroxylation about 1.5-fold in wild-type CYP2C9, with similar results observed in the 
*2 and *3 variants, while almost 5-fold activation was observed in the F114L mutant.  
Meanwhile, dapsone activation of naproxen demethylation in wild-type CYP2C9 was 
almost 6-fold, substantially higher than observed for flurbiprofen, while the *2 variant 
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and F114L mutant exhibited an approximately 5-fold activation.  Interestingly, piroxicam 
5’-hydroxylation activity in the F114L mutant was almost 2-fold higher than wild-type 
CYP2C9 in the absence of dapsone.  However, no activation was observed in the F114L 
mutant despite this higher turnover rate, whereas the wild-type *2 and *3 variants all 
exhibited 2-3-fold activation.  Kinetic studies with dapsone and flurbiprofen 
demonstrated that Km values for flurbiprofen were decreased in all recombinant CYP2C9 
enzymes in the presence of dapsone, with the greatest effect observed for the F114L 
mutant, while Vmax estimates generally increased.  These results suggest that dapsone 
binding results in positive cooperativity regarding binding interactions within the active 
site.   
Observations of non Michaelis-Menten or atypical CYP450 kinetics have 
increased in the area of drug metabolism, with the CYP3A4 isoform being the most 
studied [1;2;15;16].  Atypical kinetic events such as activation, autoactivation, and 
substrate inhibition are now being observed in other relevant CYP450 isoforms, 
suggesting that these observations may be common to all CYP450 isoforms to some 
extent [2;3].  This in vitro phenomenon is particularly relevant because it makes 
predicting in vivo pharmacokinetic behavior very complex [17].  Our lab has 
demonstrated that CYP2C9-mediated flurbiprofen 4’-hydroxylation is activated by 
dapsone in human liver microsomes, as well as purified CYP2C9 [2].  We have since 
demonstrated the full kinetic effects of dapsone on flurbiprofen metabolism [18].  
However, the exact mechanism for this activation remains to be defined, although it is 
believed that dapsone and flurbiprofen are bound in the active site simultaneously, being 
described by a two-site model describing activation [1;2].  Therefore, active site 
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properties and binding interactions may be of substantial importance in the mechanism of 
dapsone activation. 
CYP2C9 is polymorphically expressed in humans, with the three major alleles 
being referred to as CYP2C9*1 (wild-type), *2 (R144C), and *3 (I359L).  These allelic 
variants, along with an F114L mutant affecting the “pi-stacking” region of CYP2C9, 
have been shown to variably affect the metabolism of certain substrates [4-8].  Studies 
utilizing these variant enzymes have been instrumental in determining structure-function 
relationships.  Because of these allelic functional differences, it was hypothesized that 
study of the variants and F114L mutant with various substrates and dapsone would 
provide insight into binding characteristics and the activation phenomenon.  
Within the CYP2C9 active site, it has been suggested that there are six substrate 
recognition sites (SRS), which variably contribute to the recognition and binding of 
substrates [19].  While it has been shown that position 144 is not in any known substrate 
recognition sequence [19], Crespi and Miller [6] suggest that this residue plays an 
important role in the interaction between CYP2C9 and oxidoreductase.  However, 
position 359 falls within SRS 5, and thus would be expected to affect binding of certain 
substrates.  The F114L mutant is also important in substrate recognition, as it lies within 
SRS1, and is believed to play a critical role in pi-pi stacking interactions between certain 
aromatic substrates and the active site of CYP2C9 [8].  Therefore, it is likely that these 
variants and F114L mutant will have an affect on dapsone activation of CYP2C9.  
Similar studies by Domanski et al. [20;21] have demonstrated  the importance of specific 
active site residues in the cooperativity of CYP3A4 by α-naphthoflavone.  Additional 
evidence through the use of a L211F/D214E double mutant in the analysis of CYP3A4 
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cooperativity suggests that the effector site is part of the active site [22].  Thus, it is 
possible that the CYP2C9 effector site is also present in the active site.   
While we have shown that dapsone activates flurbiprofen metabolism in vitro, it 
is important to determine how dapsone affects other CYP2C9 substrates.  It has been 
demonstrated with CYP3A4 that in vitro drug-drug interactions are substrate dependent 
[14], and thus, similar observations may be noted with CYP2C9.  Naproxen and 
piroxicam have been shown to be O-demethylated and hydroxylated, respectively, by 
CYP2C9 [11-13].  As a result, these compounds were chosen as prototypical substrates of 
CYP2C9 in addition to flurbiprofen.  Thus, by determining the effects of dapsone on 
various substrates of CYP2C9 in allelic variant and mutant enzymes, the role of various 
active site residues important to the mechanism of activation by dapsone was more fully 
elucidated.  
Experimental results indicate that position 114 in SRS1 is an important 
determinant of CYP2C9 activation of flurbiprofen and piroxicam.  Firstly, flurbiprofen 
hydroxylation was activated almost 5-fold in the F114L mutant, compared to 1.5-fold 
activation in wild-type.  This suggests that without the phenylalanine residue and the 
resulting lack of pi-stacking interaction in the active site, flurbiprofen can bind in a more 
productive orientation (less restricted), resulting in enhanced flurbiprofen hydroxylase 
activity.  Alternatively, piroxicam metabolism was not activated in the F114L mutant.  In 
fact, activity was higher in the F114L mutant than wild-type CYP2C9 in the absence of 
dapsone, suggesting that a pi-stacking interaction with the phenylalanine residue perhaps 
limits maximal piroxicam metabolism.  The results from naproxen are interesting in that 
its metabolism was activated substantially more than either flurbiprofen or piroxicam, 
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suggesting that naproxen may have a different binding orientation than the other CYP2C9 
substrates.  This is not completely unexpected since naproxen demethylation exhibits a 
biphasic kinetic profile suggestive of homotropic cooperativity in and of itself [12].  In 
addition, there was no substantial difference in the level of activation for the *2 variant 
and F114L mutant when compared to wild-type, indicating that these residues are not 
important determinants in the activation of naproxen.  Conversely, the *2 variant did 
seem to have a minor positive effect on the activation of piroxicam (3-fold activation), 
compared to wild-type CYP2C9 (2-fold activation).  However, the effect was opposite of 
what would be expected if the theory of Crespi et al. [6] is followed, which argues that 
the arginine at position 144 provides an important charge pair for the 
P450/oxidoreductase interaction.  Thus, a decrease in the degree of activation in this 
variant with piroxicam would have been expected, due to reduced electron flow.  This 
argues that the R144C variant more likely alters piroxicam activation by having the less 
bulky cysteine residue present in the active site, resulting in enhanced productive binding 
by piroxicam. 
Kinetic studies with dapsone and flurbiprofen support the theory that dapsone and 
flurbiprofen have their own distinctive binding regions within the active site, as dapsone 
lowered flurbiprofen Km in all enzymes (Table 4.1), thus increasing the affinity and not 
displacing flurbiprofen from the active site.  The greatest affect was observed by the 
F114L mutant, where the Km for flurbiprofen hydroxylation decreased from 246 to 44 
µM, additional evidence suggesting the importance of the pi-stacking region to the 
activation of flurbiprofen.  In a previous manuscript, we have measured both flurbiprofen 
and dapsone metabolite in a single incubation [18], further supporting the presence of 
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dapsone in the active site, and thus the two-site binding model.  In addition, Lineweaver-
Burke plots shown in figure 4.3-4.6 were indicative of ternary complex formation, except 
for the *3 variant (Figure 4.5).  Reasons for this may be the almost linear Michaelis-
Menten fits due to substantially lower activity.  The ternary complex model is in 
opposition to the ping pong model, which describes the release of one product at a time.   
It appears likely then that dapsone binding within the CYP2C9 active site causes a 
change in the active site conformation, resulting in a heterotropic positive cooperativity 
that differentially affects CYP2C9 substrates, depending upon binding location in the 
active site. 
Overall, results suggest that the interactions important for activation most likely 
take place in the active site, as the F114L mutant displayed enhanced activation for 
flurbiprofen, while diminishing activation for piroxicam, and not affecting naproxen 
activation.  This, coupled with naproxen being activated substantially more than 
flurbiprofen or piroxicam support the notion that the level of CYP2C9 activation by 
dapsone is substrate dependent.  These results provide additional evidence that dapsone 
activation  (positive cooperativity) occurs as a result of binding interactions within the 
CYP2C9 active site, and not at an external allosteric site.  Studies utilizing chimeric 
2C9/19 and CYP2C19 mutant enzymes to more specifically determine important 
regions/residues for binding of the prototypical CYP2C9 substrates, as well as spectral 
binding studies for flurbiprofen in the absence/presence of dapsone are ongoing and will 
be reported in the next chapter.   
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Table 4.1.14 Activation of CYP2C9 Allelic Variant Enzymes by Dapsone 
Kinetic parameters for formation of 4'-hydroxy flurbiprofen in absence and presence of 
dapsone (Standard Error) 
 
Vmax expressed as pmol/min/pmol P450, Km as µM    
 Treatment 2C9 WT 2C9*2     
(R144C) 
2C9*3 
(I359L)  
       2C9  
     (F114L) 
 
       
Vmax 0 Dapsone 13.2 (0.3) 3.3 (0.2) 0.46 (0.1) 5.8 (0.3)  
 2µM Dapsone 14.5 (0.9) 3.7 (0.2) 0.59 (0.1) 5.1 (0.2)  
 5µM Dapsone 13.0 (0.4) 3.5 (0.1) 0.78 (0.05) 5.9 (0.1)  
       
Km 0 Dapsone 30.6 (1.8) 28.1 (4.8) 81.3 (19.9) 246 (21.1)  
 2µM Dapsone 26.0 (4.6) 17.2 (2.9) 73.8 (22.7) 64.4 (4.7)  
 5µM Dapsone 16.0 (1.5) 10.8 (1.1) 64.5 (8.1) 44.1 (1.5)  
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Figure 4.1.25 Structures of Three CYP2C9 Substrates 
Structures of the three CYP2C9 substrates studied for activation by dapsone.  Arrows 
indicate site of metabolism. 
C
CH3
COOH
H
F CH3O
C
CH3
H
COOH
NaproxenFlurbiprofen
N
S
N
O
N
H
O O
CH3
OH
Piroxicam
102 
 
 
 
 
Figure 4.2.26 Screen of Dapsone Activation of CYP2C9 Allelic Variants and F114L 
Mutant 
Activation of flurbiprofen 4’-hydroxylation (Panel A), naproxen demethylation (Panel 
B), and piroxicam 5’-hydroxylation (Panel C) by 10 µM dapsone in CYP2C9 WT, *2 
(R144C) and *3 (I359L) allelic variants, and F114L mutant.  Flurbiprofen, naproxen and 
piroxicam concentrations were also at 10 µM.  Numbers in parentheses above shaded 
bars indicate (-fold) activation by dapsone. 
 
 
 
 
 
 
2C9WT R144C I359L F114L
0
2
4
6
8
10
12
Fl
ur
bi
pr
of
en
 4
'-H
yd
ro
xy
la
tio
n 
(p
m
ol
/m
in
/p
m
ol
 P
45
0)
0 Dapsone
10 uM Dapsone
(2.1 x)
A
(1.6 x)
(2.0 x)
(4.8 x)
2C9WT R144C I359L F114L
0.0
0.5
1.0
1.5
Na
pr
ox
en
 D
em
et
hy
la
tio
n 
(p
m
ol
/m
in
/p
m
ol
 P
45
0)
0 Dapsone
10 uM Dapsone
B
(5.7 x)
(5.1 x)
(1.5 x)
(5.1 x)
2C9WT R144C I359L F114L
0.00
0.02
0.04
0.06
0.08
0.10
Pi
ro
xi
ca
m
 5
'-H
yd
ro
xy
la
tio
n 
(p
m
ol
/m
in
/p
m
ol
 P
45
0)
0 Dapsone
10 uM Dapsone
C
(2.2 x)
(3.2 x)
(1.1 x)
103 
 
 
 
 
 
Figure 4.3.27 Dapsone Activation of Flurbiprofen 4’-Hydroxylation in CYP2C9 
Wild Type 
Kinetic effects of 2 and 5 µM dapsone on flurbiprofen  4’-hydroxylation in purified 
CYP2C9 wild-type enzyme. Inset shows Lineweaver-Burke plot displaying formation of 
a ternary complex. 
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Figure 4.4.28 Dapsone Activation of Flurbiprofen 4’-Hydroxylation in CYP2C9 *2 
Kinetic effects of 2 and 5 µM dapsone on flurbiprofen  4’-hydroxylation in purified 
CYP2C9*2 (R144C) variant. Inset shows Lineweaver-Burke plot displaying formation of 
a ternary complex. 
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Figure 4.5.29 Dapsone Activation of Flurbiprofen 4’-Hydroxylation in CYP2C9 *3 
Kinetic effects of 2 and 5 µM dapsone on flurbiprofen  4’-hydroxylation in purified 
CYP2C9*3 (I359L) variant. Inset shows Lineweaver-Burke plot displaying lack of 
formation of a ternary complex. 
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Figure 4.6.30 Dapsone Activation of Flurbiprofen 4’-Hydroxylation in F114L 
Mutant 
Kinetic effects of 2 and 5 µM dapsone on flurbiprofen  4’-hydroxylation in purified 
CYP2C9 F114L mutant.  Inset shows Lineweaver-Burke plot displaying formation of a 
ternary complex. 
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CHAPTER V 
 
 
 
Additional Studies into the Mechanism of CYP2C9 Activation 
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5.1.  Introduction 
 
The cytochrome P450 superfamily of enzymes are the most important enzymes 
responsible for metabolism of exogenous xenobiotic substrates.  It has been found that 
many of these substrates, particularly those metabolized by CYP3A4, display kinetic 
profiles that are not consistent with the Michaelis-Menten model.  In fact, it was initially 
thought that CYP3A4 was the only major CYP isoform contributing to atypical kinetic 
profiles.  Other groups have since shown that other CYP isoforms can display atypical 
kinetics as well [1-3].  Recently, our group has shown that dapsone, a compound used to 
treat Pneumocystis carinii infections in AIDS patients, can activate the metabolism of a 
number of CYP2C9 substrates, including flurbiprofen, naproxen, and piroxicam [4].  
Kinetic evidence from this study supports our main hypothesis, which is that both 
effector (dapsone) and the substrate may be present in the active site simultaneously, both 
having access to the reactive oxygen.  Studies have been conducted to determine the 
structural requirements for this activation (chapter 3), as well as the effects of amino acid 
mutations on the ability of dapsone to activate CYP2C9-mediated metabolism (chapter 
4).  However, evidence is still lacking for what regions or residues within the active site 
are important in the catalysis of certain CYP2C9 substrates relative to one another within 
the active site, and just how dapsone affects this binding and/or orientation of substrates.   
It has been proposed that the CYP2C enzymes possess six substrate recognition 
sites (SRSs) or regions that variably recognize and bind substrates [5].  One approach to 
determining the important regions and residues within a given CYP for catalytic activity 
is the use of chimeric and mutant enzymes.  Human P450s CYP2C9 and CYP2C19 both 
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metabolize a number of clinically relevant drugs.  However, these isoforms have very 
different substrate specificities despite differing in only 43 of 490 amino acids.  For 
example, CYP2C9 metabolizes many NSAIDs such as flurbiprofen [6;7], naproxen [8;9], 
and ibuprofen [10], whereas CYP2C19 lacks substantial activity towards these substrates.  
As a result, amino acid regions may be interchanged between these enzymes through 
cloning techniques to determine which ones are vital to binding certain substrates or 
inhibitors.  For example, it has been shown that by replacing amino acids 227-338 (SRS 3 
and 4) in CYP2C19 with the corresponding region of CYP2C9, a high-affinity enzyme 
for binding of the CYP2C9 inhibitor sulfaphenazole was created [11].  In addition, it was 
found that two amino acid substitutions in CYP2C19 (N286S, I289N), which are present 
in SRS 4, also result in high-affinity sulfaphenazole binding [11].  This same technique 
was utilized to determine binding regions important for catalytic activity towards 
flurbiprofen, naproxen, and piroxicam, as well as activation of these chimeric and mutant 
enzymes by dapsone.  
Despite kinetic evidence suggesting the presence of dapsone in the active site 
during activation of CYP2C9 [4], and literature suggesting that dapsone is also a 
substrate for CYP2C9 [12], conclusive evidence for the mechanism of how dapsone 
causes activation is still lacking.  Examples of possible mechanisms are that dapsone 
simply causes flurbiprofen to bind with higher affinity, or in a more productive 
orientation due to steric or electronic constraints imposed upon the active site.  A 
technique often used to measure affinity for binding to CYP isoforms is difference visible 
spectroscopy, or spectral binding studies.  To date, spectral binding studies involving 
CYP2C9 are few in number.  However, spectral binding studies have been performed to 
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determine structural requirements for sulfaphenazole inhibition of CYP2C9 [13;14], for 
which it is a known potent, selective inhibitor [15] [16].  We have performed similar 
studies with the goal of determining if the presence of dapsone directly affects the affinity 
of CYP2C9 for binding of flurbiprofen, as kinetic evidence suggests [4].   
In addition to dapsone affecting the binding affinity of substrates, it may also 
affect the binding orientation of substrate within the active site.  Ibuprofen is a chiral 
substrate for CYP2C9, with both the (S)- and (R)-enantiomers being 2- and 3-
hydroxylated [10].  Having two major products from both enantiomers has allowed study 
of the regiospecificity and enantioselectivity for activation of CYP2C9-mediated 
ibuprofen metabolism.  Similar studies have been performed with CYP3A4 by studying 
the ratio of 1’- and 4-hydroxy triazolam formed from triazolam under different incubation 
conditions [17].  Thus by observing a difference in the ratio of 2- and 3-hydroxy 
ibuprofen formation, the effects of dapsone on the relative orientation of ibuprofen within 
the active site will be studied in hopes of discovering additional evidence for the presence 
of multiple binding regions within the CYP2C9 active site.   
In addition to dapsone analog studies for activation of CYP2C9-mediated 
flurbiprofen 4’-hydroxylation (chapter 3), it has been theorized that perhaps the major 
metabolite of dapsone, hydroxy dapsone, could also be an activator of CYP2C9.  To our 
knowledge, this would represent the first example of a non-parent compound (metabolite) 
activating CYP-mediated metabolism.  Consequently, studies were performed to screen 
the ability of hydroxy-dapsone to activate flurbiprofen, naproxen, and piroxicam 
metabolism.  Overall, this group of studies has been performed to gain an increased 
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understanding of the binding characteristics and activation of CYP2C9-mediated 
metabolism. 
 
5.2.  Methods 
 
Chemicals.  Acetonitrile and dibasic potassium phosphate were obtained from 
Fisher Scientific Co. (Pittsburgh, PA).  (S)-Flurbiprofen, 4’-hydroxy flurbiprofen, and 2-
fluoro-4-biphenyl acetic acid (internal standard) were gifts from Pharmacia Corp. 
(Kalamazoo, MI).  Dapsone was purchased from Sigma Chemical Co. (St. Louis, MO) 
and hydroxy-dapsone was a gift from Reggie Frye at Pittsburgh University.  All other 
chemicals were obtained from commercial sources and were of the highest purity 
available.  CYP2C9/19 chimeric enzymes were constructed by Dr. Robert L. Haining and 
provided to us by Dr. Allan E. Rettie at the University of Washington as described below.  
CYP2C19 mutant enzymes were also provided by Dr. Allan E. Rettie at the University of 
Washington and constructed as described below.  CYP2C9 expressed microsomes were a 
gift from Camitro Corp. (Menlo Park, CA). 
Chimera construction.  The plasmids pFB2C9 and pFB2C19 were used for all 
DNA manipulations, taking advantage of the common, unique, and naturally occurring 
restriction-endonuclease sites SmaI (at the codon specifying amino acid 228), PstI (291-
292), and SphI (340) within each cDNA.  Standard techniques were used for the 
digestion, analysis, isolation, and subsequent re-ligation of subcloned DNA fragments.  
Insertions were confirmed by restriction mapping and the complete re-sequencing of each 
newly created cDNA.  Reconstructed plasmids (pFB2C9/19 [340-490], pFB2C19/9 [340-
490], pFB2C19/9 [228-292], pFB2C9/19 [228-292], pFB2C9/19 [228-340]) were used 
112 
directly in the creation of recombinant baculovirus DNA by the Bac-to-BacTM method 
(Life Technologies).  Recombinant ‘bacmid’ DNA was then used to transfect T.ni cells, 
resulting in a long-term viral stock for subsequent amplification and infection of T.ni 
expression cultures.  All five purified chimeric proteins provided typical P450 spectra 
with little or no evidence of P420 formation upon treatment with carbon monoxide and 
sodium dithionite.   
Chimera incubation conditions.  Chimeric P450 enzymes were reconstituted with 
P450 reductase and cytochrome b5 in a 1:2:1 ratio (5 pmol P450: 10 pmol reductase: 5 
pmol b5 per incubation) with dilauroylphosphatidylcholine vesicles (10 µg) extruded 
through a 200 nm filter.  The reconstituted enzymes were incubated in the presence of 
300 µM (S)-flurbiprofen, (S)-naproxen, or piroxicam and 50 mM potassium phosphate 
buffer, pH 7.4 in a total volume of 200 µL (in triplicate).  Reactions were initiated by the 
addition of 1mM NADPH and carried out for 20 minutes (45 minutes for piroxicam) at 
37°C.  Incubations with flurbiprofen were quenched by adding 200 µl acetonitrile 
containing internal standard (180 ng/mL 2-fluoro-4-biphenylacetic acid), followed by 
addition of 40 µl ½-strength H3PO4.  Incubations with naproxen were quenched by 
adding 200 µl acetonitrile followed by addition of 40 µl ½-strength H3PO4, while 
piroxicam reactions were quenched by adding 20 µl perchloric acid, followed by directly 
placing incubation tubes on ice.  Samples from all incubations were then centrifuged at 
10,000 rpm for 5 minutes, placed into autosampler vials, and 10-100 µl injected onto 
HPLC system.  Incubations examining dapsone (20 µM) activation of chimeras 
exhibiting flurbiprofen hydroxylase activity were carried out as described above with 300 
µM (S)-flurbiprofen.  
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CYP2C19 mutant enzymes.  CYP2C19 mutant enzymes are labeled as 2C19 KS, 
KSN, KSEN, KN, and SN(2).  Amino acid mutations were made at positions 241 (Glu 
(E) to Lys (K)), 286 (Asn (N) to Ser (S)), 288 (Val (V) to Glu (E)), and 289 (Ile (I) to 
Asn (N)) in various combinations, and were constructed according to methods previously 
reported [11].  Incubation conditions of CYP2C19 mutants with (S)-flurbiprofen were 
same as described above for 2C9/19 chimeric enzymes with regards to activity screening 
and dapsone activation. 
Analysis of 4’-hydroxy flurbiprofen.  4’-Hydroxy flurbiprofen was analyzed by 
HPLC with fluorescence detection and comparison to a standard dissolved in 50:50 (v/v), 
acetonitrile:50 mM potassium phosphate buffer pH 7.4.  The HPLC system consisted of a 
Waters 501 HPLC pump, a Waters 717 autosampler and a Waters 470 fluorescence 
detector set at an excitation wavelength of 260 nm and an emission wavelength of 320 
nm.  The mobile phase consisted of 45:55 (v/v), acetonitrile:20 mM K2HPO4, pH 3.0 
pumped at 1 ml/min through a Brownlee Spheri-5 C18 4.6 x 100 mm column. 4’-
Hydroxy flurbiprofen and internal standard eluted at approximately 2.2 and 4.8 minutes, 
respectively. 
Analysis of desmethylnaproxen.  Desmethylnaproxen was analyzed identically to 
4’-hydroxy flurbiprofen except that the fluorescence detector was set at an excitation 
wavelength of 230 nm and an emission wavelength of 340 nm, and no internal standard 
was used.  Desmethylnaproxen eluted at approximately 2.1 minutes. 
Analysis of 5’-hydroxy piroxicam.  5’-Hydroxy piroxicam was analyzed by HPLC 
with UV detection (365 nm).  The HPLC system was as described above, but was fitted 
to a Waters 486 UV detector.  The mobile phase consisted of 50:50 (v/v), acetonitrile:50 
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mM K2HPO4, pH 3.0 pumped at 1 mL/min through a Phenomenex Luna C18 5 µm, 4.6 x 
150 mm column.  Retention time for 5’-hydroxy piroxicam was approximately 4.3 
minutes.   
Data Presentation.  All bar graph data of CYP2C9/19 chimeric and 2C19 mutant 
enzymes are presented as mean of three determinations with error bar signifying standard 
deviation.   
Hydroxy-dapsone activation of flurbiprofen.  Hydroxy dapsone was incubated 
with (S)-flurbiprofen (2-300µM) in a 6x6 matrix design experiment containing 1 pmol 
expressed CYP2C9 microsomes co-expressed with reductase (Camitro Corporation, 
Menlo Park, CA).  Hydroxy dapsone was dissolved in methanol and added to incubations 
such that incubations did not exceed 2.5% organic concentration, with appropriate 
controls used.  Final incubation volume was 0.2 ml and reactions were initiated with 1 
mM NADPH and allowed to incubate at 37°C for 20 minutes.  Incubations were 
quenched by adding 200 µl acetonitrile containing internal standard (180 ng/mL 2-fluoro-
4-biphenylacetic acid), followed by addition of 40 µl ½-strength H3PO4.  Samples were 
then centrifuged at 10,000 rpm for 5 minutes, placed into autosampler vials, and 30-50 µl 
injected onto the HPLC system.  4’-Hydroxy flurbiprofen was analyzed as described 
above, and data were fit in Sigma Plot (Version 6.0) to the two-site model equation [1]:   
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where S is the substrate, B is the effector, Vmax and Km are kinetic constants for substrate 
metabolism, KB is the binding constant for the effector, α is the change in Km resulting 
from effector binding, and β is the change in Vmax from effector binding.  For activation, 
α<1 and/or β>1.   
Spectral Binding Studies. Expressed CYP2C9 microsomes (gift from Camitro 
Corp.) were diluted from 0.7 to 0.2µM in 50mM potassium phosphate buffer with 1mM 
EDTA and 1mM N-acetyl cysteine (an antioxidant to prevent breakdown of hydroxy-
dapsone), at pH 7.4, and equally divided between sample and reference blocked cuvettes 
(900µL).  The instrument used was a DW-2000 UV-Vis Spectrophotometer (SLM 
Instruments, Inc.), specifically designed to analyze turbid samples.  In the study with 
flurbiprofen alone, 5µL of a methanolic solution (6% DMSO) was added to both cuvettes 
as a background control, since both dapsone and hydroxy-dapsone were dissolved in this 
vehicle.  After a baseline was recorded, 5µL aliquots of racemic-flurbiprofen was added 
to the sample cuvette, with the same volume of 100mM potassium phosphate pH 7.4 
being added to the reference cuvette.  After 3 minutes, the difference spectra were 
recorded between 350 and 500nm at room temperature.  Concentrations of flurbiprofen 
ranged to 155µM with successive aliquot additions.  The binding experiments of 
flurbiprofen in the presence of dapsone and hydroxy dapsone (20µM added at the 
beginning) were carried out exactly the same as flurbiprofen alone.  The slit width was 
set to 6.0nm and a scan rate of 1.0nm/sec was used.  The difference in absorbance 
between the peak (~390nm) and trough (~420nm) of a type I spectra was then plotted vs. 
flurbiprofen concentration and analyzed by nonlinear regression (Sigma Plot, Version 
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6.0) to estimate the Ks (spectral binding constant) from the titration binding curve using 
the following equation:                                 
∆A = BmaxS/Ks + S  (5.2) 
 
Ibuprofen-Dapsone Incubation Conditions.  Human liver tissue for preparation of 
microsomes was obtained through the Liver Tissue Procurement and Distribution 
System.  Based on chart review, none of the patients from whom tissues were obtained 
was taking any medications known to inhibit or induce the P450s.  Microsomal samples 
were prepared according to established methods [18].  Protein content was measured by 
the method of Lowry et al. [19] and P450 content by the method of Omura and Sato [20].  
The final microsomal protein concentration was 200 µg/mL and the total incubation 
volume was 500 µL in 100 mM potassium phosphate, pH 7.4.  Either (R)- or (S)-
ibuprofen (5-200 µM) was added to each tube in the absence or presence of 5 or 10 µM 
dapsone, and reactions were initiated with 1 mM NADPH and allowed to run for 20 
minutes at 37°C.  Reactions were quenched by addition of 500 µL of ethyl acetate: 
hexane (80:20 v/v), and 200 ng ketoprofen was added as internal standard, followed by 
addition of 50 µL 40% phosphoric acid.  Next, 3 mL ethyl acetate:hexane (80:20 v/v) was 
added and samples were vortexed for 20 seconds, then centrifuged at 2000 g for 10 
minutes.  The organic layer was then pipetted off and transferred to a 13x100 tube and 
evaporated to dryness.  These tubes were then sent to Mitch Hamman at Indiana 
University Division of Clinical Pharmacology for analysis.  Data were analyzed and fit 
the Michaelis-Menten equation to generate Km and Vmax estimates for ibuprofen 2- and 3-
hydroxylation. 
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5.3.  Results 
 
CYP2C9/19 Chimeric Enzyme Studies.  CYP2C9/19 chimeric enzymes (Figure 
5.1) were constructed in order to determine which amino acid regions were important for 
catalysis of flurbiprofen, naproxen, and piroxicam.  This provided insight into the active 
site binding characteristics of these compounds.  Results from incubations with 
CYP2C9/19 chimeric enzymes and flurbiprofen show that chimeras 2C9/19 (340-490) 
and 2C19/9 (228-292) had flurbiprofen hydroxylase activity, with mean velocities of 7.38 
and 6.92 pmol/min/pmol P450, respectively (Figure 5.2).  All other chimeras exhibited 
minimal activity towards flurbiprofen.  These same chimeras catalyzed naproxen 
demethylation, although less than CYP2C9 wild-type (Figure 5.3), while only the 2C19/9 
(228-292) chimera exhibited substantial piroxicam hydroxylase activity (Figure 5.4).  In 
fact, this chimera showed higher piroxicam hydroxylase activity than wild-type CYP2C9 
(Figure 5.4).  For activation studies with dapsone involving the chimeras with 
flurbiprofen hydroxylase activity, the 2C9/19 (340-490) chimera was activated in the 
presence of 20 µM dapsone 1.2-fold, while the 2C19/9 (228-292) chimera showed no 
activation (Figure 5.5).   
CYP2C19 Mutant Enzyme Studies.  CYP2C19 mutant enzymes were constructed 
to determine which residues could confer flurbiprofen hydroxylase activity to CYP2C19, 
which has minimal activity towards this substrate.  As can be seen in Figure 5.6, the 
2C19 KSN and KSEN mutants had the greatest activity towards flurbiprofen, with the 
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KSN mutant exhibiting higher activity than wild-type CYP2C9.  Activation studies with 
these enzymes showed that dapsone did not activate flurbiprofen hydroxylase activity in 
either of these CYP2C19 mutants (Figure 5.5).   
Hydroxy-Dapsone Activation of Flurbiprofen 4’-Hydroxylation.  Hydroxy-
dapsone (HDA), the major phase I metabolite of dapsone, was found to activate 
flurbiprofen 4’-hydroxylation.  Data were fit to the two-site effector model equation 
(equation 5.1) to generate a surface plot (Figure 5.7), yielding an α value of 0.98 and a β 
of 1.5 (Table 5.1), indicating no effect on Km, but a increase in Vmax.  This is different 
from dapsone, which affected both the Km and Vmax of flurbiprofen 4’-hydroxylation 
(Figure 5.8) with an α of 0.23 and a β of 1.9 (Table 5.1).  Eadie Hofstee plots were 
prepared to confirm effects on Km and Vmax of flurbiprofen 4’-hydroxylation by hydroxy-
dapsone (Figure 5.9) and dapsone (Figure 5.10).  Interestingly, activation by hydroxy-
dapsone became saturated around 50 µM, while activation by dapsone saturated around 
100 µM (Figures 5.7 and 5.8).   
Spectral Binding Studies.  To determine whether dapsone and hydroxy-dapsone 
affect binding of flurbiprofen directly, spectral binding titration studies were performed.  
Plotting the difference in absorbance between the peak at ~390 nm and trough at ~420 
nm vs. flurbiprofen concentration yields a hyperbolic curve that can be fit by nonlinear 
regression to equation 5.2 to estimate the spectral binding constant (Ks).  In the absence 
of effector, flurbiprofen gave a type I spectra (Figure 5.11, A) with a Ks of 14.1 µM 
(Figure 5.11, B), while in the presence of 20 µM dapsone, flurbiprofen also gave a type I 
spectra (Figure 5.12, A), but with a lower Ks of 2.1 µM (Figure 5.12, B), indicating that 
the presence of dapsone increases the affinity of CYP2C9 for flurbiprofen.  On the other 
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hand, in the presence of hydroxy-dapsone, flurbiprofen gave a type I spectra (Figure 5.13, 
A), with a Ks of 14.0 µM (Figure 5.13, B), similar to flurbiprofen alone, suggesting that 
hydroxy-dapsone does not affect binding of flurbiprofen directly, agreeing with kinetic 
data showing no effect of hydroxy-dapsone on the Km of flurbiprofen.  
Ibuprofen-Dapsone Interaction.  In the absence of dapsone, ibuprofen is 
regioselectively metabolized, with 3-hydroxylation being greater than 2-hydroxylation 
(Figure 5.14).  In the presence of dapsone, however, 3-hydroxylation of (S)-ibuprofen 
was substantially activated (Figure 5.15A), with the Vmax increasing from 1435 to 3026 
pmol/min/mg protein and Km decreasing from 14.2 to 9.2 µM (Table 5.2).  Meanwhile, 
dapsone minimally affected 2-hydroxylation of (S)-ibuprofen (Figure 5.15B).  In 
contrast, dapsone inhibited both the 3- and 2-hydroxylation of (R)-ibuprofen (Figures 
5.16A and B), as Vmax values decreased from 408 to 281 pmol/min/mg protein and 765 to 
569 pmol/min/mg protein, respectively (Table 5.2).  
 
5.4.  Discussion 
 
In this study, CYP2C9 substrate metabolism was monitored by using CYP2C9/19 
chimeric and CYP2C19 mutant enzymes to better understand important binding 
regions/residues within the active site, and perhaps shed some light on atypical kinetics 
(i.e. activation) observed by this isoform.  In addition, the direct effect of dapsone, as 
well as hydroxy-dapsone, on binding of flurbiprofen was studied to provide mechanistic 
information of why dapsone activates flurbiprofen 4’-hydroxylation, and to confirm 
observed kinetic effects of dapsone on CYP2C9.  Lastly, the effect of dapsone on the 
regioselectivity of ibuprofen metabolism was studied to show how the presence of 
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effector can potentially alter the binding orientation of substrate within the active site of 
CYP2C9.  Briefly, the CYP2C19/9 (228-292) and 2C9/19 (340-490) chimeras displayed 
good activity towards flurbiprofen, naproxen, and piroxicam, while the CYP2C19 KSN 
mutant showed the greatest activity towards flurbiprofen, suggesting the importance of 
residues 241, 286, and 289 in catalysis of this substrate.  Dapsone was only able to 
activate flurbiprofen 4’-hydroxylation in the 2C9/19 (340-490) chimera.  It was also 
discovered that hydroxy-dapsone can activate flurbiprofen 4’-hydroxylation similar to 
dapsone, although primarily through a Vmax effect, which spectral binding studies 
confirmed.  Lastly, ibuprofen metabolism was regioselectively and stereoselectively 
altered by dapsone, suggesting a change in ibuprofen binding orientation in the presence 
of dapsone. 
Despite the numerous studies describing atypical kinetics such as positive 
cooperativity, progress has been limited in clearly defining the underlying causes of this 
phenomenon. Cytochrome P450 3A4 is particularly interesting, considering it is the most 
abundant CYP enzyme and metabolizes numerous compounds [21;22].  It has been 
observed that many substrates of CYP3A4 show atypical kinetic profiles [1;23-26], and 
thus, with respect to atypical kinetics, CYP3A4 has been by far the most studied isoform.  
The preponderance of evidence suggests that there are at least two distinct binding 
regions within the CYP3A4 active site.  One model in particular suggests that both 
substrate and effector may be present in the active site simultaneously, each having 
access to the reactive oxygen [1;24].  Our lab has shown evidence that this two-site 
model applies to CYP2C9, an isoform for which dapsone has been shown to cause 
heterotropic positive cooperativity (activation) [4].  However, this study only provides 
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kinetic evidence to support the simultaneous presence of multiple compounds within the 
active site.  Studies exploring binding within the active site would be more helpful in 
understanding the interactions necessary for positive cooperativity to occur.   
Studies with CYP2C9/19 chimeric enzymes suggest that amino acid region 228-
292 is necessary for catalysis of flurbiprofen, naproxen, and piroxicam, as substantial 
activity towards these substrates was conferred when this amino acid region from 
CYP2C9 was placed into CYP2C19.  According to Gotoh, this region lies in SRS 3 and 
part of SRS 4, two of the six proposed substrate recognition sites of CYP2C enzymes [5].  
Interestingly, the CYP2C19 mutants KSN and KSEN, which have single mutations 
within SRS 3 also had good activity towards flurbiprofen 4’-hydroxylation.  The 
mutation at residue 241 (Glutamate to Lysine) is proposed to be within helix G, while 
those at 286 (Asparagine to Serine), 288 (Valine to Glutamate), and 289 (Isoleucine to 
Asparagine) are proposed to be within helix I, which is associated with the substrate 
binding pocket and is one of the most structurally conserved regions of CYP450s [27;28].  
Similar studies have been performed to determine important binding regions for other 
compounds with CYP2C9.  Jung et al. reported that replacement of amino acids 227-338 
in 2C19 with the corresponding region of 2C9 lead to an enzyme with a high affinity for 
sulfaphenazole [11].  In addition, two amino acid substitutions in 2C19 (N286S and 
I289N) conferred high-affinity sulfaphenazole binding [11].  Likewise, Klose et al. found 
that residues 286 and 289 were important in conferring diclofenac and ibuprofen 
hydroxylase activity to CYP2C19 [29].  However, it must be understood that this does 
not necessarily suggest that residues 286 and 289 directly contact the substrate.  In fact, 
based on a homology model generated by Jung et al. [11], these residues are too far away 
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from the heme to directly contact the substrate.  In addition, it was deduced from this 
homology model that the I289N difference lies at the interface of helix I with helix G, 
which has a considerable range of motion according to molecular dynamics studies.  This 
mutation could thus serve to alter the motion of these helices, which in turn could affect 
access of substrate to the heme oxygen or overall protein conformation [11].  However, 
other factors are likely contributing.  Overall, the regions/residues important for catalysis 
of flurbiprofen, naproxen, and piroxicam appear to coincide with a number of other 
studies.  
The effect of dapsone on chimeric and mutant enzyme activity was also 
examined.  It was found that only the CYP2C9/19 (340-490) chimera could be activated 
by dapsone, albeit only 1.2-fold.  We suspect that this may result from this chimeric 
enzyme being primarily CYP2C9 (only residues 340-490 are from CYP2C19), thus still 
possessing the region allowing dapsone to bind and cause positive cooperativity.  In 
addition, the 2C19/9 (228-292) chimera also has residues 340-490 from 2C19, in addition 
to residues corresponding to SRS 1 and 2, and was unable to be activated by dapsone.  
On the other hand, SRS 1 and 2 in the 2C9/19 (340-490) chimera (activated) were from 
CYP2C9, suggesting that these regions may be important for binding dapsone.  This is 
assuming that the catalytic site and effector site for dapsone are one in the same.  
Interestingly, He et al. [30] suggest that perhaps dapsone may interact electrostatically in 
the active site through its sulfone group.  In addition, Ridderstrom et al. have noted that 
Arginines 97 and 108 are important in the catalytic activity of CYP2C9 [31], which are 
present in SRS 1 according to Gotoh [5], implicating this as a possible binding 
determinant for dapsone.  Unfortunately, no chimeric or mutant enzyme has been 
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constructed to explore this potential binding region and its effects on activation.  Until 
more mammalian P450s are crystallized for modeling these interactions, predictions of 
binding sites will be difficult and remain theoretical. 
In addition to dapsone activating CYP2C9-mediated metabolism, it has also been 
shown to be a substrate for this isoform [12;32], with N-hydroxy dapsone being the major 
metabolite.  In previous studies, we have explored effector structural requirements for 
activation of CYP2C9.  One compound that we did not initially screen for activation was 
the hydroxy metabolite of dapsone.  Our studies show that hydroxy-dapsone does activate 
flurbiprofen 4’-hydroxylation, but not naproxen or piroxicam metabolism.  To our 
knowledge, this is the first example of a metabolite that activates CYP-mediated 
metabolism.  Compared to dapsone, however, hydroxy-dapsone causes an increase in 
Vmax without much effect on the Km for flurbiprofen 4’-hydroxylation, whereas dapsone 
increases Vmax and decreases Km, as can be seen by α and β values in table 5.1.  Eadie-
Hofstee plots confirm these effects on Km and Vmax estimates by hydroxydapsone and 
dapsone (Figures 5.9 an 5.10).  In particular, it can be seen that the slope of the Eadie-
Hofstee plots in the presence of increasing concentrations of hydroxy-dapsone are 
relatively parallel, suggesting minimal changes on Km, whereas slopes in the presence of 
dapsone are not parallel, indicating a Km effect.  Based on this kinetic evidence, dapsone 
increases the affinity (decreases Km) of CYP2C9 for flurbiprofen, whereas hydroxy-
dapsone does not.  With regard to the Vmax effects of hydroxy-dapsone on CYP2C9, 
similar results have been observed for CYP3A4, as Shou et al. [24] observed that 7,8-
benzoflavone increased the Vmax for phenanthrene metabolism with minimal changes to 
the Km.   
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To confirm the effects of dapsone and hydroxy-dapsone on binding affinity of 
flurbiprofen, spectral titration binding studies were performed.  Results confirm that the 
presence of dapsone does cause flurbiprofen to bind CYP2C9 more efficiently, as 
spectral binding constant (Ks) estimates for flurbiprofen were decreased from 14.1 to 2.1 
µM.  This increased binding efficiency likely contributes to an increase in catalytic 
efficiency for CYP2C9-mediated flurbiprofen 4’-hydroxylation.  It is conceivable to 
suggest that the presence of dapsone effectively reduces the size of the active site, thus 
forcing flurbiprofen to bind more tightly, explaining the Km and Ks effects observed.  On 
the other hand, the presence of hydroxy-dapsone had no direct effect on binding of 
flurbiprofen, with Ks values remaining unchanged.  Nonetheless, hydroxy-dapsone is still 
able to activate flurbiprofen 4’-hydroxylation.  Reasons for this difference are likely 
numerous and complicated.  One possibility is that hydroxy-dapsone may in some way 
provide an environment which leads to more efficient electron flow, and hence, reactive 
oxygen.  It has also been suggested that hydrogen bonding and disordering the orientation 
of water molecules within the active site may affect catalytic activity of the enzyme.  For 
example, through site-directed mutagenesis studies, Atkins and Sligar have found an 
important role for hydrogen bonding within the active site of cytochrome P450cam [33].  
They determined that a hydrogen bond between Tyr96 and the ketone group of camphor 
placed camphor in such a position as to promote efficient catalysis.  By mutating this 
residue to a phenylalanine (resulting in no H-bond), it was found that the free energy 
(∆G) for binding was unaffected, while the ∆G for spin state conversion was much higher 
compared to wild-type enzyme, with only 59% conversion from low to high spin, versus 
95% for wild-type enzyme [33].  This was rationalized by suggesting that the hydrogen 
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bond placed camphor in such a way as to protect the heme from solvent interaction, thus 
promoting efficient electron flow to the heme, and hence higher spin state conversion 
[33].  Other groups have proposed that Vmax effects may stem from expulsion of water 
molecules from the active site, which may help prevent uncoupling of the P450 cycle, 
leading to production of hydrogen peroxide or excess water formation [34-36].  It is 
reasonable to suggest that hydroxy-dapsone, although it has a very similar structure, 
interacts within the active site differently than does dapsone, perhaps disrupting the water 
orientation and driving the enzyme towards a higher percentage of high-spin state without 
affecting binding of the activated substrate. 
Similar to the NSAIDs flurbiprofen and naproxen, ibuprofen is a substrate whose 
metabolism is activated by dapsone.  Ibuprofen is a chiral substrate for CYP2C9 that 
undergoes both 2- and 3-hydroxylation for both enantiomers.  We have observed that 3-
hydroxylation of these enantiomers is greater than 2-hydroxylation, which agrees with a 
previous study [10].  Interestingly, in the presence of dapsone, the 3-hydroxylation of (S)-
ibuprofen is activated (Figure 5.15), while 2-hydroxylation is minimally affected.  
Meanwhile, dapsone appears to weakly inhibit the 2- and 3-hydroxylation of (R)-
ibuprofen.  Thus, there appears to be a regioselective, as well as an enantioselective effect 
of dapsone on ibuprofen metabolism.  Results from (S)-ibuprofen suggest that dapsone 
not only alters the regioselectivity towards 3-hydroxylation, but activates the enzyme 
overall, as the sum of the velocities for 2- and 3-hydroxylation are substantially 
increased.  This information suggests that dapsone does alter the shape of the active site, 
such that the binding orientation of ibuprofen is altered, as opposed to just increasing the 
catalytic activity of the CYP2C9 enzyme through some other mechanism.  This is not to 
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say that alteration of active site shape is the only factor involved, but it likely contributes 
to activation.  Similar studies have been conducted with CYP3A4 and triazolam 
metabolism.  Schrag and Wienkers [17] studied the 1’- and 4-hydroxylation of triazolam 
by CYP3A4 and observed altered ratios of the 4-hydroxy to 1’-hydroxy metabolite under 
different incubation conditions.  They rationalized their findings by suggesting that data 
was consistent with a two-site model for binding.  Whether the change in active site 
topology induced by dapsone is a result of dapsone being in the active site, or due to a 
change in protein conformation still remains unclear.  However, kinetic evidence from 
one of our previous studies suggests the presence of dapsone in the active site 
simultaneously with substrate [4].  Results for (R)-ibuprofen are different in that dapsone 
appears to inhibit 2- and 3-hydroxylation of this enantiomer, although rather weakly.  It is 
likely that the (R)-enantiomer itself has a slightly different binding orientation than the 
(S)-enantiomer, resulting in the observed differences and suggesting multiple binding 
domains or sites. 
Overall, results from these studies provide additional information about binding 
of substrates to CYP2C9 active site, as well as possible mechanisms of activation, one of 
which is alteration of binding orientation by dapsone.  Perhaps the most interesting result 
from these studies is the discovery that the major metabolite of dapsone (hydroxy-
dapsone) can also serve to activate flurbiprofen 4’-hydroxylation, although apparently 
through a slightly different mechanism.  Future studies will include measuring oxygen 
consumption and hydrogen peroxide formation by CYP2C9 in the presence of dapsone 
and hydroxy-dapsone to characterize potential effects on uncoupling mechanisms. 
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Figure 5.1.31 Constructed CYP2C9/19 Chimeric Enzymes 
CYP2C9/19 chimeric enzymes constructed for binding region studies.   
SRS refers to substrate recognition sequences and restriction enzymes are shown at  
splice sites.  All chimeras were composed of 490 residues. 
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Figure 5.2.32 Flurbiprofen 4’-Hydroxylation by CYP2C9/19 Chimeric Enzymes 
Flurbiprofen 4’-hydroxylation in CYP2C9/19 chimeric enzymes.   Activity for CYP2C9 
and 2C19 wild-type are included for comparison.   
Figure 5.3.33 Naproxen Demethylation by CYP2C9/19 Chimeric Enzymes 
Naproxen demethylation in CYP2C9/19 chimeric enzymes.  Activity for CYP2C9 and 
2C19 wild-type are included for comparison.  
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Figure 5.4.34 Piroxicam 5’-Hydroxylation by CYP2C9/19 Chimeric Enzymes 
Piroxicam 5’-hydroxylation in CYP2C9/19 chimeric enzymes.  Activity for CYP2C9 and 
2C19 wild-type are included for comparison. 
Figure 5.5.35 Dapsone Activation in CYP2C9/19 Chimeric and 2C19 Mutant 
Enzymes 
Screen for activation of flurbiprofen 4’-hydroxylation in active 2C9/19 chimeras and 
2C19 mutants. 
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Figure 5.6.36 Flurbiprofen 4’-Hydroxylation in CYP2C19 Mutant Enzymes 
Flurbiprofen 4’-hydroxylation in E.coli purified CYP2C19 mutant enzymes. Mutated 
residues are explained in the Methods section.   
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Figure 5.7.37 Hydroxy-Dapsone Activation of Flurbiprofen 4’-Hydroxylation (3-D 
Plot) 
Three-dimensional surface plot showing activation of flurbiprofen 4’-hydroxylation by 
hydroxy-dapsone.  The surface is the fit to equation 5.1. 
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Figure 5.8.38 Dapsone Activation of Flurbiprofen 4’-Hydroxylation (3-D Plot) 
Three-dimensional surface plot showing activation of flurbiprofen 4’-hydroxylation by 
dapsone.  The surface is the fit to equation 5.1. 
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Table 5.1.15 Activation of Flurbiprofen 4’-Hydroxylation by Hydroxy-Dapsone and 
Dapsone 
Kinetic parameters for activation of flurbiprofen 4’-hydroxylation by dapsone and 
hydroxy-dapsone (HDA).  Parameters were estimated by fitting data to equation 5.1. 
 
Effector Km (SE) Vmax (SE) KB (SE)    
 (µM) (pmol/min/pmol 
P450) 
(µM) α (SE) β (SE) R2 
Dapsone 6.6 (0.5) 6.8 (0.2) 35.7 (5.7) 0.2 (0.03) 1.9 (0.06) 0.99 
HDA 9.5 (1.2) 7.3 (0.3) 2.6 (0.8) 0.98 (0.2) 1.5 (0.1) 0.99 
Km is the Michaelis-Menten constant; Vmax is the maximal velocity; KB is the binding 
constant for the effector; α is the change in Km resulting from effector binding; β is the 
change in Vmax resulting from effector binding.  An α or β value=1 indicates no change in 
Km or Vmax, respectively. 
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Figure 5.9.39 Eadie-Hofstee Plot for Hydroxy-Dapsone Effect on Flurbiprofen 4’-
Hydroxylation 
Eadie-Hofstee plots showing the effect of hydroxy-dapsone on flurbiprofen 4’-
hydroxylation.  Relatively parallel lines indicates minimal effect on Km, while different 
y-axis intercepts indicate increase in Vmax. 
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Figure 5.10.40 Eadie-Hofstee Plot for Dapsone Effect on Flurbiprofen 4’-
Hydroxylation 
Eadie-Hofstee plots showing the effect of dapsone on flurbiprofen 4’-hydroxylation.  
Different slopes indicate effect on Km while different y-axis intercepts indicate increase 
in Vmax. 
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Figure 5.11.41 Flurbiprofen Type I Difference Spectra 
Titration of CYP2C9 with flurbiprofen alone. (A) Observed type I difference spectra. (B) 
Plot of ∆A 390-420 (from A) vs flurbiprofen concentration fit to equation 5.2 with a Ks = 
14.1. 
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Figure 5.12.42 Flurbiprofen Type I Difference Spectra in Presence of Dapsone 
Titration of CYP2C9 with flurbiprofen in presence of 20 µM dapsone. (A) Observed type 
I difference spectra. (B) Plot of ∆A 390-420 (from A) vs flurbiprofen concentration fit to 
equation 5.2 with a Ks = 2.1. 
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Figure 5.13.43 Flurbiprofen Type I Difference Spectra in Presence of Hydroxy-
Dapsone 
Titration of CYP2C9 with flurbiprofen in the presence of 20 µM hydroxy-dapsone. (A) 
Observed type I difference spectra. (B) Plot of ∆A 390-420 (from A) vs flurbiprofen 
concentration fit to equation 5.2 with a Ks = 14.0. 
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Figure 5.14.44 Ibuprofen Metabolism 
Metabolic pathways for both (S)- and (R)-ibuprofen. 
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Figure 5.15.45 (S)-Ibuprofen 2- and 3-Hydroxylation 
(S)-ibuprofen 3-hydroxylation (A) and 2-hydroxylation (B) in absence and presence of 5 
and 10 µM dapsone.  Fits were to equation 5.3. 
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Figure 5.16.46 (R)-Ibuprofen 2- and 3- Hydroxylation 
(R)-ibuprofen 3-hydroxylation (A) and 2-hydroxylation (B) in the absence and presence 
of 5 and 10 µM dapsone. Fits were to equation 5.3. 
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Table 5.2.16 Effect of Dapsone on (S)- and (R)-Ibuprofen Metabolism 
Kinetic parameters for (S)- and (R)-ibuprofen metabolism in the absence and presence of 
dapsone.  Data were fit to Michaelis-Menten equation (equation 5.3). 
 
                                  (S)-Ibuprofen 3-hydroxylation        (S)-Ibuprofen 2-hydroxylation 
Dapsone Vmax (SE) Km (SE) Vmax (SE) Km (SE) 
µM pmol/min/mg protein µM pmol/min/mg protein µM 
0  1435.1 (89.7) 14.2 (4.0) 615.4 (40.3) 18.5 (5.1) 
5 1949.5 (139.2) 12.4 (4.2) 472.1 (64.6) 66.2 (23.7) 
10  3025.2 (117.2) 9.2 (1.9) 700.8 (43.5) 26.9 (6.1) 
 
                                  (R)-Ibuprofen 3-hydroxylation        (R)-Ibuprofen 2-hydroxylation 
Dapsone Vmax (SE) Km (SE) Vmax (SE) Km (SE) 
µM pmol/min/mg protein µM pmol/min/mg protein µM 
0  764.3 (65.2) 23.7 (7.7) 407.8 (41.3) 19.6 (8.1) 
5 749.1 (81.8) 13.1 (6.6) 313.8 (17.4) 11.4 (3.1) 
10  569.4 (65.6) 16.6 (8.3) 281.0 (30.3) 14.4 (7.0) 
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CHAPTER VI 
 
 
 
Sensitive and Specific High-Performance Liquid 
Chromatographic Assay for 4'-Hydroxyflurbiprofen and 
Flurbiprofen in Human Urine and Plasma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter published in Journal of Chromatography B [749, 119-125 (2000)]. 
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6.1.  Introduction 
 
Flurbiprofen is an arylpropionic non-steroidal anti-inflammatory drug used in the 
treatment of pain and inflammation.  In humans, flurbiprofen is eliminated primarily by 
oxidation to form 4'-hydroxyflurbiprofen (Fig. 6.1), which accounts for about 86% of the 
oxidative metabolites [1].  The oxidative metabolites and parent compound are also 
subject to glucuronidation or sulfation [2;3].  It has been shown that the formation of 4'-
hydroxyflurbiprofen is mediated almost exclusively by cytochrome P450 2C9 in a non-
stereoselective manner [4;5].  As a result, flurbiprofen may be used as an in vitro probe 
for CYP2C9 activity, without the need for measuring the enantiomers.  More recently, it 
has been shown that flurbiprofen may be used as an in vivo probe to estimate the activity 
of CYP2C9 in human subjects [6]. 
Other HPLC methods have been described for the detection of racemic 
flurbiprofen and its metabolites in urine and plasma [3;7-9], in which the analytes must 
be extracted from their respective biological matrices.  This paper describes a sensitive 
and specific procedure for the detection of flurbiprofen and its 4’-hydroxy metabolite in 
which no extraction step is utilized, thus reducing the amount of time and error involved 
in quantitation.  The method involves a reverse-phase liquid chromatography column and 
fluorescence detection, and is sufficiently sensitive to quantitate flurbiprofen and 4'-
hydroxyflurbiprofen in amounts as low as 0.25 µg/ml and 0.05 µg/ml, respectively.  This 
assay was used to quantitate concentrations of flurbiprofen and 4'-hydroxyflurbiprofen in 
urine and plasma from human subjects to evaluate the use of flurbiprofen as an in vivo 
probe for cytochrome P450 2C9 activity.  
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6.2.  Methods 
 
Reagents and chemicals.  Acetonitrile, dibasic potassium phosphate buffer, 
hydrochloric acid and phosphoric acid were obtained from Fisher Scientific Co. 
(Pittsburgh, PA, USA).  rac-Flurbiprofen was purchased from Sigma Chemical (St. 
Louis, MO, USA).  4’- Hydroxyflurbiprofen and 2-fluoro-4-biphenylacetic acid (internal 
standard (IS)) were gifts from Pharmacia (Kalamazoo, MI, USA).  All other chemicals 
were obtained from commercial sources and were of the highest purity available.  Drug-
free human plasma was obtained from the blood bank and drug-free human urine was 
obtained from laboratory personnel. 
 Instrumentation.  The HPLC system consisted of a Waters 501 HPLC pump, a 
Waters 717  autosampler and a Waters 470  scanning fluorescence detector set at an 
excitation wavelength of 260 nm and an emission wavelength of 320 nm (Waters Assoc., 
Milford, MA, USA).  The mobile phase for both urine and plasma consisted of 
acetonitrile—20 mM K2HPO4, pH 3.0 (40:60, v/v) pumped at 1 ml/min through a 
Brownlee Spheri-5  C18 4.6 x 100 mm reversed phase column, with a typical pressure of  
67 bar. 
  Preparation of stock solutions.  Flurbiprofen and 4'-hydroxyflurbiprofen stock 
solutions were prepared by dissolving each in 50:50 acetonitrile:H20 to make a 1 mg/ml 
solution.  From this stock solution, dilutions were made to prepare 50, 10, 5, and 0.5 
µg/ml solutions for preparation of the standards.  2-fluoro-4-biphenylacetic acid (IS) was 
dissolved in acetonitrile to prepare a 1 mg/ml stock solution.  From this stock solution a 
1000 ng/ml solution was prepared  by adding 0.5 ml of the 1 mg/ml stock to 500 ml 
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acetonitrile.  A 500 ng/ml internal standard solution was prepared by adding 0.25 ml of 
the 1 mg/ml stock to 500 ml acetonitrile.  All stock solutions were stored at 4°C.  
Flurbiprofen and 4'-hydroxyflurbiprofen in urine.  Urine samples (50 µl) were 
prepared by adding 400 µl of purified water and 100 µl 6 M HCl, followed by vortexing 
and incubation at 90°C for 30 minutes to facilitate glucuronide cleavage via acid-
hydrolysis.  Following incubation, 500 µl acetonitrile containing IS (1000 ng/ml of 2-
fluoro-4-biphenylacetic acid) was added and the samples vortexed.  The samples were 
then centrifuged at 14,000g for 5 minutes, and 150 µl of sample transferred to 
autosampler vials and 3-12 µl injected onto the HPLC system for analysis.  Standard 
amounts for flurbiprofen and 4'-hydroxyflurbiprofen ranged from 0.5 to 40 µg/ml (0, 0.5, 
1.0, 2.0, 5, 10, 20, and 40 µg/ml).  Appropriate amounts of 4’-hydroxyflurbiprofen and 
flurbiprofen were added to 50 µl blank urine to prepare standards and then brought to 
final volume of 450 µl by addition of purified water and treated as subject samples. 
Flurbiprofen and 4'-hydroxyflurbiprofen in plasma.  Plasma samples (100 µl) 
were prepared by adding 100 µl acetonitrile, 200 µl IS (500 ng/ml of 2-fluoro-4-
biphenylacetic acid in acetonitrile), and 40 µl  of ½-strength H3PO4  (50:50 H3PO4 : H20), 
followed by vortexing.  The samples were then centrifuged at 14,000g for 10 minutes, 
and 150 µl placed into autosampler vials and 20-75 µl injected onto the HPLC.  The 
standards were prepared to contain concentrations of 0, 0.05, 0.1, 0.25, 0.5, 1.0, 2.0, and 
3.0 µg/ml for 4'-hydroxyflurbiprofen and 0, 0.25, 0.5, 1.0, 2.5, 5.0, 10, and 15 µg/ml for 
flurbiprofen.  Appropriate amounts of 4’-hydroxyflurbiprofen and flurbiprofen were 
added to 100 µl blank plasma and acetonitrile was then added to bring the final volume to 
200 µl, followed by treatment as with the subject samples. 
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Assay validation procedure.  Urine assay validation consisted of replicates of a 
low concentration (1 µg/ml), a middle concentration (12 µg/ml), and a high concentration 
(30 µg/ml) quality control (QC) sample for flurbiprofen and 4’-hydroxyflurbiprofen.  
Plasma assay validation QC concentrations were 1 µg/ml, 12 µg/ml, and 30 µg/ml for 
flurbiprofen, and 0.1 µg/ml, 0.5 µg/ml, and 1.5 µg/ml for 4’-hydroxyflurbiprofen.  Intra-
day variability was tested with 12 replicates of each quality control concentration.  Inter-
day variability was conducted over three days with 6 replicates of each QC concentration.  
Furthermore, low and high QC concentrations (in triplicate) were subjected to three 
freeze-thaw cycles and analyzed.  Finally, processed stability after pretreatment was 
tested by injecting low and high QC samples every 2 hours for 24 hours.  Means, 
standard deviations and coefficients of variation were calculated by standard methods. 
 
6.3. Results 
 
 
Representative HPLC chromatograms illustrating the analysis of 4'-
hydroxyflurbiprofen and flurbiprofen in urine and plasma, as well as a blank for each, are 
shown in Figures 6.2-6.5.  4'-Hydroxyflurbiprofen, IS, and flurbiprofen were separated 
within 16 minutes, with retention times of approximately 3.6, 9.0, and 14.0 minutes, 
respectively.  The standard curves for 4'-hydroxyflurbiprofen and flurbiprofen in urine 
were linear through 40 µg/ml, while the curves for 4'-hydroxyflurbiprofen and 
flurbiprofen in plasma were linear through 3 µg/ml and 15 µg/ml, respectively.  Limits of 
quantitation for 4'-hydroxyflurbiprofen and flurbiprofen in urine and plasma were 0.5 
µg/ml in urine and 0.05 µg/ml and 0.25 µg/ml, respectively, in plasma.  A representative 
subject log plasma concentration versus time curve in Figure 6.6 shows the ability of this 
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assay to sensitively detect flurbiprofen and low 4'-hydroxyflurbiprofen concentrations in 
plasma.  In addition, in 12 subjects receiving flurbiprofen orally, the average urinary 
recovery of total drug after acid cleavage of glucuronide metabolite was 21 mg out of a 
50 mg dose, or about 42% (data not shown). 
Calibration and linearity.  Calibration curves were constructed using seven 
standard concentrations in urine or plasma.  Curves were obtained daily for four days by 
plotting the peak-area ratios of flurbiprofen and 4’-hydroxyflurbiprofen to the IS against 
the corresponding nominal concentration.  Linear calibration curves were generated by 
weighted (1/y) linear regression analysis.   The mean ± s.d. coefficients of determination 
and slopes for 4’-hydroxyflurbiprofen and flurbiprofen in urine (n=4) were 0.996 ± 0.005 
(slope = 6.84 x 10-4 ± 3.99 x 10-5) and 0.994 ± 0.003 (slope = 1.92 x 10-3 ± 1.40 x 10-4), 
respectively, while in plasma (n=4) they were 0.995 ± 0.004 (slope = 4.49 x 10-3 ± 1.78 x 
10-4) and 0.996 ± 0.001 (slope = 1.42 x 10-2 ± 2.45 x 10-4), respectively.  The lower limit 
of quantitation (LOQ) for flurbiprofen and 4’-hydroxyflurbiprofen in each matrix was 
selected as the lowest concentration of the standard curve  
Precision and accuracy.  The precision and accuracy of the urine and plasma 
assays were determined by three days of quality control analysis.  Intra-day (n=12) and 
inter-day (n=3 days; n=24 samples) variability is shown in Tables 6.1 and Table 6.2, 
respectively.  Analyte stability was demonstrated in both urine and plasma by subjecting 
the samples to three freeze-thaw cycles, and injecting the processed quality control 
samples every two hours over a 24 hour period.  Three freeze-thaw cycles had no effect 
on the stability of the analytes in both urine and plasma, as the accuracy of all low and 
high QC concentrations (n=3) for flurbiprofen and 4’-hydroxyflurbiprofen was within 
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15% of expected values (Tables 6.1 and 6.2).  In addition, the coefficients of variation 
were below 11% for all LC and HC amounts (data not shown).  Likewise, processed 
stability after processing was not a factor, as the accuracy of all low and high QC 
concentrations (n=12) was within 10% of expected values, and all coefficients of 
variations were within 8.5% (Tables 6.1 and 6.2). 
6.4.  Discussion 
 
This study describes a rapid and sensitive HPLC method for the detection and 
quantitation of flurbiprofen and 4'-hydroxyflurbiprofen in urine and plasma.  The method 
uses simple protein precipitation with acetonitrile followed by direct sample injection 
resulting in short sample preparation times.  Quality control analysis indicates that the 
assay is precise (C.V.<14%) and accurate (within 15%).  The urinary recovery data and 
the representative plasma concentration-time curve suggest that this method is sufficient 
for attaining accurate clinical pharmacokinetic data following single dose administration 
of flurbiprofen.  This assay has been used to validate use of the flurbiprofen eight hour 
urinary recovery ratio (
FOHF
OHFFLRR
+
=
'4
'4 ) as an in vivo probe of cytochrome P450 
2C9 activity in human subjects ({Frye, Tracy, et al. 2000 2493 /id}, manuscript in 
preparation).  Applications of this methodology will allow determination of relative 
CYP2C9 metabolizing capacity in individuals, phenotypic identification of individuals 
possessing mutant CYP2C9 alleles (e.g., *2 and *3 [10;11]) which result in altered 
metabolizing capacity and determination of the effects of disease states on CYP2C9 
activity. 
151 
Table 6.1.17 Detection of Flurbiprofen and 4’-Hydroxflurbiprofen in Urine 
Intra- and Inter-day precision and accuracy for flurbiprofen and 4'-hydroxyflurbiprofen  
in urine 
          
Compound      Concentration       
   Added  Found  C.V. (%)  % Deviation 
   (µg/ml)       
Intra-assay reproducibilitya   Mean+/- S.D.      
Flurbiprofen   1.0  0.90+/-0.09  9.5  -10.0  
   12.0  10.29+/-0.40  3.9  -14.2  
   30  28.23+/-2.58  9.1  -6.0  
4'-hydroxyflurbiprofen  1.0  1.12+/-0.06  5.8  10.0  
   12.0  11.46+/-0.47  4.1  -4.2  
   30  29.96+/-2.77  9.3  -0.3  
           
Inter-assay reproducibilityb   Mean +/- S.E.      
Flurbiprofen   1.0  0.88+/-0.02  2.7  -10.0  
   12.0  10.39+/-0.34  3.6  -13.3  
   30  29.34+/-1.10  3.8  -2.3  
4'-hydroxyflurbiprofen  1.0  1.09+/-0.03  3.0  10.0  
   12.0  11.30+/-0.39  3.5  -5.8  
   30  30.54+/-1.00  3.4  1.7  
           
Freeze-thaw stabilityc     Mean +/- S.D.      
Flurbiprofen   1.0  0.85+/-0.07  8.2  -14.5  
   30  29.64+/-1.56  5.3  -1.2  
4’-hydroxyflurbiprofen   1.0  1.01+/-0.04  4.0  1.0  
   30  30.65+/-1.39  4.5  2.2  
           
Processing stabilityd     Mean +/- S.D.      
Flurbiprofen   1.0  0.92+/-0.03  3.3  -7.7  
   30  31.14+/-0.76  2.4  3.8  
4’-hydroxyflurbiprofen   1.0  1.01+/-0.02  2.0  0.8  
   30  31.99+/-0.63  2.0  6.6  
a,dTwelve samples per concentration       
bSix samples per day per concentration for three days     
cThree samples per concentration 
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Table 6.2.18 Detection of Flurbiprofen and 4’-Hydroxyflurbiprofen in Plasma 
 Intra- and Inter-day precision and accuracy for flurbiprofen and 4'-hydroxy- 
flurbiprofen in plasma 
          
Compound      Concentration        
   Added  Found  C.V. (%)  %Deviation  
   (µg/ml)        
Intra-assay reproducibilitya   Mean+/- S.D.       
Flurbiprofen   0.5  0.48+/-0.03  6.3  -4.0   
   6.0  5.49+/-0.23  4.2  -8.3   
   15  13.93+/-0.69  4.9  -7.3   
4'-hydroxyflurbiprofen  0.1  0.12+/-0.02  13.7  16.7   
   0.5  0.46+/-0.03  6.9  -8.0   
   1.5  1.39+/-0.07  4.9  -6.7   
            
Inter-assay reproducibilityb   Mean +/- S.E.       
Flurbiprofen   0.5  0.46+/-0.02  4.4  -8.0   
   6.0  5.41+/-0.18  3.3  -10.0   
   15  13.97+/-0.04  0.3  -6.7   
4'-hydroxyflurbiprofen  0.1  0.10+/-0.02  14.3  1.0   
   0.5  0.45+/-0.01  2.7  -10.0   
   1.5  1.41+/-0.02  1.2  -6.7   
            
Freeze-thaw stabilityc     Mean +/- S.D.       
Flurbiprofen   0.5  0.49+/-0.01  2.0  -2.9   
   15  14.51+/-1.41  9.7  -3.2   
4’-hydroxyflurbiprofen   0.1  0.09+/-0.01  11.1  -6.9   
   1.5  1.45+/-0.16  11.0  -3.3   
            
Processing stabilityd     Mean +/- S.D.       
Flurbiprofen   0.5  0.52+/-0.02  3.8  4.2   
   15  14.11+/-0.55  3.9  -5.9   
4’-hydroxyflurbiprofen   0.1  0.09+/-0.01  11.1  -8.6   
   1.5  1.45+/-0.04  2.8  -3.1   
a,dTwelve samples per concentration       
bSix samples per day per concentration for three days     
cThree samples per concentration 
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               Flurbiprofen                                                                4'-hydroxyflurbiprofen                                         
Figure 6.1.47 Flurbiprofen Metabolism 
Structures for flurbiprofen and its primary metabolite, 4'-hydroxyflurbiprofen. 
 
F
CH3
H COOH
CYP450 2C9 OH
F
CH3
H COOH
154 
 
Figure 6.2.48 HPLC Chromatogram of Flurbiprofen and 4’-Hydroxyflurbiprofen in 
Urine 
Representative HPLC chromatogram illustrating the detection of 4’-hydroxy flurbiprofen (5 
µg/mL), internal standard, and flurbiprofen (5 µg/mL) in urine. 
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Figure 6.3.49 HPLC Chromatogram from Blank Urine Sample 
Representative HPLC chromatogram from a blank urine sample.
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Figure 6.4.50 HPLC Chromatogram of Flurbiprofen and 4’-Hydroxyflurbiprofen in 
Plasma 
Representative HPLC chromatogram illustrating the detection of 4’-hydroxy flurbiprofen (0.05 
µg/mL), internal standard, and flurbiprofen (0.25 µg/mL) in plasma. 
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Figure 6.5.51 HPLC Chromatogram from Blank Plasma Sample 
Representative HPLC chromatogram from a blank plasma sample.
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Figure 6.6.52 Flurbiprofen Log Plasma Concentration Time Profile 
Representative log plasma concentration-time profile for flurbiprofen and 4'- 
hydroxyflurbiprofen from a healthy subject who received a 50 mg dose of racemic 
flurbiprofen. 
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CHAPTER VII 
 
 
 
Minimal In vivo Activation of CYP2C9-Mediated Flurbiprofen 
Metabolism by Dapsone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter published in European Journal of Pharmaceutical Sciences [14 , 47-52 
(2001)]. 
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7.1.  Introduction 
 
The CYP450 enzymes are one of the most important groups of enzymes involved 
in the biotransformation of hydrophobic compounds such as drugs, carcinogens, and 
other xenobiotics.  The majority of CYP450 reactions are oxidations (e.g., hydroxylation) 
that exhibit Michaelis-Menten kinetics and competitive inhibition between substrates.  As 
a result, most pharmacokinetic properties can be predicted with standard kinetic analyses, 
which may be helpful in the prediction of drug interactions.  However, it has been shown 
that some CYP450 reactions show unusual enzyme kinetics such as activation, 
autoactivation, and substrate inhibition [1;2].  Though reactions involving atypical 
kinetics are most commonly associated with CYP3A4, they have also been noted with 
CYP2C9 [2].  CYP2C9 is responsible for metabolizing several clinically relevant drugs 
such as S-warfarin, phenytoin, and many of the NSAIDs [3].  One NSAID in particular, 
flurbiprofen, is metabolized exclusively by CYP2C9 [4;5], and thus serves as a selective 
in vitro probe for CYP2C9 activity.   Furthermore, this CYP2C9 mediated metabolism of 
flurbiprofen is non-stereoselective [4;5], implying that administration of commercially 
available racemic-flurbiprofen would be feasible for in vivo studies of CYP2C9 
metabolism.  To this end, we have recently shown that flurbiprofen may also be useful as 
an in vivo probe for CYP2C9 activity [6] 
Dapsone is a sulfone drug that has been used in the treatment of leprosy, and more 
recently for the treatment of Kaposi’s sarcoma and pneumocystis carinii in patients with 
AIDS [7].  Dapsone itself is metabolized by CYP2C9 [CYP3A4 and CYP2E1 may also 
provide a contribution] [8-11], and has been shown to participate in a complex in vitro 
interaction with flurbiprofen, whereby it can activate CYP2C9-mediated flurbiprofen 
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metabolism [2].  The addition of dapsone in vitro can increase CYP2C9 mediated 
flurbiprofen metabolism by 50-100% in human liver microsomes and purified CYP2C9 
enzyme, respectively [2].  This observation of CYP2C9 activation in vitro at 
concentrations of both dapsone and flurbiprofen observed in vivo, suggests that CYP2C9 
might display cooperativity in vivo and thus leads to the hypothesis that dapsone may 
activate flurbiprofen metabolism (via CYP2C9) in vivo.  In this study, flurbiprofen was 
administered in the presence and absence of low and high concentrations of dapsone, to 
evaluate whether the metabolism of flurbiprofen could be activated in vivo by dapsone. 
 
7.2. Methods 
 
 
Chemicals and reagents.  S-Flurbiprofen, 4’-hydroxyflurbiprofen, and 2-fluoro-4-
biphenyl acetic acid (internal standard) were gifts from the Pharmacia, Inc. (Kalamazoo, 
MI, USA).  Dapsone was obtained from Sigma Chemical Co. (St Louis, MO, USA) and 
monoacetyl-dapsone was synthesized by the method of Uetrecht et al. [12].  All other 
chemicals and solvents were obtained from commercial sources and were of the highest 
purity available. 
Inclusion/exclusion criteria.  Twelve healthy subjects between 18 and 45 years of 
age participated in the study.  The study protocol was approved by the Institutional 
Review Boards of both the University of Pittsburgh and West Virginia University and all 
subjects gave written, informed consent.  The subjects consisted of non-smoking men and 
women who underwent screening tests based on history, physical examination and 
routine biochemical and urinalysis tests.  Women must not have been pregnant at the time 
of the study, and all subjects must have abstained from alcohol (of any form) for 8 days 
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and any caffeine containing products for 48 hours before and during the period of study.  
Subjects were specifically questioned about the last time they consumed alcohol or any 
caffeine containing products.   
Flurbiprofen-dapsone pharmacokinetic study.  The pharmacokinetics of 
flurbiprofen were evaluated before (visit A) and after the first and seventh dose(s) of 
dapsone 100mg (visits B and C, respectively).  Visits A and B (before and after dapsone) 
were separated by at least 2 weeks.  Racemic-Flurbiprofen (Ansaid®) 50mg was 
administered orally after an overnight fast on each occasion and given 2 hours after the 
single or seventh dose of dapsone (Avlosulfon®).  Prior to drug administration, 40 ml of 
blood was obtained.  Following drug administration, blood samples (20 ml with sodium 
EDTA) were obtained at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours.  Total voided 
urine was collected before and at the following time intervals after flurbiprofen 
administration:  0-2 hr, 2-4 hr, 4-6 hr, 6-8 hr, 8-10 hr, 10-12 hr, and 12-24 hr.  Subjects 
were kept at the Clinical Research Unit for 12 hours during each study and returned the 
next morning for the 24 hr blood sample draw and to provide the overnight (12-24 hr) 
urine collection.  Plasma was obtained from the blood samples by centrifugation and 
together with aliquots of the urine samples, stored frozen at -20°C until analysis.  
Urine 4’-hydroxyflurbiprofen and flurbiprofen concentration analysis. Plasma 
and urinary concentrations of 4’-hydroxyflurbiprofen and flurbiprofen were measured 
using the method of Hutzler et al., [13].  Samples were prepared using 50µl of urine, 
followed by addition of 400 µl of purified water and 100 µl 6M HCl.  The samples were 
then incubated at 90°C for 30 minutes to facilitate deconjugation of the glucuronides of 
flurbiprofen and its 4’-hydroxy metabolite.  Once cooled, 500µl of acetonitrile containing 
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internal standard (500ng of 2-fluoro-4-biphenyl acetic acid) was added.  Samples were 
then vortexed and centrifuged at 10,000 rpm for 5 minutes.  Next, 150 µl of the 
supernatant was transferred to autosampler vials and injected onto the HPLC.  The HPLC 
system consisted of a Waters 501 HPLC pump, a Waters 717 autosampler and a 
Waters 470 fluorescence detector set at an excitation wavelength of 260nm and an 
emission wavelength of 320nm.  The mobile phase consisted of acetonitrile:20mM 
K2HPO4, pH 3.0 (40:60) pumped at 1mL/min through a Brownlee Spheri-5 C18 4.6 x 
100mm column. The inter-day coefficients of variation for 4’-hydroxyflurbiprofen and 
flurbiprofen in urine were less than 5%. 
Plasma 4’-hydroxyflurbiprofen and flurbiprofen concentration analysis.  Plasma 
samples were prepared by adding 200 µl internal standard solution (180 ng/ml 2-fluoro-
4-biphenylacetic acid in acetonitrile) to 100 µl plasma, followed by brief vortexing.  
After 200 µl acetonitrile was added, samples were vortexed and centrifuged for 10 
minutes.  Next, 100µl of sample was transferred to HPLC autosampler vials, and 50µl 
was injected.  The mobile phase was pumped in a gradient fashion through a Thomson 
20-20 column C18 4.6 x 200mm 5µm column.  Mobile phase A consisted of acetonitrile, 
containing 0.1% acetic acid, and mobile phase B consisted of 0.1% acetic acid.  Using a 
Hewlett Packard 1050 HPLC system pumping at 1mL/min, the gradient was initiated at a 
ratio of 30%A:70%B and altered in a linear fashion to 100% A over 20 minutes.  The 
system was returned to initial conditions over 6 minutes and then allowed to equilibrate 
for 5 minutes, for a total run time of 31 minutes.  Samples were quantitated with 
fluorescence detection using an excitation wavelength of 260nm and an emission 
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wavelength of 320nm.  The inter-day coefficients of variation for 4’-hydroxyflurbiprofen 
and flurbiprofen in plasma were 14.3% or less. 
Plasma dapsone and N-acetyldapsone concentration analysis.  The 
concentrations of dapsone and N-acetyl dapsone were determined by HPLC as described 
previously {May, Arns, et al. 1992 1140 /id}.  The inter-day coefficients of variation for 
dapsone and N-acetyldapsone in plasma were 13% or less. 
Data analysis.  Plasma concentration-time data were analyzed by non-
compartmental methods.  Pharmacokinetic parameters including half-life, clearance, area 
under the concentration-time curve (AUC) and metabolite formation clearance were 
estimated using WinNonlin (Pharsight, Palo Alto, CA).  The AUC for flurbiprofen and 
4'-hydroxyflurbiprofen were determined using the trapezoidal rule with extrapolation to 
infinity.  Flurbiprofen apparent oral clearance was calculated as Cl/F  = Dose/AUC.  4’-
hydroxyflurbiprofen formation clearance (4’-OHF FCL) was calculated as: 
OH
FMCL
4  = Urinary excretion of 4’-OHF (24hours) 
                               AUC  Flurbiprofen (0-∞) 
The AUC (0-12 hours) for dapsone and N-acetyl dapsone was also determined using the 
trapezoidal rule.  Mean concentrations were calculated by dividing the AUC of these 
compounds by the time interval (12 hours). 
Statistical analysis.  Data are presented as mean ± s.d.  Data were analyzed by 
repeated measures analysis of variance followed by Tukey’s multiple comparison test.  
Clearance values were log transformed prior to analysis.  Differences were regarded as 
statistically significant when P values were ≤ 0.05.  All analyses were performed using 
SAS software (v. 6.12). 
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7.3.  Results 
 
The apparent oral clearances of flurbiprofen during each of the treatment periods 
are presented in Figure 7.1.  The apparent oral clearance of flurbiprofen was unchanged 
when given concomitantly with a single dose of dapsone but increased slightly (~11%) 
(P<0.02) after seven days of dapsone dosing (Table 7.1).  It is of note that though there 
were substantial differences in baseline flurbiprofen apparent oral clearance values 
among the patients, the reproducibility of changes within subjects were similar in extent 
(Figure 7.1).  Thus, averaging of the data somewhat obscures the changes noted within an 
individual patient.  The remaining pharmacokinetic parameter estimates for all three 
visits are listed in Table 7.1.  
To assess whether dapsone affected the glucuronidation of flurbiprofen and its 4’-
hydroxyflurbiprofen metabolite, urine samples from Visits A and C (without and with 
dapsone) from three patients were analyzed with and without acid hydrolysis of the 
glucuronides (data not shown).  The ratio of 4’-hydroxyflurbiprofen recovered to total 
parent and metabolite recovered from Visit A (no dapsone) did not differ regardless of 
whether unconjugated flurbiprofen and metabolite or total flurbiprofen and metabolite 
after hydrolysis were measured.  Furthermore, the same equality was found in the 
hydrolyzed and un-hydrolyzed urine samples from patients taking dapsone concurrently.  
Likewise, measuring unconjugated drug did not alter the calculations of percent 
activation as compared to measuring total drug excreted. These findings suggest that 
dapsone had no effect on excretion of the flurbiprofen and metabolite glucuronides.   
The AUC (0-12h) of dapsone and N-acetyldapsone estimated by the trapezoidal 
rule is shown in Table 7.2.  Average plasma dapsone levels after single and multiple 
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doses were 5 ± 2µM and 11 ± 4µM, respectively (Table 7.2).  Likewise, mean N-
acetyldapsone levels in plasma were 2 ± 1µM after a single dose and 4 ± 2µM after seven 
daily doses (Table 7.2).  These average concentrations of dapsone (5 µM and 11 µM) 
were well within the range of dapsone concentrations shown to produce activation of 
CYP2C9 mediated flurbiprofen metabolism in vitro [2].  Furthermore, there was no 
correlation between N-acetylator status (slow or rapid acetylators) and degree of 
activation as measured by the flurbiprofen recovery ratio (data not shown). 
 
7.4.  Discussion 
 
The present study evaluated the ability of dapsone to activate (interact 
cooperatively with) flurbiprofen metabolism to 4-hydroxyflurbiprofen in vivo.  
Flurbiprofen is an NSAID that is exclusively metabolized by CYP2C9 via 4’-
hydroxylation [4;5].  As a result, it may be used as a selective probe to monitor the 
activity of CYP2C9 under various in vitro conditions.  More recently, it has been 
determined that flurbiprofen may also be used as a phenotypic measure of CYP2C9 
activity in vivo [6].  Results of the present study demonstrate minimal activation of 
flurbiprofen metabolism in vivo by dapsone, as reflected by an increase in flurbiprofen 
apparent oral clearance.  
In vitro experiments utilizing microsomes and purified CYP2C9 enzyme have 
shown that dapsone activates 2C9-mediated flurbiprofen 4’-hydroxylation [2].  This 
activation phenomenon was first discovered in microsomes, where a 50% activation was 
observed, with maximum activation occurring at approximately 10µM dapsone 
concentrations [2].  Studies using a purified CYP2C9 reconstituted enzyme system were 
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also conducted, with flurbiprofen metabolism being doubled in the presence of low 
concentrations of dapsone, and the maximum effect again at 10µM dapsone [2].  Our 
laboratory has determined that this activation is not an isolated case, as observations that 
dapsone can activate CYP2C9 mediated metabolism of the NSAID naproxen in vitro 
have also been made [2].     
Activation of CYP-mediated metabolism has primarily been associated with 
CYP3A4.  Studies by Schwab et al. [14] and Shou et al. [1] have shown that purified 
CYP3A enzymes are activated by 7,8-benzoflavone.  Likewise, purified CYP3A4-
mediated meloxicam metabolism was activated by quinidine in a dose-dependent manner, 
160% at 10µM and 510% at 100µM compared to control experiments [15].  Most 
recently, Tang et al. demonstrated in rhesus monkeys substantial (2-fold) in vivo 
activation of CYP3A4 metabolism of diclofenac by quinidine [16].  More recent evidence 
from Korzekwa et al., [2] and Ekins et al. [17] suggest activation is not unique to 
CYP3A4 and that other isoforms may undergo activation as well.  
Based on in vitro data showing activation of CYP2C9, we hypothesized that 
similar findings might be observed in vivo using the CYP2C9 probe flurbiprofen.  
Though the direction of the observed change in flurbiprofen apparent oral clearance is 
consistent with this hypothesis, the in vivo interaction is of much lesser magnitude than 
observed in vitro.  At this time it is unclear why the degree of activation observed in vitro 
is of a greater magnitude than observed in vivo.  One factor that may contribute to the 
decreased activation in vivo is protein binding.  Recent work by McLure et al. [18]has 
demonstrated that the binding of naproxen (an NSAID structurally related to 
flurbiprofen) exhibits very little non-specific binding to microsomal (enzyme) protein in 
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vitro.  The in vitro binding of dapsone in microsomal preparations is unknown.  
However, both flurbiprofen (99.95%) [19;20], and dapsone (~70-90%) [21] are 
substantially bound to serum albumin in vivo.  If a drug is highly protein bound, then the 
amount of free drug available for metabolism and/or activation may be small.  Since total 
levels of dapsone were measured, and dapsone is 70-90% protein bound, then we may 
assume that only about 20% of the dapsone was available to act on CYP2C9 in vivo, 
potentially resulting in less activation compared to in vitro.  As previously mentioned, the 
average concentrations of dapsone in the subjects after one and seven doses were 5 ± 2 
µM and 11 ± 4 µM, respectively, which corresponds to free dapsone concentrations of ~ 
1 µM and 2 µM, respectively, assuming 80% protein binding.  By taking the average 
AUC0-∞ of flurbiprofen from visit A, the average flurbiprofen concentration can be 
calculated as being approximately 7 µM, resulting in an unbound concentration of 0.0035 
µM.  These estimated unbound concentrations result in an average in vivo unbound 
dapsone/flurbiprofen molar ratio of ~600 after seven days of dapsone therapy.  Even 
without knowing the in vitro non-specific binding of dapsone, it is obvious that the 
unbound dapsone/flurbiprofen ratio in vitro is less than 600 suggesting that though 
protein binding may play some role in the lack of in vitro-in vivo correlation, it is 
probably not the entire explanation.    
Dapsone and flurbiprofen both have several routes of metabolism, which may also 
have affected our in vivo observations.  Dapsone is metabolized via both oxidative and 
conjugative pathways, forming the hydroxylamine of dapsone and the N-acetylated 
metabolites monoacetyldapsone and hydroxymonoacetyldapsone [22;23].  In vivo, 
dapsone is concurrently undergoing both oxidative and conjugative metabolism, resulting 
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in less dapsone available to act upon the CYP2C9 isoform and potentially reducing 
activation, as compared to our in vitro experiments [2] in which only phase I pathways 
were operational.  Besides dapsone metabolism, another potential confounder in these in 
vitro-in vivo correlations is that flurbiprofen also undergoes glucuronidation [24;25], 
which may serve as a competitive reaction, lowering the effective flurbiprofen 
concentration available for oxidation, even though dapsone does not appear to affect 
flurbiprofen glucuronidation.  Thus, protein binding and additional metabolism pathways 
likely play a role in the disparity between in vitro and in vivo degrees of flurbiprofen 
activation by dapsone.  However, it is possible that other unidentified factors may also 
participate in the modulation of activation in vivo.   
In conclusion, the activation of flurbiprofen metabolism by dapsone observed in 
vitro has been observed in man.  However, the activation does not appear to occur at the 
same magnitude.  Thus, it can be expected that co-administration of dapsone with other 
CYP2C9 substrates would not result in clinically significant interactions.  It remains 
possible that in vivo study of compounds exhibiting greater in vitro activation than 
flurbiprofen or involving other CYP isoforms (e.g., CYP3A4 with its broad substrate 
specificity) may result in a greater change in clearance.  An improved understanding of 
this activation phenomenon should permit a better assessment of its potential clinical 
significance.  
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Table 7.1.19 Flurbiprofen Pharmacokinetic Parameter Estimates 
Mean flurbiprofen kinetic parameter estimates. 
Variable Units Visit A Visit B Visit C 
AUC 0-∞ µg/L*hr 43.8±13.8 39.3±9.4 38.3±8.5 
Cl/F  L/hr 1.23±0.32 1.33±0.29 1.37±0.30* 
Cmax µg/ml 10.5±2.9 9.9±4.2 10.0±3.4 
T1/2 hours 3.7±1.0 3.6±1.3 3.3±0.6 
Tmax hours 1.5±0.9 1.8±1.0 1.4±0.8 
Vd/F L 6.2±1.2 6.9±3.2 6.5±2.2 
4’-OH FCl  L/hr 0.38±0.14 0.39±0.13 0.40±0.16 
 
Data are mean values ±SD 
Visit A = Flurbiprofen 50mg alone. 
Visit B = Flurbiprofen 50mg + Dapsone 100mg. 
Visit C = Flurbiprofen 50mg after 7 days of Dapsone 100mg daily. 
 
AUC 0-∞ ,area under the plasma concentration-time curve extrapolated to infinity; Cl/F, clearance; T1/2, 
half-life; 4’-OH FCl, 4’-hydroxy flurbiprofen formation clearance. 
*P<0.02 
 
 
 
 
 
Table 7.2.20 Plasma Levels of Dapsone and N-acetyl Dapsone 
Mean plasma levels for dapsone and N-acetyl dapsone. 
 
                   Dapsone                                       N-acetyl dapsone 
Visit B C B C 
AUC (0-12h)µM*hr 59.5±18.8 130.5±45.9 24.0±15.0 47.8±24.5 
Cmax (µM) 7.5±2.2 14.5±4.9 3.3±2.3 5.9±3.4 
Caverage (µM) 5.0±1.6 10.9±3.8 2.0±1.2 4.0±2.0 
 
Dapsone dose =100mg 
B=single dose 
C=7th dose 
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Figure 7.1.53 Flurbiprofen Oral Clearance in 12 Healthy Subjects 
Comparison of flurbiprofen oral clearance in the 12 subjects when receiving either 
flurbiprofen alone (Visit A), flurbiprofen and single dose dapsone (Visit B) or seven days 
of dapsone therapy and then flurbiprofen (Visit C). 
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Summary and Conclusions 
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Over the past several years, it has come to our attention that CYP450 enzymes do 
not always behave as would be expected.  Many display kinetics that are not consistent 
with the Michaelis-Menten model, resulting in data that is often hard to interpret and 
correlate to the in vivo situation.  As a result, it is important that we understand, as best 
we can, the underlying causes of atypical kinetics.  This understanding will help to better 
predict when atypical kinetics are likely to occur.  Historically, CYP3A4 has been the 
focus of study because it has presented the most examples of atypical kinetics.  However, 
it is now being discovered that other isoforms often show atypical kinetic profiles as well.  
Our lab has discovered that dapsone can activate CYP2C9-mediated metabolism of 
several compounds.  This was first discovered in human liver microsomes, but little was 
known about the underlying causes.  The work done since that initial discovery, and 
reported here, has shed some light on this subject and provided valuable information 
regarding the mechanism of activation of CYP2C9.   
It was first discovered that dapsone activated flurbiprofen 4’-hydroxylation, but 
we know now that naproxen demethylation and piroxicam 5’-hydroxylation are also 
activated by dapsone, indicating that multiple CYP2C9 substrates can be activated by 
dapsone.  Kinetic studies exploring the activation of these substrates indicates that 
activation of CYP2C9 may be explained by a two-site binding model, which suggests that 
both dapsone and substrate may fit in the active site simultaneously, both having access 
to the active oxygen.  In addition, we have the capability of fitting activation kinetic data 
to a two-site effector model equation, which gives α and β values indicative of activation.   
Next we have shown that the effector structural requirements are rather strict, 
which is consistent with other specific protein-substrate interactions.  It is evident from 
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these dapsone analog studies that the best activators possess a sulfone moiety, preferably 
directly between two benzene rings.  Para positions on these benzene rings also are 
important, as replacement of an amino group (dapsone) with a nitro group (4-NPSA) 
results in inhibition of CYP2C9.  This small structural change in 4-NPSA, linked to the 
substantial change in enzyme activity in its presence, suggests that the effector site that 
causes activation is very specific, and may be in the active site.  To study the effects of 
active site changes on activation of dapsone, we have studied the *2 and *3 allelic 
variants and F114L mutant of CYP2C9.  Results suggested that the F114 residue may 
play a role in activation, as 5-fold activation of flurbiprofen 4’-hydroxylation was 
observed in this mutant, compared to 1.5-fold in wild-type CYP2C9.  In addition, 
piroxicam 5’-hydroxylase activity was higher in the F114L mutant than wild-type 
CYP2C9 in the absence of dapsone, indicating that active site conformation alone 
contributes to enzyme activity.   
In addition, it has been found that CYP2C9 may be activated by more than one 
mechanism.  Hydroxy-dapsone has been found to activate flurbiprofen 4’-hydroxylation, 
although differently from dapsone.  Hydroxy-dapsone activates CYP2C9 solely through a 
Vmax effect, with no effect on Km, whereas dapsone affects both Vmax and Km.  These 
effects were confirmed by spectral binding studies which showed the direct effect of 
dapsone on the binding affinity for flurbiprofen, while hydroxy-dapsone had no effect on 
affinity for flurbiprofen.  This Vmax effect by hydroxy-dapsone may be the result of 
disrupting ordered water molecules within the active site, resulting in decreased 
uncoupling of the P450 cycle and enhanced product formation.  This suggests that 
multiple factors are likely involved in activation of CYP2C9 activity.  We have also 
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found from CYP2C9/19 chimeric and CYP2C19 mutant enzymes the important 
regions/residues for catalytic activity towards flurbiprofen, naproxen, and piroxicam.  
Additionally, only the CYP2C9/19 (340-490) chimera was able to be activated to any 
extent by dapsone.  Results from the same study suggest that dapsone may bind in SRS 1 
of CYP2C9, but this has yet to be confirmed.  Lastly, the orientation of ibuprofen is 
apparently changed in the presence of dapsone, as a different ratio of 3-hydroxy to 2-
hydroxy ibuprofen is produced in the presence of dapsone, indicating the active site 
conformation effects of dapsone on CYP2C9. 
One of the ongoing arguments regarding effector binding and atypical kinetics is 
exactly where the effector site is.  Most data presented in the literature suggests that the 
effector site is in the active site, while others still believe in the presence of an allosteric 
site, which upon binding by effector causes a conformational change in the protein.  None 
of our studies have conclusively shown the presence of the effector site in the active site.  
However, we have shown some pretty compelling kinetic and structural evidence to 
support this theory, including the ability to measure dapsone metabolite formation in the 
presence of flubiprofen, indicating dapsone’s presence in the active site (chapter 2).  
Despite the information collected thus far to help in the understanding of activation of 
CYP2C9, there is still much to be studied before we can truly state that we fully 
understand atypcal kinetic profiles.  It is also possible that overall protein conformational 
changes are contributing to the observed activation of CYP2C9, which is an area of focus 
for the future.  The information reported here, while important, is just the beginning. 
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